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SUMMARY
Herpes simplex virus (HSV) has been associated with cervical 
neoplastic disease for a number of years and has been shown to induce 
m orphological transform ation of rodent cells. HSV infection alone is not 
thought to induce cancer but rather it is proposed to act as a co-factor 
initiating one of the many steps towards a potentially cancerous phenotype. 
A num ber of possible mechanisms of HSV transform ation have been 
proposed, but the oncogenic properties of the virus are still not fu lly  
understood. The subject matter of this thesis will be concerned with one of 
these mechanisms, namely the postulate that transformation may occur by 
altering the expression of host cell polypeptides.
A set of polypeptides called transformation associated polypeptides 
was previously found to be recognised in immunoprecipitation reactions by 
both sera from tumour bearing animals and antisera raised against HSV 
infected cells. This observation implicated the induction of such cellular 
polypeptides by HSV infection in the changes involved in the progression 
from a norm al cell to that of a transform ed phenotype. One of these 
transform ation associated polypeptides a 90,000MW polypeptide called the 
U90, has been investigated.
The U90 polypeptide was previously thought to be specific to the 
transformed state as it could only be immunoprecipitated from radiolabelled 
transform ed cells and not from prim ary control cells. Characterization 
studies have now shown that the U90 is, in fact, a highly conserved 
polypeptide and as such is likely to play an important role in the cell.
HSV infection was found to increase the expression of the U90 by up 
to 8 fold (at 3 hours post-infection) and resulted in the accumulation of the 
U90 in the cytoplasmic fraction - as opposed to the membrane associated 
fraction from where it is normally isolated in the uninfected tumour cell.
The accumulation of the U90 in the cytoplasm following HSV 
infection, enabled the protein to be purified with much greater ease as a 
consequence of (1) the increased amount of the protein and (2) the soluble 
nature of the U90. The purified U90 was subsequently used to generate 
partial internal amino acid sequence (after enzymatic digestion) and also 
used to generate a polyclonal mono-specific antibody.
Comparison of the amino acid sequences of the seven different U90 
peptides with sequences entered in the NBRF databases resulted in no 
significant homology being found with any of the entries and confirmed
iv
that the U90 was not a stress protein such as hsp90 or GRP94 which had 
previously been suggested. This indicated that the U90 is a n o v e l 
transform ation associated polypeptide. The sequence data generated was 
insufficient to allow searches for functional domains to be completed and 
therefore the function of the U90 is still not known.
By applying the U90 purification strategy to control RE cells and 
using the U90 monospecific antibody it was found that control cells did in 
fact express a homologue of the U90, which was recognised by the 
monospecifc U90 antibody. This 90K polypeptide behaved in an highly 
similar m anner to the U90 - HSV infection resulted in the accumulation of 
the polypeptide in the cytoplasmic fraction and it could be purified in an 
identical m anner to the U90 using the U90 purification strategy.
Comparison of the U90 isolated from the Bn5T tumour cells to the U90 
homologue isolated from control prim ary RE cells showed that in the 
transformed cells the U90 had a much slower turnover than in the control 
cells (approximately 13 hours as opposed to 31 minutes). If the U90 is 
implicated in regulation of cell growth or d ifferentiation as suggested 
previously by the detection of the U90 in rat embryos up to 14 days gestation, 
increasing the total amount of the protein in the cell by HSV infection could 
have a significant affect on the cell regulation. A similar affect is seen in 
the transform ed cell where the increased half life of the U90 means that 
more of this protein is present in the cell for extended periods.
During these studies HSV-1 but not HSV-2 infection, was found to 
increase the levels of a second host polypeptide, a glucose regulated  
polypeptide GRP94. The increase in the total amount of GRP94 in the cell 
following HSV-1 infection appears to be a consequence of a translational or 
post-translational change, but in contrast to HSV induction of U90, 
immediate early gene expression was found to be inadequate to increase 
GRP94. Due to time limitations studies were concentrated on the U90. 
However the increase of GRP94 by HSV type 1 but not type 2, marks an 
interesting distinction between the host cell interactions of the two viruses.
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CHAPTER 1 : INTRODUCTION 
SECTION 1. TUMOUR VIRUSES AND VIRAL ONCOGENES
Investigations of age specific cancers which showed an exponential 
increase with age (Armitage & Doll, 1954) provided the initial basis for the 
concept that m ultiple events causing damage to the cell, can result in 
tum ourigenesis. Carcinogens which induce such events can be chemical, 
physical or viral (reviewed by Doll & Peto, 1981). Exposure to such factors can 
result in the alteration of a normal cellular gene (termed a proto-oncogene) to 
an activated oncogene (termed a cellular oncogene or c-onc). A proto-oncogene 
has recently been defined as a gene where "if m anipulation of any sort 
engenders a transforming allele (or oncogene), convention admits the norm al 
counter part to the ranks of proto-oncogene" (Bishop, 1991). These proto­
oncogenes frequently have functions associated with growth (Hunter, 1989), 
and therefore, alteration to their regulation or function can have im portant 
consequences for the cell. Alternatively, if the oncogene is introduced to the 
cell by a virus, it is term ed a viral oncogene or v-onc. Such v-oncs are 
transduced cellular genes lacking introns which are normally present in the 
gene in the normal cell environment. In addition the v-onc are usually mutated 
in some way and/or contain rearrangements.
A num ber of carcinogens have been directly linked to specific human 
tumours. Over two hundred years ago, exposure to soot was found to be the cause 
of cancer of the scrotum in chimney sweeps, as documented by Pot in 1775 
(Cairns, 1978). In the 1850’s, the development of a new industry producing 
synthetic dyes resulted in the exposure of workers to the e x tre m e ly  
carcinogenic agent 2-naphthylamine. This was the starting m aterial for the 
production of synthetic dyes. Exposure to 2-napthylamine resulted in a number 
of cases of cancer of the bladder- although it took over 50 years for the use of 
this chemical to be stopped (Cairns, 1978). A third well documented carcinogen 
is asbestos, which causes asbestosis and can also result in a specific lung 
cancer, mesothelioma. Asbestos and its involvement with cancer of the lung, 
illustrates the proposal that multiple factors are involved in cancer, as lung 
cancer in patients exposed to asbestos occurs almost exclusively in people who
2smoke. Certain viruses have also been demonstrated to act as carcinogens and 
have a direct involvement in tumour induction (Bishop, 1991). Examples of such 
viruses include adenoviruses, herpesviruses, papovaviruses and retroviruses.
In 1892 Koch compiled postulates to evaluate the relationship of a casual 
agent to the disease with which it was associated. These postulates were based on 
the following points:
1. The micro-organism should be found in all cases of the disease in  
question, and its distribution in the body should be in accordance with the 
lesions observed.
2. The micro-organism should be grown in pure culture in v itro  (or 
outside the body of the host) for several generations.
3. When such a pure culture is inoculated into susceptible animal species, 
the typical disease must result.
4. The micro-organism must again be isolated from the lesions of such 
experimentally produced disease. (Koch, 1892).
Koch's postulates have been used to establish if an infection with a 
particular virus is associated with the development of a specific cancer. Some 
viruses however, implicated in cancer do not fulfil these postulates. This is 
because of the particular way in which they are implicated in tum our 
progression.
Evans (1976) revised these conditions to enable them to be applied more 
readily to viruses and cancer. This was required because of the complications 
which arise during infection and carcinogenesis, i.e. the nature of the host, the 
long incubation period, the possibility of cofactors, and the inability to fulfil 
the third condition in humans, that is, to induce tumour formation using the 
isolated virus. Aurelian et al. (1987) subsequently revisited the postulates with 
specific reference to HSV and cervical cancer. The modified Koch's postulates 
are listed in Table 1.
Some of the tumour viruses identified by these rules, and some which do 
not fulfil all the conditions will be discussed in this section. These viruses, and 
the diseases with which they are associated, are summarized in Table 2. These 
viruses can be divided into two groups: the first group of RNA viruses, consists 
of only one family, the retroviruses, and the second group of DNA viruses, 
consists of the majority of DNA virus families, the exceptions being the parvo
TABLE 1
KOCH'S POSTULATES:- ADAPTED FOR VIRAL CARCINOGENISIS
1. Cancer patients should be exposed more than controls to the putative virus 
and cancer patients should have greater virus specific antibody or cell 
mediated responses than age/sex matched controls within that geographical 
area.
2. Cancer associated immune response should be indicative of viral expression.
3. The immunological response should be specific for the virus in question and 
a similar response should not be seen with other viruses or cancers.
4. The disease should follow exposure to the virus.
5. Prospective sero-epidemiological studies should show virus specific antibody 
present prior to the onset or recurrence of the disease.
6. Virus or genetic material of the virus should be present in the affected 
tissue.
7. Expression of viral information should occur in the affected tissues.
8. Virus or genetic information from the virus should be able to induce 
neoplastic transformation of cells in vitro.
9. Reproduction of the disease should be possible in animal models.
10. Elimination or modification of the putative cause should reduce the 
incidence of the disease.
11. The whole thing should make biological and epidemiological sense.
12. If the association between virus and cancer is seen in some populations but 
not in others, then the presence of cofactor(s) should be sought.
(adapted from Aurelian et al. 1987)
TABLE 2
SOME VIRUSES ASSOCIATED WITH TUMUQRS IN ANIMALS AND MAN
VIRUS ASSOCIATED DISEASE
RETROVIRUSES 
Rous sarcoma virus 
FLV 
HTLV-1
Sarcomas and leukaemias in chickens
Leukaemia in cats
Adult T cell leukaemia/lymphoma
PAPOVAVIRUSES 
Polyoma virus 
SV40
BK and JC viruses 
Papillomavirus
Carcinomas and sarcomas in mice
Sarcomas in rodents
Neural tumours in rodents and monkeys
Genital and skin warts in man, progressing to
cervical or skin carcinoma
In cattle, genital, alimentary and skin warts
progressing to carcinomas
HEPADNOVIRUSES 
Hepatitis B virus Primary hepatocellular carcinoma in man
ADENOVIRUSES
Adenovirus types 2, 5 + 12 Sarcomas in hamsters
HERPESVIRUSES 
Lucke Herpes virus 
Mareks disease virus 
Herpes virus saimiri 
Epstein Barr virus
Herpes simplex virus 
(types 1 and 2) 
Human cytomegalovirus
Renal adenocarcinomas of the frog 
Neurolymphomatosis in fowl 
Leukaemia and T cell lymphomas in monkeys 
Burkitt's lymphoma, nasopharyngeal carcinoma 
and immunoblastic B cell lymphoma in man 
Cervical neoplasia (?)
Kaposi's sarcoma and cervical neoplasia (?)
3and poxvirus families. The different mechanisms by which tumour viruses can 
transform cells are illustrated in Figure 1.
1(a) RETROVIRUSES
Retroviruses have a small infectious diploid RNA genome of between 5- 
10,000 nucleotides and code for an RNA dependent DNA polymerase activity 
known as reverse transcriptase (Fenner, 1975). This enzyme is crucial in the 
unique replicative cycle of the virus which involves the production of a double 
stranded DNA intermediate called the provirus, which is covalently inserted 
into the host's genome (Weiss et aL 1984). Retroviruses can either act as acutely 
transforming retroviruses, inducing tum our form ation within a very short 
period of time, or as non-acute retroviruses which can result in the induction 
of slow forming tumours.
Acute retroviruses transduce v-oncs into the host genome resulting in 
cell transformation, whereas the non-acute retroviruses transform the cell by 
inserting the provirus into the host genome in a position such that the long 
terminal repeats (LTRs) of the virus which contain strong promoters, act "in 
trans" and alter the regulation of proto-oncogenes. This can account for the 
difference in the length of time for which a tumour takes to develop. Ellerman 
and Bang first induced leukaemia in chickens in 1908 by the injection of avian 
leukosis virus (ALV). Peyton Rous followed this some 3 years later by inducing 
leukaemias and later sarcomas in chickens with Rous sarcoma virus (RSV). 
Since then, studies involving retroviruses have facilitated the discovery of 
more than 20 cellular oncogenes largely by using retrovirus induced tumours 
in animal models.
A num ber of retroviruses have been isolated from animals and are found 
to be associated with a variety of diseases including cancer. However, it has only 
been in the last 10-15 years that retroviruses have been found to be the cause of 
specific human diseases. Human T cell lymphotrophic virus (HTLV-1), which 
causes adult T cell human leukeamia or lymphoma (Poisez et a l. 1980) was first 
discovered in southern Japan. A second retrovirus HTLV-H, was isolated from a 
T cell variant of hairy cell leukaemia (Kalyanaraman et al. 1982). The third 
human retrovirus to be discovered was the human immunodeficiency virus
FIGURE 1 : VIRUS INDUCED NEOPLASIA
VIRUS INFECTION 
)
INDIRECT MECHANISM 
+
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(a) tissue regeneration after 
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(b) mitogenesis
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I
1. Hit and Run - no viral 
persistence required
2. Persistence of viral function 
or DNA
(a) introduction of an oncogene 
to either directly or indirectly 
initiate or maintain neoplasia
(b) insertion mutagenesis by 
the virus
4(HIV), which is not contained within the oncovirus sub-group of retroviruses, 
but instead is classified within the lentivirus sub-group. HIV, the causative 
agent of acquired im m unodeficiency syndrom e (AIDS), unlike o ther 
lentiviruses is associated with tum our form ation, but this is only as a 
consequence of the ability of the virus to destroy the immune system of the 
patient. HIV patients frequently develop the normally very rare mesenchymal 
tumour, Kaposi's sarcoma (Fauci, 1988) or B cell non-Hodgkin's lym phom a 
(Ziegler et al. 1984).
The oncovirus sub-group of the retroviruses transform s cells by a 
num ber of mechanisms which, due to the unique replicative cycle of 
retroviruses, are specific for these viruses. These mechanisms will be discussed 
in Section 3 of this chapter.
1(b) PAPOVAVIRUSES
The Papovavirus family is a group of small double stranded DNA tumour 
viruses of 5-8Kb which includes polyomavirus, simian vacuolating virus (SV40), 
and  papillomaviruses. Papillomaviruses will be discussed in this category as 
they have historically been classified as papovaviruses, however recent genetic 
and molecular studies indicates that papillomaviruses should constitute a sub­
group of their own. In contrast to RNA viruses DNA tumour viruses do not carry 
viral oncogenes which have direct cellular counterparts. The evolutionary 
origins of the oncogene products of DNA tumour viruses remains obscure, but 
the function of these products is becoming clearer, with m any of them  
interacting directly with specific host cell proteins (Lane, 1989). This aspect 
will be discussed in Section 4.
Specific immortalizing genes have been isolated from  each of the 
papovaviruses: large tumour (T) antigen from polyomavirus (Rassoulzadegen gt 
al, 1983; Jat & Sharp, 1986), large T antigen from SV40 (Petit et al. 1983) and E6 
and E7 from papillomaviruses (Matlashewski et aL 1987; Muneer et al. 1989).
Polyomavirus, which induces various carcinomas and sarcomas in the 
mouse, encodes three proteins of particular interest, large T, middle T and small 
t. These are 100, 55, and 22Kd in size respectively and are produced by 
alternative splicing of the mRNA, with all three species having the same 5'
5sequence. Large T antigen will imm ortalize cells in culture, resulting in 
indefinite growth and diminished requirem ents for cell growth factors and 
middle T antigen will complement large T, by transforming immortalized cells 
(Rassoulzadegen et al. 1982, 1983). Middle T antigen which has a protein- 
tyrosine kinase activity (Courtneidge & Smith, 1983) is found to complex with 
various host proteins including c-src, c-yes and c-fyn (which are ty ro sin e  
kinases). Large T antigen is also found to complex with cell polypeptides, 
binding the retinoblastoma gene product p i  10 (Rb), a tumour suppressor (Lane, 
1989). Although small t is not essential for transformation it appears to effect 
the cell's cytoskeleton and augments both transformation of cells in culture and 
tumourigenesis in animals (Sleigh et al. 1978; Lewis & Martin, 1979; Martin et al. 
1979).
SV40 was discovered in rhesus monkey kidney cell cultures which were 
used to produce the polio vaccine (Sweet & Hilleman, 1960). This virus is a 
5,200bp closed circular virus which becomes covalently integrated into the 
transformed cell's genome. Differential splicing of SV40 RNA produces large T 
and small t antigen RNA. These mRNA have the same 5' and 3' ends, but the 
presence of a stop codon in the small t antigen mRNA prevents translation of 
the entire RNA. The large T antigen in isolation is able to transform cells and 
maintain the transformed state (Kriegler, 1984), and in a similar manner to the 
small t antigen of polyomavirus, SV40 small t can enhance both immortalization 
and transformation stages (Bikel et al. 1987). Large T antigen is a multi-domain 
protein with an ATP dependent DNA helicase activity. This function however, is 
not thought to be essential for transform ation, as m utations affecting this 
function do not affect the ability of large T antigen to transform cells. Large T 
antigen can also bind to both p53 and RbllO (both tumour suppressor genes), a 
function which is thought to play an im portant role in transform ation. The 
large T antigen is reviewed by Rigby & Lane (1983) and Livingstone & Bradley 
(1987).
Papovaviruses BK and JC which are similar to SV40 and polyomavirus 
have been isolated from human patients. These viruses are associated with the 
development of neural tumours in rodents and monkeys (reviewed by Wyke, 
1991).
6The papillomaviruses, of which there are in excess of 62 types (DeVillers, 
1989; DeVillers, personal communication) are found in 90% of all cervical 
cancers tested world-wide, with types 16 and 18 being present in 70-80% of cases 
(zur Hausen, 1989; Knebel Doeberitz et al. 1990). The papillomaviruses have a 
complex transcription pattern, and unlike SV40 and polyomaviruses, the mRNAs 
are transcribed from only one strand of viral DNA. The host cells of 
papillomaviruses are restricted to squamous epithelial cells with productive 
infection occuring only in terminally differentiated epithelial cells (reviewed 
by Pfister, 1987). Until recently this has prevented advances in the study of 
papillomaviruses as no in vitro tissue culture system was available which 
allowed permissive replication of the virus. The development of new m odel 
systems such as the raft system (McCance et a l 1988) which allows epithelial 
cells to progress from an undifferentiated to a differentiated state in vitro has 
enabled papillomaviruses to be grown in culture. A mouse model system is also 
currently  being developed using the European harvest mouse (M icrom vs 
m inutus) and the harvest mouse papillomavirus. This mouse papillomavirus has 
been identified in a variety of benign and malignant tumours and the virus has 
been isolated, cloned and characterized. Attempts are being made to transmit the 
harvest mouse papillomavirus to inbred laboratory strains to enable th e  
development of a well defined mouse system for immunological studies of 
papillomavirus-induced disease (reviewed by Sundberg & O'Banion, 1989).
Papillomaviruses have long been associated with benign tum our 
production and infect a variety of animals and birds. The cottontail rabbit Shope 
papillomavirus (CRPV) was the first oncogenic papilloma tum our virus to be 
isolated and characterized (Shope & Hurst, 1933). Other known viruses resulting 
in malignant progression include bovine papillomavirus type 4, canine oral 
papillomavirus, colobus monkey papillomavirus types 1 and 2, equine venerial 
papillomavirus and rhesus monkey papillomavirus (Sundberg & O’Banion, 
1989).
Papillomaviruses are associated with a number of diseases in humans, but 
only a sub-set of the HPV types are involved with malignant progression. HPV 
types 6, 11, 31 and 35 are associated with condyloma accuminata and dysplasias 
such as low grade cervical intraepithelial neoplasia (CIN), ie CIN I and possibly 
type II. These types of papilloma viruses are considered to be "low risk" viruses,
7whereas HPV types 16, 18 and 33 are associated with high grade CIN, ie type III 
and carcinoma of the cervix (Tidy & Farrel, 1991) and are "high risk" viruses.
Squamous cervical carcinoma arises in the area of the uterine cervix 
named the transform ation zone. During the reproductive era  this region 
undergoes a differentiation process known as squamous m etaplasia which 
results in the formation of squamous epithelium. The transform ation zone is 
situated between the endocervix and ectocervix of the uterine cervix as 
illustrated in Figure 2. In the transformation zone a large number of cells are 
in the premitotic or mitotic phase and are therefore probably more susceptible 
to progression to a cancerous phenotype than quiescent epithelial cells. Such 
dysplasia can occur resulting in CIN which is graded into three precancerous 
stages I, II and III as described previously. In a normal healthy patient the 
squamous epithelium covering the vagina and ectocervix is composed of 4 
distinct levels: three - four layers of parabasal cells are separated from the 
basem ent membrane by a single layer of basal cells, below which is th e  
underlying stroma. Dysplasia of the parabasal cells can result in CIN I to III, 
with the latter being the most severe and corresponding to dysplasia of the 
entire epithelium  which is also known as carcinoma in situ. A cancerous 
progression from CIN III results in invasive carcinoma when the basement 
membrane is breached.
Identification of adenocarcinom as of the colum nar epithelium  has 
recently increased, with up to 10% of all cervical tumours being of this nature. 
It is possible that the increase in the development of such adenocarcinomas 
could be linked with the widespread use of oral contraceptives (Kitchener, 
personal communication)
HPV has been associated with malignancy in e p id e rm o d y s p la s ia  
verruciformis (EV) which is characterized by chronic widespread warts which 
often progress to squamous cell carcinoma (Orth et aL 1978). HPV has also been 
identified in flat condylomas of the uterine cervix which frequently occur in 
women who subsequently develop cervical carcinoma (Meisels & Fortin, 1976). 
However, it was not until 1983 that HPV-16 was shown to be in 61% of cervical 
tumours in a study using DNA-DNA hybridization techniques (Durst et al. 1983) 
and then cloned from a cervical tumour (Gissman et al. 1983). The percentage of 
samples positive for HPV varies from study to study however, 80-100% of
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FIGURE 2 : Anatom y o f  the uterine cervix
8invasive squamous cancers and most high grade CIN lesions have been found to 
be positive for HPV (McCance et a l  1985; Young et a l  1989). HPV-16, 18 and 31 
are most commonly isolated in CIN III and cervical cancer (Tidy & Farrel, 1991). 
Geographical d istribu tion  however may influence this as in the West of 
Scotland HPV-16 is the most prevalent, even in low grade CIN (Murdoch et al. 
1988). Head-to-tail dimeric episomes of HPV-16 DNA have been found in genital 
cancer biopsy samples (Kennedy et al. 1987) but HPV-16 DNA has also been 
found to be integrated in control tissues (Macnab et al. 1986; Murdoch et al.
1988). Cases of HPV infections were found to be very frequent when com pared 
with precancers and cancers suggesting that HPV alone may be insufficient to 
produce m alignant change (Macnab et aL 1986). This suggestion has been 
substantiated by studies which show that E6 and E7 of HPV can only immortalize 
cells (W oodworth et al. 1989). More recent studies have shown no clear 
correlation between the detection of HPV-16 either by DNA/DNA hybridization 
or by PCR and histological changes in the appearance of the cervix (Kitchener 
et al. 1991). and it has been stated that additional factors should be taken into 
consideration in future studies, eg HPV gene expression, tum our associated 
proteins and HPV cell targeting (Kitchener et a l  1991).
It has been shown that as a consequence of papillomavirus integration, 
the viral genes El and E2 are lost or disrupted (Schneider-Maunoury et al. 1987; 
Schwarz et al. 1987) and it is proposed that this results in the over-expression of 
E6 and E7 (the transforming genes of human papillomaviruses). E7 is the most 
abundant protein in HPV transform ed cells and is thought to play a role in 
transformation via an interaction with the p i  10 Rb protein. Comparison of the 
SV40 T antigen, the adenovirus E1A and papillomaviruses E7 coding sequences 
reveals homology in a region which is implicated in binding to p i  10 Rb 
suggesting a common mechanism of action of the different viral transforming 
proteins (Phelps et a l. 1988). In vitro E6 complexes with a cellular tum our 
suppressor protein p53, resulting in p53 degradation. This degradation is 
proposed to occur via the action of the ubiquitin-dependent protease system 
(Scheffner et al. 1990). Such degradation of a host negative regulator protein 
has been proposed as a novel mechanism of oncogenesis (Scheffner et al. 1990). 
Other nuclear oncoproteins such as N-myc, c-myc and c-fos have also been 
proposed to be degraded by the ATP-dependent ubiquitin system, enabling the
9cell to alter the levels of their regulatory proteins very quickly (Ciechanover et 
al, 1991).
Cofactors have been im plicated in m alignant progression following 
papillomavirus infection such as UV light, smoking and co-infection with other 
viruses for example, HSV or cytomegalovirus (discussed in Tidy & Farrel, 1991). 
In humans, UV irradiation from sunlight can act as a cofactor following HPV-5 
or 8 infection resulting in the progression of EV to malignant disease in up to 
50% of cases (Orth, 1986). In addition to human cytomegalovirus (HCMV), herpes 
simplex virus (HSV) (section le), has been implicated as a cofactor in anogenital 
cancer. Immunosuppression has also been suggested as a cofactor with HPV and 
cervical neoplasia (Jablonska et al. 1987). The immune response to warts in 
patients is reported to be primarily cell mediated immunity (CMI), and it is 
thought that the persistence of papillomavirus induced warts may be related to 
defects in CMI (Jablonska et al. 1987). It has also been shown that patients with 
persistent anogenital lesions induced by potentially oncogenic HPVs have 
reduced CMI, and the degree of CMI suppression is also related to the degree of 
malignancy of any resulting anogenital cancer (Malejczyk et al. 1987).
Papillomaviruses also infect and cause tumour development in cattle. This 
however appears to occur by quite a distinct mechanism from tum our 
developm ent in humans. In bovine papillomavirus type 1 the transforming 
gene is E5, whereas E6 and E7 are involved in transform ation by hum an 
papillomaviruses. HPV also differs significantly from BPV as E6 and E7 are 
found to integrate in the human tumours but no BPV DNA has been detected in 
transformed cells or in alimentary tumours associated with BPV. Consequently, 
BPV does not fulfil Koch’s postulates.
Cofactors are also thought to play a role in tumour development in cattle 
(Jarret et al. 1978). Although BPV-4 induces papillomatosis, quercetin found in 
bracken is thought to be required for progression to squamous cell carcinoma 
(Jarret et a l. 1978). In addition it is believed that BPV may alter the h o st's  
immune response and this too may play a role in tumour progression. These 
latter studies have been carried out in cattle where vaccinated cows can be 
shown to reject BPV induced tumours more quickly than unvaccinated cattle. 
However the differences between BPV and HPV and how they interact with
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their host calls into question the ability to produce HPV vaccines based on the 
BPV model.
1 (C) HEPADNOVIRUSES
The hepadnovirus family includes human hepatitis B virus and hepatitis 
viruses isolated from ducks, squirrels and woodchucks (Schodel et al. 1989). 
These small, enveloped, partially double stranded DNA viruses of approximately 
3Kb, (reviewed by Tiollais et a l . 1985) exhibit a tropism for hepatocytes. 
Hepatitis B is associated with prim ary hepatocellular carcinoma in humans, 
with chronic carriers of the virus being at least 200 times more likely to 
develop hepatocellular carcinoma than a healthy patient (Beasley et al. 1981). 
Hepatocellular carcinoma is one of the most common tumours world-wide but is 
most prevalent in certain regions of Asia and particularly Southern China and 
Taiwan (Beasley et al. 1981).
How hepatitis B could be involved in the progression of this cancer was 
unknown until very recently. Persistence of the virus with subsequent 
inflam m atory response was thought to be im portant. In addition it was 
previously postulated that virus, by integrating in the host genome may have 
filtered the expression of a cellular oncogene. However, the discovery that the 
viral transactivator, the product of the X gene (Twu & Schloemer, 1987) when 
expressed in transgenic mice, induced liver cancer in these animals (Kim et al. 
1991) directly implicated a viral gene product in neoplastic progression. Despite 
this, the persistent nature of hepatitis B infection is still thought to be the most 
important factor in the development of hepatocellular carcinoma.
Cofactors are also postulated to be im plicated with hepatocellular 
carcinoma, in particular a  mutagen aflatoxin B originating from Aspergillus 
flavo. The hotspot of mutations consistently seen in the cellular anti-oncogene 
p53 in cases of hepatocellular carcinoma in China suggests the action of a 
single mutagen. This has been postulated to be aflatoxin B (Bressac et al. 1991; 
Hsu et al. 1991).
1(d) ADENOVIRUSES
i
i  A denoviruses have a linear double stranded  DNA genome of
| approximately 36Kbp and are divided into 6 subgroups, A-F. Sub-group A (eg
I
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A dl2), induce tumours at a high frequency in laboratory rodents, and the 
viruses of sub-group B (eg Ad3 and Ad7) are weakly oncogenic. The left most 
11% of the genome comprises 2 regions, E1A and E1B which are involved in 
adenovirus transform ation (Gallimore et al. 1974; Graham et al. 1974). The 
integration of these viral genes into the genome of transform ed cells is 
required to maintain the transformed phenotype (Gallimore et al. 1985).
The products of the El A and E1B regions are multi-functional proteins 
which in addition to cell transformation, are involved with transcription, post- 
transcriptional events, DNA stability and replication (reviewed by Boulanger & 
Blair, 1991). Two of the E1A products are proposed to be involved in the 
establishment of immortalized cells in vitro , with E1B cooperating with E1A to 
induce transform ation (Houweling et a l. 1980; van der Elsen et a l. 1983). 
Transfection studies with El A indicate that transfected El A will immortalize 
cells, but this is 30 fold less efficient than immortalization as a consequence of 
adenovirus infection (Gallimore et al. 1985). Two of ElA's three conserved 
domains (Kimelman et al. 1985; Moran & Mathews, 1897) are claimed to be 
analogous to myc, acting as an immortalizing gene. The oncoproduct of E1B is 
proposed to act in a similar m anner to activated ras, cooperating to give 
complete and stable transformation (Bernards & van der Eb, 1984).
Cell transformation by adenoviruses may occur as a consequence of viral 
proteins interacting with host cell tumour suppressor gene products. This is 
supported by the fact that E1A in a similar m anner to E7 of papillomavirus and 
the large T antigen of SV40, binds to Rb, and E1B binds p53 (reviewed by 
Boulanger & Blair, 1991).
l i e )  HERPESVIRUSES
A num ber of viruses in the Herpesvirus family have been associated with 
m alignant disease. These include Marek's disease virus which causes 
lymphoblastosis in chickens (Kato & Hirai, 1985), herpes virus saimiri, isolated 
from  monkeys which induces T cell lymphomas in inoculated marmosets 
(Melendez et a l. 1970) and m alignant lymphom a in cotton-top m armosts 
inoculated with Epstein-Barr virus (Shope et al. 1973), ie animals other than the 
natural host. In humans, herpes simplex virus (HSV) has been associated with 
cervical carcinoma, as has hum an cytomegalovirus (HCMV) (Stevenson &
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Macnab, 1989), although the latter association is more controversial (reviewed 
by Macnab, 1987; Macnab & Kitchener, 1989). Nevertheless, HCMV has been 
detected in CIN tissue by DNA/DNA hybridization (Fletcher et al. 1986), and  
using a 20Kb fragment encoding the major IE gene HCMV has been cloned from 
CIN samples (Fletcher & Macnab, 1988). This fragment has been shown to 
transform  Helu cells (Geder et al. 1976) and human endothelial cells in culture 
(Smiley et al. 1988). In addition mouse cervices treated with UV irradiated HCMV 
developed carcinomas and had elevated levels of dysplasia (Heggie et al. 1986).
Epstein-Barr virus (EBV) is a th ird  hum an herpes virus which is 
associated with cancer. The association of EBV with a number of diseases is well 
established (zur Hausen et al. 1970; Dambaugh et al. 1986). These include EBV as 
the etiological agent of infectious mononucleosis and the association of EBV 
with endemic Burkitt lymphoma (BL), a B cell lymphoma, nasopharyngeal 
carcinoma (NPC), an epithelial cell tumour and secondary B cell proliferations 
in immunosuppressed individuals (zur Hausen et al. 1970; Dambaugh et al. 1986).
EBV has a large genome (176Kb) which is characteristic of a herpes virus 
and expresses a large number of viral gene products (reviewed by Farrel, 1989). 
The virus is a lymphotropic hum an herpes virus which establishes latent 
infection in B lymphocytes with little o r no virus production. However, in 
latently infected growth transformed B lymphoblastoid cell lines, EBV expresses 
6 Epstein Barr nuclear antigens (EBNA), (reviewed by Speck & S trom inger,
1989). These are EBNA 1, 2, 3A, 3B, 3C and leader protein LP. Three integral latent 
membrane proteins (LMP) are also expressed - 1, 2A and 2B (reviewed by Kieff & 
Leibowitz, 1990).
Expression patterns of EBNAs and LMPs can differ with EBV protein 
expression frequently restricted to EBNA-1A in Burkitt lymphoma tissue or 
newly established cell lines (Hitt et al. 1989; Allday et al. 1990). It has been 
reported  tha t only EBNA-1 transcripts could be found in NPC, whereas in 
latently infected B lymphocytes the six EBNAs were seen (Hitt et al. 1989). In 
transplant and B cell lymphomas from cotton tail tamarins Allday et al. (1990) 
found that the full range of antigens found in EBV immortalized lymphoblastoid 
cell lines were expressed. This is in contrast to BL and NPC, which were found 
only to express EBNA-1 (Allday et al. 1990). In NPC (but not in BL) LMP may also 
be expressed. Two possible explanations as to why only EBNA-1 is expressed
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under these circumstances have been proposed. Sample et al. (1991) suggest that 
although the EBNAs are generated by differential splicing, EBNA-1 may have a 
d ifferent transcription initiation site perm itting EBNA-1 transcrip tion  in 
isolation. Allday et aL (1990) suggest that CpG methylation of viral DNA may be 
responsible for the restricted pattern of EBNA expression.
Experim ents to investigate  the involvem ent of LMP in EBV 
transform ation have been reported where LMP was expressed from either of 
two heterologous promoters and introduced into two different established cell 
lines. This resulted in the cells being able to grow in an anchorage- 
independent manner (Wang et al. 1985; Baichwal & Sugden, 1988).
Burkitt1 s lymphoma (BL), a B cell tum our (Klein et a l. 1968), is an 
excellent example of the multistep development of cancer, as three factors are 
implicated in the disease (discussed by Rowe & Gregory, 1989). These are firstly 
the geographical and climatic features coincident with holoendemic m alaria 
resulting in the immuno-suppression of the host and activation of B cells (Lam 
et al. 1991). Secondly, characteristic chromosomal translocations involving 8q24 
are seen (Manolor & Manolora, 1972; Bernheim et al. 1981), with the common 
breakpoint at c-myc (Dalla-Farera et al. 1982; Neel et al. 1982). These result in a 
translocation near to the immunoglobulin loci (Rabbitts & Rabbitts, 1989) which 
was assumed to cause the deregulation of c-myc and has been confirmed by 
transfection studies (Lambardi et al. 1987) and transgenic experiments (Adams 
et al. 1985). The third factor is the virus EBV. Although there is little doubt that 
EBV is involved in BL, its mode of action has been unclear. Possible explanations 
include the action of viral proteins, as indicated previously, or the involvement 
of the cellular EBV receptor CR2, which as a result of viral attachment causes B 
cell proliferation (Gordon, 1989). The order of these three events in the 
developm ent of BL may be unclear, but EBV is firmly implicated, and 
furthermore, complies with Koch's postulates.
Herpes simplex virus type 2 (HSV-2) was originally associated with 
squamous cell carcinoma of the uterine cervix based on seroepidemiological 
evidence (Rawls et al. 1969; Nahmias et al. 1970; Royston & Aurelian, 1970). These 
studies dem onstrated a higher HSV antibody titre in cancer cases than in 
controls. Gilman et al. (1980) analyzed sera of such patients but grouped them 
according to param eters which could influence the presence or absence of 
HSV-1 or HSV-2 antibodies. This resulted in a significant difference in the
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am ount of two different HSV-2 antibodies seen in the case versus control 
samples. Although not all studies agree with the sero-epidemiological studies 
(Vonka et al. 1984b), it has been proposed that such negative results are due to 
the overmatching of case and control sera (Reeves et al. 1989). In addition, 
previously type specific testing could not be perform ed and it has been 
proposed tha t HSV-1 antibodies could neutralize HSV-2 antigens during 
investigations (discussed by Whitley, 1984).
Current epidemiological studies suggest that HSV is not the major cause of 
cervical cancer (DiPaolo et al. 1990), but may act in conjunction with human 
papillomaviruses to result in malignant disease. Indeed Gius & Laimins (1989) 
previously showed that Vmw 65 of HSV-1 can activate E7 of HPV type 18, and 
Hildesheim  et al (1991) showed a 8.8 increased relative risk fold in the 
development of cervical cancer if antibodies to both HSV-2 and HPV16 or 18 
were present in a patient.
Peto, (personal communication) in a comparative study of cerv ica l 
cancer patients in Greenland and Denmark, found that although both countries 
have similar incidences of HPV, patients in Greenland had a high incidence of 
cervical cancer which correlated to a high incidence of HSV antibodies. In 
Greenland 46% of patients who were positive for HPV developed cervical 
cancer, but in Denmark where HSV is less prevalent only 2% of HPV positive 
patient developed cervical cancer. It has recently been shown that sera o f 
patients with cancer of the cervix contain antibodies against a cellular 
polypeptide which is induced by HSV-2 infection (Macnab et al. in press). These 
studies suggest that HSV infection may play an important role as a cofactor in 
the development of cervical cancer or alternatively they may indicate that HSV 
induces some proteins also expressed in cervical cancer.
HSV-2 has also been shown to induce cervical neoplasia in the mouse 
model. The application of uv inactivated HSV-1 or HSV-2 virus (Wentz et al. 1981; 
Wentz et al. 1983b) and HSV-2 DNA (Anthony et al. 1989) induced cervical 
carcinoma in the mouse. Moreover, vaccination of such mice with HSV-1 
stopped the development of abnormal cervices and the progression to tumours, 
further suggesting a role for HSV in tumour formation (Wentz et al. 1983a). The 
possible mechanisms of action of HSV as a tumour virus will be discussed in 
more detail in Section 5 of this chapter.
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2. COOPERATION BETWEEN VIRAL ONCOGENES AND ACTIVATED PROTO- 
ONCOGENES TO IMMORTALIZE AND TRANSFORM CELLS
As indicated previously, many events in the life of a cell can contribute 
to what may finally become a cancerous phenotype. Up to 6 events have been 
proposed to be involved, each of which can cooperate to convert a normal cell to 
a transformed cell (Peto et al. 1975).
Oncogenes can be divided into two distinct groups - nuclear oncogenes 
and cytoplasmic oncogenes. These two groups are proposed to have different 
functions in cancerous progression. Nuclear oncogenes such as E1A, E7 and 
polyoma and SV40 large T antigens are proposed to act as "im m ortalizing 
oncogenes". This is because the expression of these oncoproteins does not alter 
cell morphology, the requirement for growth factors or anchorage dependence, 
but may immortalize cells. Cytoplasmic oncogenes conversely are able to induce 
cell shape changes, lead to anchorage independent growth and reduce growth 
factor requirements, but cannot immortalize cells. This is an over-simplified 
view as there are exceptions which can fit into both categories, however, this 
provides a basis for classification of oncogenes (reviewed by Marshall, 1989; 
Hunter, 1991).
Cooperation can occur between these nuclear and cytoplasmic oncogenes, 
with the first such evidence coming from  experiments carried out with 
combinations of polyomavirus oncogenes (Rassoulzadegan et al. 1982). The 
observation that specific combinations of oncogenes were able to cooperate led 
to the introduction of the concept that nuclear oncogenes cooperate best with 
cytoplasmic oncogenes (Weinberg, 1985).
A similar model for progression to a transformed phenotype is reviewed 
by Balmain & Brown (1988), where the mouse skin carcinoma model is used to 
define two distinct stages in malignant progression, initiation and promotion. 
Low levels of a non-carcinogenic agent are thought to initiate the cell, with 
m ultiple trea tm en ts of a tum our p rom oter resulting in the eventual 
morphologically transformed cell. Infection by a tumour virus as described in 
Section 1 either introduces a virus encoded oncogene or activates a cellular p- 
onc. In both situations the resultant oncogene(s) can then cooperate with other 
events which have already occurred or will occur at a later stage so
i
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contributing to a transformed phenotype. Such cellular and viral oncogenes 
can have a wide variety of functions, some of which are outlined in Table 3.
3. ONCOGENE ACTIVATION AT THE GENETIC LEVEL
Proto-oncogenes are cellular genes encoding proteins which under 
norm al circum stances are  functionally  im portan t in the growth a n d  
development of the cell. "Activation" of these proto-oncogenes to c-onc can 
resu lt in either an alteration in  oncogene regulation or a change i n 
oncoprotein function. Oncogene activation can occur either by infection with a 
tumour virus or by exposure to carcinogens or radiation. The mechanisms by 
which proto-oncogenes can be activated are outlined in Figure 3, and described 
in more detail below (reviewed by Paul, 1987).
TRANSDUCTION of a proto-oncogene occurs by retrovirus infection where the 
provirus becomes inserted into the host genome adjacent to the p-onc such that 
c o -tra n sc rip tio n  of the viral and  p-onc sequences occur. Genomic 
rearrangem ent can result in the virus incorporating the p-onc which is now 
under viral control and therefore constitutes an activated oncogene. As a 
consequence of the mechanism of viral replication, the proto-oncogene is more 
likely to become mutated which is seen in the case of v-src.
INSERTIONAL MUTAGENESIS can also occur following retrovirus infection. 
The long terminal repeats (LTRs) in the retrovirus are instrum ental for this 
form of oncogene activation as they contain transcription initiation sequences 
which can act on both the viral genes and the adjacent host genes. The LTRs 
also contain enhancer elements which can alter host gene expression (proto­
oncogene), without being directly adjacent to the gene.
CHROMOSOMAL REARRANGMENTS also result in alteration in the control of 
proto-oncogenes, but by a mechanism which involves translocation of the 
proto-oncogene to a site of expression such as the immunoglobulin gene. 
Chromosomal breaks are required to facilitate such oncogene activation.
POINT MUTATIONS may occur naturally in the host, but occur with higher 
incidence if the p-onc has become incorporated in a retrovirus because of the 
more error prone mode of replication of an RNA virus. Mutation hot-spots can 
be seen in oncogenes and tumour suppressor genes (see following section) such
TABLE 3 : POTENTIAL ONCOGENE FUNCTIONS
FUNCTION EXAMPLES
Growth factors v-sis (subunit of PDGF-2/B)
Protein tyrosine kinases (either transmembrane receptors for 
growth factors or cytoplasmic proteins 
associated with membranes)
Transmembrane receptors v-erb B (truncated epidermal growth
factor)
v-fms + v-ros
Peripheral membrane proteins v-abl, v-fes/fps, v-src, v-gfr + v-yes
Adenylate cyclase regulators Ha-ras, Ki-ras (functionally similar to G
proteins)
Protein serine/threonine 
kinases
v-m il/raf + v-mos
DNA binding activity c-myc
F I G U R E  3
MECHANISMS OF ONCOGENE ACTIVATION
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representing a normal proto-oncogene (a), and mechanisms by which 
proto-oncogene could be activated following tumour virus infection or 
to carcinogens (b-f). Reproduced from Paul, (1987).
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as ras and p53 (eg. in hepatocellular carcinoma) indicating that such regions of 
the proteins are functionally important.
GENE AMPLIFICATION is often seen in advanced and m ore aggressive 
tumours. The exact mechanism of such oncogene activation is uncertain but is 
thought to involve end-to-end replication of the gene followed by reinsertion.
4. PROTEIN-PROTEIN INACTIVATION OF TUMOUR SUPPRESSOR GENES
Discussion has so far centred on one class of oncogenes which result in 
tumourigenesis following activation. A second class of oncogenes exist called 
recessive oncogenes, anti-oncogenes or tum our suppressor genes, which as a 
consequence of inactivation, result in tumourigenesis (reviewed by Marshall, 
1991). I shall adopt the term tumour suppressor gene as this appears to be 
currently more widely used in the literature.
DNA tum our virus oncoproteins frequently  in teract with host cell 
proteins, some of which are now known to be tum our suppressor genes. 
Interaction with p53 and the retinoblastoma susceptibility gene product (Rb) 
are the two best documented cases and will be discussed in this section.
The tumour suppressor p53 is thought to either regulate the assembly or 
function of the DNA replication-initiation complex (Braithwaite et al. 1987, 
Gannon & Lane, 1987) or alternatively p53 may act as a transactivator of gene 
transcription, either promoting or repressing mRNA synthesis (Raycroft et al. 
1990; Fields & Jang, 1990).
Viral oncogenes complex with p53 (Levine, 1990; Levine et al. 1991) 
including SV40 T antigen, adenovirus Elb-55K and HPV E6. The formation of 
such viral oncogene-tumour suppressor protein complexes may alter either the 
function of p53 or the viral oncogene by protein-protein interactions. In SV40, 
T antigen mutants which fail to bind p53 also fail to transform cells (Peden et al.
1989). Complexing of p53 to the T antigen blocks the DNA polymerase binding to 
T antigen (Gannon & Lane, 1987) and prevents the initiation and replication of 
SV40 DNA (Braithwaite et al. 1987, Struzbecher et al. 1988, Wang et aL 1989). In 
HPV, only with those viruses which are associated with a high risk o f  
anogenital cancers, has it been shown that E6 binds to p53 (Wemess et al. 1990) 
correlating the ability of the virus proteins to complex with p53 with their 
association with cancer. The complexing of E6 to p53 is proposed to stimulate the
18
degradation of p53 by a ubiquitin dependent pro tease system (Scheffner et al.
1990). In Ad5 and Ad7 transform ed cells p53 is complexed with E1B p55 
(discussed by Boulanger & Blair, 1991), however, in Adl2 transformed cells, no 
stable E1B p55/p53 complexes can be detected (Zantema et al. 1985; Mak et al. 
1988; Blair-Zajdel & Blair, 1988). The reason for this is uncertain as the E1B 
sequences of Ad5 and 12 are identical (reviewed by Boulanger & Blair, 1991).
The Rb protein is thought to inhibit proliferation within the cell with 
control of this function being determined by the level of Rb phosphorylation 
(Cooper & Whyte, 1989). It is proposed that the phosphorylation status of Rb 
alters its ability to form tight nuclear interactions which are essential for 
growth regulation and that the binding of viral oncoproteins to Rb polypeptide 
pre-em pt this interaction (Mittnacht & Weinberg, 1991). SV40 and polyoma 
large T antigens, adenovirus type 5 E1A and HPV types 16 and 18 E7, all bind Rb 
(De Caprio et al. 1988; Dyson et al. 1989a, 1990; Whyte et al. 1988).
HSV has also been shown to in teract with both p53 and Rb. This 
interaction is seen to colocalize with HSV replication complexes in infected cells 
(Wilcock & Lane, 1991). The relevance of this observation is as yet 
undetermined and no HSV coded proteins have been detected binding to p53 or 
Rb (Lane personal communication).
In addition to p53 and Rb, other cellular proteins are found to interact 
with viral oncogenes. One such polypeptide is a 107Kd protein (Whyte et a l.
1989) which may be related to Rb, but is clearly distinct (Dyson et al. 1989b). 
This polypeptide interacts with the large T antigens of both SV40 and JC virus in 
addition to E1A of adenovirus (Dyson et aL 1989c). The functions of this and 
other such proteins are as yet unknown.
5. HSV TRANSFORMATION : POSSIBLE MECHANISMS
Both HSV-1 and HSV-2 have been shown to induce m orphological 
transformation of rodent embryo cells (Duff & Rapp, 1971, 1973; Darai & Munk, 
1973,1976; Macnab, 1974,1975,1979; Wilkie et al. 1974; Boyd et al. 1975; Cameron, 
1982). One region in HSV-1 capable of inducing morphological transformation, 
called the morphological transforming region MTRI, maps within the Bgl Hi 
fragment (0.311-0.415mu), (Camacho & Spear, 1978; Reyes et al. 1979). This is 
adjacent to the two transforming fragments of HSV-2, MTRII, mapping in the
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Bgl Iln fragment (0.58-0.62mu), (Reyes et a l. 1979; Macnab & McDougall, 1980; 
Galloway & McDougall, 1981; Cameron et al. 1985), and MTRIII, in the Bgl lie 
fragment of HSV-2 (0.54-0.58mu), (Jariwalla et a l  1983). The MTRII activity was 
later localized to 737bp in the left hand region of Bgl Iln (Galloway et al. 1984). 
The positions of these regions are outlined in Figure 4. In a model system in 
mice, HSV has also been shown to induce u terine  cancer, with p rio r 
immunization of these mice with HSV preventing the development of tumours 
(Wentz et al. 1983b).
HSV-2 DNA sequences have been detected in a small proportion (10%) of 
cervical carcinomas (Galloway & McDougall, 1983; Park et al. 1983; Macnab et al. 
1985b, 1986; Prakash et a l. 1985). However, despite extensive studies no 
transforming DNA sequences of HSV are found to be retained at the level of one 
copy in the transformed cell (Cameron et al. 1985) nor has any HSV encoded 
transforming protein been found to be essential for the m aintenance of the 
transformed state (reviewed by Macnab, 1987). This has led to the proposal that 
HSV induced transformation occurs via a "hit and run" mechanism (Galloway & 
McDougall, 1983). Many different possibilities exist as to how HSV could 
transform  cells via a "hit and run" mechanism, some of which are b riefly  
described.
(1) The DNA stem loop structure in the BglII n fragm ent has been 
proposed to act as either an enhancer, a mutagen or to activate a cellular 
oncogene (Gallowav et al. 1984).
(2) Ribonucleotide reductase (RR) has been speculated to be involved in 
transformation by Huszar & Bacchetti (1983) as this is encoded by the region of 
the virus which can transform cells (Reyes et al. 1979; Jariwalla et al. 1980; 
Galloway & McDougall, 1981; Dutia, 1983). Prior to this RR had previously been 
suggested to be involved in transform ation by destabilizing dNTP pools in 
infected cells resulting in mutagenesis (Jamieson & Bjursell, 1976). Recent 
experiments using transient gene expression of RR in mammalian cells did not 
increase mutagenesis in cells, nor did its expression in transgenic mice affect 
the mice. However, in both cases inefficiencies of the experimental systems 
used could not be ruled out as the cause of the negative results (Clarke, 1990). 
Further experiments have shown that MTRIII which encodes the N terminal 
half of the large RR (amino acids 71-502) induces neoplastic transformation of
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FIGURE 4 : Diagrammatic representation of the HSV genome and the 
positions (in map units) of the morphological transformation regions (MTR) 
of HSV- 2
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immortalized cell lines. By transient expression of this region a distinct protein 
domain (of 65Kd) was observed in these constructs as was a protein kinase 
autophosphorylation potential (Ali et a l. 1991). However, it remains to be 
established whether this protein kinase activity is necessary or sufficient for 
MTRIII induced transformation.
(3) HSV may transform cells by acting as a biological carcinogen or as a 
mutagen (Pilon et al. 1985) by inducing gene amplification, Jones et al. (1986) 
and Jariwalla et al. (1986) proposed that the MTRs of HSV contain repetitive 
sequences which could be implicated in gene rearrangem ent or activation. It 
was then later reported that MTRIII could in fact function as a complex 
promoter (Jones, 1989). HSV infection has also been demonstrated to inhibit host 
cell DNA methylation (Macnab et al. 1988), a mechanism which may also alter 
host gene expression resulting in an important step in transformation by HSV.
(4) HSV has also been shown to activate endogenous C-type viruses which 
could act as co-carcinogens. In addition to this HSV has also been proposed to act 
as a co-carcinogen with human papilloma viruses (Di Paolo et al. 1990), acting 
as one of the multiple steps required to result in a transformed phenotype.
(5) Finally HSV may transform cells by a mechanism which results in the 
altered expression of host cell polypeptides by cellular gene activation. A series 
of experiments (Macnab, 1974, 1975, 1979; Buultjens & Macnab 1981) was 
previously thought to indicate that HSV functions were being expressed in the 
HSV transformed cell, however Cameron et al. (1985) reported that no virus DNA 
at the level of 0.01 copies/cell, nor functional RR encoded protein was expressed 
in HSV transform ed cells when tested by Southern blot analysis. Further 
analysis with a range of antibodies against HSV-coded proteins, showed no HSV 
polypeptides could be consistently detected in HSV transformed cells (Macnab,
1987). These polypeptides previously thought to be virus encoded, were found to 
be cellular in origin and found in all virus transformed and immortalized cells 
tested (Macnab et al. 1985). This was the first report of specific cellular gene 
products which were induced by HSV infection and where the expression of 
these products continued in the transformed cell.
Filion & Suh (personal communication, 11th International Herpesvirus 
Workshop; Filion et a l . 1988) have identified cDNAs which are increased 
following HSV-2 transform ation. Several groups have reported  a similar
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increased expression of cellular genes following HSV-2 infection (LaThangue et 
al, 1984; Kemp et al. 1986a, Kemp et al. 1986b; Patel et al. 1986; LaThangue & 
Latchman 1988; Kemp & Latchman, 1988b; Jang et a l. 1991). The stimulation of 
mRNA levels of the estrogen receptor by HSV infection has been observed 
(Offord et al. 1989) and Goswami (1987) has reported transcriptional induction of 
c-fos in the host cell following HSV-2 infection. One cellular polypeptide, U90, 
increased by HSV infection and also present in transform ed cells will b e  
investigated in the results section of this thesis.
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SECTION 2 : HERPES SIMPLEX VIRUS
1. CLASSIFICATION OF HERPESVIRUSES
The Herpesviridae is a large family of double stranded DNA viruses 
consisting of over eighty members which lytically and /o r latently infect a wide 
range of hosts spanning many species (reviewed by Roizman, 1982). These 
viruses have been identified by means of base composition, genome structure, 
immunological cross reactivity and size (Nahmias, 1972).
The herpesvirus particle which can range from 150-200nm in diameter 
has four distinct morphological features which characterize the virus (Fenner, 
1976). These features are detailed below:
The core was previously reported  to be an electron dense fibrillar 
spindle surrounded by genomic DNA (Epstein, 1962). Furlong et al. (1972) 
proposed that the DNA was wound in a toroidal m anner around a cylindrical 
structure and Schrag et al. (1989) hypothesized that the viral DNA was contained 
within an inner icosahedral shell. It has recently been established that the 
viral DNA is not in fact wound around any structure but is packaged in a similar 
manner to phage DNA (Booy et al. 1991).
The capsid is composed of 162 capsomers (Wildy et al. 1960), 150 of 
which are hexavalent and 12 are pentavalent capsomers (Schrag et aL 1989). 
These capsomers which are roughly cylindrical create a 5nm thick shell around 
the core.
The tegum ent which surrounds the capsid is described as a layer of 
amorphous material lying between the capsid and the viral membrane (Morgan 
et al. 1968; Schwartz & Roizman, 1969; Roizman & Furlong, 1974).
The viral m em brane is derived from the host cell's nuclear membrane 
(Wildy et al. 1960) as the virus buds from the cell, but contains numerous viral 
encoded glycoprotein spikes (Morgan et al. 1959; Wildy et al. 1960; Asher et al. 
1969; Spear & Roizman, 1972).
The Herpesviridae can be further divided into three groups based on the 
biological properties of cytopathology, host range, the reproductive cycle and 
the characteristics of the latent infection of the virus (Mathews, 1982; Roizman, 
1982).
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A lpha h e r p e s v i r u s e s  in c lu d e  HSV-1, HSV-2, VZV and  
pseudorabiesvirus. Members of this group can have either a narrow or a wide 
host range in tissue culture and a replicative cycle of less than 24 hours. 
Infection results in cell destruction, however, latent infection is frequently 
established in neural cells.
Beta herpesviruses include HCMV. These viruses have a narrow host 
range in tissue culture, a long replicative cycle and slow lytic infection 
resulting in the enlargement of infected cells (called cytom egalia). These 
viruses can establish latent infections bu t usually only in kidney cells, 
lymphoreticular cells and secretory glands.
Gamma herpesv iruses include EBV. These also have a limited host 
range with replication only occurring in the host T or B-lymphocytes. Such 
viruses have a variable replicative cycle and often result in persistent 
infection (as opposed to lytic infection) in lymphoid tissue.
2. PATHOGENICITY OF HUMAN HERPESVIRUSES
Herpesvirus infections can occur as a result of a primary infection or by 
reactivation of a latent infection. HSV-1 and HSV-2 infection can result in a 
num ber of clinical syndromes (reviewed by Nahmias et al. 1991). Mild to 
m oderately severe disease includes urogenital infection in both males and 
females, predominantly, but not exclusively by HSV-2. However, studies show a 
50% incidence of HSV-1 in Glasgow and 80% HSV-1 in Edinburgh (M acnab, 
personal communication). Gingivostomatitis of the mouth, herpes labialis of the 
lip, keratitis and conjunctivitis of the cornea an d /o r the conjunctiva are also 
predom inantly a consequence of HSV-1 infections. Latent infection by HSV-1 
usually occurs in the trigeminal or thoracic ganglia whereas HSV-2 latent 
infection usually occurs in the sacral ganglia.
Severe to fatal d iseases caused  by HSV in fec tio n  inc lude  
m eningoencephalitis of the b rain  and the spinal cord, and localized or 
generalized infection of the skin, eyes, brain or visceral organs in newborn 
children. HSV-2 infection is also associated with cervical cancer, where it is 
thought to act as a cofactor (discussed in section A le).
Few people world-wide escape infection by HCMV, norm ally a self- 
lim iting  disease. Sym ptom s a re  genera lly  only a p p a re n t in the
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immunodeficient, resulting in cytomegalo mononucleosis, post transfusion and 
post transplantation syndromes. In neonates infection can be very serious 
resulting in severe neurological deficiencies. Like HSV-2, HCMV has also been 
associated with malignant disease (section le).
VZV manifests itself as two diseases, the first varicella (or chickenpox), 
occurs at primary infection, resulting in fever and a characteristic rash. The 
second, zoster (or shingles), is a consequence of reactivation of virus from the 
dorsal root ganglia or the cranial nerve resulting in painful unilateral vesicles.
EBV infection is the cause of infectious mononucleosis - an acute febrile 
illness involving children and young adults causing lymphadenopathy and sore 
throats. EBV is also associated with neoplastic disease as outlined in section le. 
The more recently discovered human herpes virus type 6 (HHV- 6) which was 
isolated from T cells in vitro (Salahuddin et al. 1986) is thought to be the 
causative agent of exanthem  subitum , a p revalen t childhood disease 
characterized by high fever and a rash (Yamanishi et al. 1988). HHV-6 has been 
associated with AIDS (Downing et al. 1987; Tedder et a l. 1987; Agut et al. 1988; 
Becker et al. 1988; Lopez et al. 1988; Pietrobani et al. 1988) but HHV-6 has also 
been isolated from the saliva of normal adults (Harnett et al. 1990; Levy et al.
1990). Infection with HHV-6 appears to occur early in childhood as sero 
conversion rates approach 100% in the first few years of life (HHV-6 reviewed 
by Cone, 1991).
A seventh herpes virus has now been isolated from CD4+ T cells (Frenkel 
et al. 1990). Human herpes virus type 7 (HHV-7) is immunologically distinct 
from HHV-6 (Wyatt et al. 1991). Unlike HHV-6 and other herpesviruses sero­
conversion occurs later in childhood but no disease as yet has been associated 
with HHV-7.
3. THE GENOMES OF HUMAN HERPESVIRUSES
The genomes of human herpesviruses vary in size, base composition and 
the pattern of repeated DNA sequences (Honess, 1984) as illustrated in Figure 5. 
McGeoch et al. (1988) published the complete HSV-1 DNA sequence showing 
152r260 nucleotides on each strand, with one overhanging nucleotide at each 
end and a G+C base composition of 68.3%. The genome is composed of two unique 
regions, Ul and Us each flanked at either end by oppositely orientated repeat
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elements termed Rl or Rs. Relative inversion of these unique regions results in 
the production of four isomers which can be isolated in equimolar amounts 
from viral DNA preparations (reviewed by McGeoch, 1989). Directly repeated 
sequences of 400bp, called the & sequences exist at the termini of the genome 
and at least one copy of this sequence is found in inverted orientation at the 
junctions of the two unique regions. The genomes of HSV type 1 and type 2 are 
reported to be co-linear as shown by intertypic recombinant studies carried out 
by Davison & Wilkie (1983). Sequencing of the HSV-2 genome is incomplete as 
yet, however no evidence suggesting that HSV-1 and HSV-2 are not co-linear 
has been found (McGeoch, personal communication). The open reading frames 
corresponding to the proposed HSV-1 genes are shown in Figure 6.
The genomes of VZV and HSV are very similar, however VZV is unique in 
herpesviruses so far in that isolated VZV DNA has unequal proportions of 
isomers present (Davison, 1984). HCMV is larger than both VZV and HSV, bu t 
again is very similar in genomic structure. HCMV contains an "a" sequence 
similar to HSV and also exists in four isomeric forms present in equ im olar 
amounts (Weststrate et al. 1983).
EBV was the first herpesvirus to be sequenced (Baer et al. 1984) and has a 
marked difference in its repeat elements compared to other herpesviruses. The 
EBV genome carries an internal set of large directly repeated elements which 
together with the terminal repeats can be present in varying copy numbers.
Preliminary investigations of HHV-6 suggests it has a genome of 166Kbp 
consisting of a single unique region flanked by direct repeats, closely related to 
HCMV (Lawrence et al. 1990). The structure of HHV-7 has yet to be determined.
4 . HSV LYTIC INFECTION : AN OVERVIEW
This section will briefly outline herpes virus lytic infection with emphasis on 
HSV-1.
4.(a) ADSORPTION AND PENETRATION
HSV adsorption to the host cell m em brane is proposed to occur via 
heparin  sulphate on the host cell surface and is m ediated via v i r a l  
glycoproteins (WuDunn & Spear, 1989) in particular gB, gC, gD and gH (Kuhn et 
al, 1990; Forrester et al. 1991). Another putative receptor has been proposed to
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be essential as a portal of cellular entry for HSV-1, the basic fibroblast growth 
factor (bFGF) receptor (Baird et al 1990; Kanner et al 1990). However, this has 
been questioned (Herold et al. 1991). Recently Muggeridge et al. (1992) have 
demonstrated that HSV infection can occur without the involvement of the bFGF 
receptor. However Muggeridge et al. (1992), state that HSV binding via bFGF 
receptor cannot be excluded as Sears et al. (1991) have provided evidence to 
support the existence of two independent receptor pathways on the one cell 
type. For this reason it may still be possible that the bFGF receptor plays a role 
in HSV entry in certain cell types. Following adsorption, the viral envelope 
fuses with the host cell plasma membrane (Morgan, 1968) releasing the viral 
capsid into the cell cytoplasm (Fuller & Spear, 1985), which then delivers the 
viral DNA to the host cell nucleus (Knipe et al. 1981; Batterson & Roizman, 1981).
4(b). VIRAL GENE EXPRESSION
Three groups of viral polypeptides exist in herpes simplex virus which 
are coordinately regulated and sequentially expressed. These are the immediate 
early (IE) polypeptides, which are mainly viral regulatory functions and 
detected one hour post infection, early (E) polypeptides, which are implicated in 
viral replication and maximally synthesized between 2-7 hours post infection, 
and finally the late (L) polypeptides which are first detected after the onset of 
viral replication a t around 2 hours post infection and are mainly viral 
structural polypeptides (Honess & Roizman, 1974). The L genes can be divided 
into two classes - true late and leaky late genes, with the distinction that only 
the true late genes are completely inhibited in the absence of viral replication.
The IE genes are transcribed by an unmodified host cell RNA polymerase, 
and are essential to enable the transition from IE to E gene expression (Watson 
& Clements, 1980). Both the IE and E polypeptides are required for L gene 
expression.
The viral polypeptide Vmw65, an essential structural polypeptide (Ace £t 
al, 1988) which is a component of the tegum ent (Campbell et al. 1984) is 
responsible for the induction of IE gene expression by binding to TAATGARAT 
regu la to ry  sequences in the upstream  contro l regions of IE genes. 
Transactivation by Vmw65 occurs independently of de novo protein synthesis 
(Post et al. 1981) with Vmw65 interacting with the viral DNA via an IE complex
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on TAATGARAT in the presence of host cell factors (McKnight et al. 1987; O’Hare 
& Goding, 1988; Preston et aL 1988).
A cellular factor named Oct-1 has been shown to be required for complex 
formation (O’Hare & Goding, 1988; Gerster & Roeder, 1988) and an additional 
cellular factor has been proposed to in teract with the GARAT region of 
TAATGARAT (Gerster & Roeder, 1988; Kristie et al. 1989). The formation of this IE 
complex is essential but not sufficient for transactivation by Vmw65. In addition 
to the above a GA element and two GC boxes (SP1 binding sites) are also proposed 
to be involved with im m ediate early gene induction by functioning as 
enhancer elements.
Following IE po lypeptide  synthesis the IE gene expression is 
autoregulated by Vmwl75, a phosphorylated IE polypeptide, which is purified as 
a hom odim er and found to localize in the nucleus (Pereira et al. 1977). 
Functional Vmwl75 is required for early gene expression, for IE gene 
repression (Watson & Clements, 1980; Dixon & Schaffer, 1980) and is also thought 
to possess a distinct function necessary for late gene expression (DeLuca et al.
1984). Most of the IE polypeptides bind DNA in vitro (Hay & Hay, 1980), but 
Vmwl75 specifically binds DNA with the element ATCGTC being considered to be 
the most important motif (Beard et aL 1986; Faber & Wilcox, 1986, 1988; Muller, 
1987; Roberts et a i 1988; Kristie & Roizman, 1986a, 1986b). Vmwl75 however, will 
also bind DNA sequences lacking the above element (Kristie & Roizman, 1986b; 
Micheal et al. 1988).
M utants in Vmwl75 fail to synthesize DNA or produce early or late 
polypeptides (Benyesh-Melnick et al. 1974; Marsden et al. 1976; Watson & 
Clements, 1978, 1980; Preston, 1979; Dixon & Schaffer, 1980) and overproduce IE 
transcripts (Preston, 1979; Dixon & Schaffer, 1980). Vmwl75, which binds its 
own prom oter resulting in repression was previously thought to act similarly 
on the VmwllO prom oter (O'Hare & Hayward, 1985). Recent work however, 
indicates that under normal HSV infection Vmwl75 has no repressive effect on 
Vm wllO gene expression (Everett & Orr, 1991). Figure 7 illustrates the 
functionally im portant regions of Vmwl75 with regards to tran scrip tio n a l 
transactivation and repression as reported by Paterson & Everett, (1988a, 1988b) 
and Deluca & Schaffer (1988).
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T he Vmw 175 se q u e n c e  is divided into structural dom ains 1-5 (M cG eoch et al.
1986). The functional dom ains and their potential roles are illustrated above (DeLuca 
& Schaffer, 1988; Paterson & Everett, 1988a, 1988b).
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Vmwl75 acts as a transactivator of E gene expression with the resulting E 
polypeptides acting in conjunction with the IE polypeptides perm itting viral 
gene replication to occur. This is then followed by L gene expression. Viral 
replication has been proposed to alleviate some restraint which prevents L 
viral gene expression such as altering viral DNA conformation (Workman et al.
1988).
4(c). HSV Replication
On entering the host cell nucleus it is proposed that the viral genome 
circularizes and that viral replication occurs via a rolling circle mechanism 
generating linear concatemers of repeating viral genomes (Jacob et al. 1979; 
reviewed by Chalberg & Kelly, 1989; Rabkin & Hanlon, 1990). Other possibilities 
have also been proposed including Cairns type replication, (where the 
separation of the daughter molecules is slow), or replication followed by the 
rapid joining of daughter molecules by recombination (reviewed by Chalberg & 
Kelly, 1989). Seven HSV genes are required for origin dependent DNA 
replication, although other additional genes are likely to be involved, mutations 
in these genes can be complemented by the dividing host cell. Some of these 
polypeptides have been characterized including the viral DNA polymerase, 
(distinguishable from the host cell polymerase), single stranded DNA binding 
protein, double stranded DNA binding protein, origin binding protein and 
helicase/primase activity.
4(d). VIRION ASSEMBLY AND RELEASE
Following replication newly synthesized v iral DNA c o n c a te m e rs  
accumulate in the host cell nucleus where site specific cleavage of the DNA 
occurs. A cleavage signal is located within the a sequence (Vlazny & Frenkel, 
1981; Mocarski & Roizman, 1982; Stow & McMonagle, 1983; Spaete & Mocarski,
1985), in addition to two cis-acting maturation and packaging signals (Varmuza 
& Smiley, 1985; Deiss et al. 1986). The cleavage and packaging of the viral DNA 
has been proposed to be linked (Deiss et al. 1986), and together with capsid 
formation, is dependent on several viral gene products (Matz et al. 1983; Preston 
et al. 1983; Sacks & Schaffer, 1987; Sherman & Bachenheimer, 1987, 1988; Rixon 
et al. 1988; Addison et al. 1990).
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Site specific cleavage of viral DNA generates unit length genomic 
molecules and packaging of viral DNA into virions takes place. Nucleocapsids 
containing an approximate genome length are then enveloped at the inner 
lamella of the nuclear membrane and transported to the cytoplasm (Roizman & 
Furlong, 1974; Vlanzy et al. 1982; Stow et al. 1986a). The mature virions are 
proposed to leave the cell via the golgi apparatus in a similar m anner to 
secreted soluble proteins (Johnson & Spear, 1982).
5. HSV LATENCY
Latency involves the maintenance of the viral genome in specific tissues 
without evidence of replication, virus gene expression or clinical disease while 
retaining the capacity to reactivate and yield infectious progeny (Stevens & 
Cook, 1971; McLennan & Darby, 1980). HSV like other herpesviruses has this 
ability and was first postulated to establish latent infections in nervous tissue in 
1929 by Goodpasture. It is now widely documented that HSV establishes latent 
infections; HSV-1 primarily in the sensory dorsal root, trigeminal and thoracic 
ganglia and HSV-2 primarily in the sacral ganglia (Klein, 1982; Knox et a l 1982; 
Hill, 1985). In addition virus can be harboured latently at the site of infection 
(Hill et al. 1980; Al-Saadi et al. 1983; Cook et al. 1987), but the significance of this 
is unclear.
Two different models have been used to further the understanding of HSV 
latency. These are the animal models (using mice, guinea pigs and rabbits) and 
tissue culture models which have lead to the elucidation of the following points. 
This work has been reviewed elsewhere (Roizman & Sears, 1987; Stevens, 1989) 
and therefore will only be briefly discussed.
Latency can be established within 24 hours of infection (Steiner et al.
1990), and is thought to spread by retrograde axonal transport within the axon 
(Cook & Stevens, 1973). In the latent state the viral DNA is thought to be endless 
(Rock & Fraser, 1983; Efstathio e t al. 1986) primarily in an extrachromosomal 
circularized or concatemerized form (Mellerick & Fraser, 1987). The viral DNA is 
present at between 0.1-0.01 copies per neuron (Harris & Preston, 1991) and is 
associated with nucleosomes in a chrom atin structure (Deshmane & Fraser,
1989).
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Viral replication does not appear to be necessary for the establishment of 
latency in the mouse eye model (Steiner et al. 1990) but is claimed to be required 
at the periphery (Fields et al. 1979) with very little or no viral gene expression 
being required for the establishment of latency (Russell et al. 1987a; Steiner et 
al, 1990: Wilcox et al. 1990).
In the latently infected cell two major viral gene transcripts termed LAT 
of around 2.2Kb and 1.5Kb are seen (Spivack & Fraser, 1987; Wagner et al. 1988), 
however a longer 8.3Kb transcript has also been detected (Wagner et al. 1988). 
Virus mutants lacking these LATs can establish and maintain latent infections 
normally and reactivate (Lieb et al. 1989; Sedarati et al. 1989; Steiner et al. 1989; 
Stevens, 1989) suggesting that the LATs are not essential for these functions. 
However, in some studies LAT mutants reactivate with normal kinetics (Block et 
al. 1990), but in others the frequency and reactivation is delayed (Leib et al. 
1989; Trousdale et al. 1991). The significance of LATs is therefore still not clear.
6. HSV NEUROVIRULENCE
The neurovirulent nature of HSV has been investigated using a range of 
HSV mutants and variants. This has allowed the identification of regions of the 
HSV genome involved with neurovirulence, and subsequently the gene and its 
product implicated with neurovirulence.
In attem pts to identify the viral gene function  associated  with 
neurovirulence Efstathiou et al (1989) showed that a thymidine kinase negative 
variant of HSV which failed to replicate in the mouse neural tissue established 
latency poorly and reactivated only following superinfection with wt virus. 
Using HSV-1 ts mutants Cameron et al. (1988) implicated both sub-units of the 
viral ribonucleotide reductase in neuro-pathogenicity. A further HSV-1 variant 
with a mutation in Vmw65, a transactivating factor, has its ability to grow in 
tissue culture severely im paired and is av iru len t following in tracran ial 
inoculation (Ace et al. 1989). In contrast however, this Vmw 65 m utant in the 
mouse trigeminal ganglia system can establish latency and will reactivate as 
normal following explantation (Steiner et al. 1990).
A neurovirulent locus has now been isolated by Brown and co-workers 
using the variant JH2604 of HSV-2 strain HG52 (Harland & Brown, 1985). This 
virus has an LD5 0  of >10^pfu/mouse (Taha et al. 1988) and is mutated in the long 
repeat region (TRl/IRl) of the genome (Taha et al. 1989a). JH2604 has a 1488bp 
deletion in the TRl and IRl regions (Taha et al. 1989b) and fails to replicate in 
the mouse brain (Taha et al. 1990), indicating that this region has a specific role 
in neural replication of HSV.
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The deletion of the homologous region in HSV-1 has also recently been 
shown to abolish neurovirulence (Chou et aL 1990; MacLean et al. 1991). A gene 
encoding a 43K polypeptide has been identified within this region and 
designated ICP34.5 (Ackermann et al. 1986; Chou & Roizman, 1986, 1990). This is 
located in the inverted repeats flanking the long unique region and is 
therefore present at two copies/genome.
Using recom binant viruses encoding ICP34.5 Chou et al (1990), have 
shown that the ICP34.5 gene product extends the host range of the virus and 
enables it to replicate and destroy brain cells. This gene product in both HSV 
type 1 and 2 has been analyzed by McGeoch & Barnett (1991), who have found 
the ICP34.5 equivalent in the two viruses to be 83% identical at the residue level, 
and  have identified a polypeptide in mouse, MyD116, which contains a 
homologue of a 63 residue domain present in the viral polypeptide. This 
polypeptide has been suggested to act as a transcription factor or modifier of 
cytoskeletal structure (McGeoch & Barnett, 1991).
SECTION 3. VIRUS/HOST CELL INTERACTIONS
1. HOST IMMUNOLOGICAL RESPONSE
HSV infection induces both the acquired immunity and innate immunity 
of the host (reviewed by Nash & Wildy, 1983). Acquired immunity is specific for 
a given antigen and consists of the T and B cell m ediated responses. Innate 
im m unity is non-specific and is com prised of a variety of factors, eg  
macrophages, natural killer (NK) cells and interferon (reviewed by Benjamini 
& Leskowitz, 1991). The two arms of the immune system act to give maximum 
immunological protection of the host, with the outcome of HSV infection being 
a result of complex interactions between both acquired and innate immunity.
The first line of defence in the host following primary HSV infection is 
generally provided by the innate immune response. However, in animal models 
the relative contribution of the two arms can vary depending on the route of 
inoculation.
Viral invasion of the host stimulates cells of the monocyte/macrophage 
cell lineage can act in a non-specific manner, engulfing and digesting virus- 
an action which may prevent viral replication (discussed by Whitley, 1990).
Natural killer cells induced by HSV infection have been shown to play an 
im portant role in resistance to HSV infection (Lopez, 1981; Rager-Zisman et al. 
1987). The NK cells recognise the Fc domain of antibodies and components of the 
complement system which are bound to virus proteins. The NK cells then 
destroy antibody or complement coated virus-infected cells by secretion of a 
variety of cytokines such as interleukin 1, interleukin 2, interferon and B cell 
growth factor, rather than by phagocytosis.
Experiments by Habu et al. (1984) and Bukowski & Welsh, (1986) showed 
that resistance to HSV-1 can correlate with early interferon production. This 
work agrees with that of Gresser et al (1976), where the neutralization of 
interferon with anti-interferon antiserum  in vivo resulted in increased viral 
replication and cell death.
HSV stimulation of the B cell mediated response of the acquired immune 
system results in the secretion of virus-specific antibodies (Martin & Rouse,
1987). These antibodies react with viral proteins either on the virus itself or on 
virus infected cells with a number of consequences: for example, by coating the 
surface of the virus particle which then allows the non-specific phagocytes to 
attack more efficiently and destroy it. The antibodies which are secreted 
initially are IgM antibodies. Two to six weeks following the prim ary infection,
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production of IgA and the more specific IgG antibodies occurs and the IgM 
secretion decreases. Such antibodies are found to be directed against a number 
of surface HSV glycoproteins including gB, gC, gD, gE, gG or gH. These 
antibodies play an important role in defence against HSV infection as they are 
neutralizing antibodies. Other antibodies have also been found to be directed 
against the non-surface polypeptides RR and Vmwl75 (or ICP4).
Four different forms of T cell response exist and are summarized below 
(Benjamini & Leskowitz, 1991). All T cells express specific surface receptors 
which can interact with the major histocompatibility complexes (MHC) and 
processed antigen on target cells. Cytotoxic T cells come in contact with such 
cells resulting in their death. T helper cells act to increase the expression of 
soluble antibody from B cells by secreting lymphokines. The third class of T 
cells are delayed type hypersensitivity (DTH) T cells. These produce an 
inflam m atory response by secreting lymphokines which in turn  activate 
monocytes and macrophages. The final form of T cell, the suppressor T cell, acts 
to modulate the immune response so preventing excess tissue damage.
Secondary infection by HSV is in general unlikely to succeed. This is due 
to the high anti-HSV antibody and T cell levels in the host induced by the 
prim ary infection.
Latent HSV infection, as discussed in Section 5, enables the virus to lie 
dorm ant in the sensory nerve ganglia of the host, where no viral expression is 
thought to occur. The immune system is therefore unable to detect the presence 
of the virus. If however the virus reactivates, it travels down the nerve and 
replicates. The immune system is then able to attack the virus. Some virus may 
escape the immune surveillance, the consequence of which, is manifested in 
the formation of lesions a t the primary site of infection.
In the im m unosuppressed host such as AIDS, cancer or transplant 
patients, HSV infections are much more severe due to the impaired ability of the 
host cell immune response (Bustamante & Wade, 1991). Reactivation of the virus 
can occur at multiple sites in such patients with the healing process taking 
over six weeks.
2 HSV INDUCED HOST CELL SHUTOFF
HSV-1 and HSV-2 infection of culture cells results in the rapid inhibition 
of both host cell DNA synthesis (Roizman & Roane, 1964) and the majority of 
RNA and protein synthesis (Roizman et al. 1965). This phenomenon has been 
named host shutoff and is one of the earliest events in lytic infection (Nishioka 
& Silverstein, 1977, 1978; Fenwick & Walker, 1978; Fenwick & Clark, 1982; Hill et
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al, 1983; Read & Frenkel, 1983; Fenwick & McMenamin, 1984; Scheie & 
Bachenheimer, 1985). This can be divided into two categories, primary or virion 
associated host shutoff and delayed or secondary expression-dependent host 
shutoff (Fenwick & Clark, 1982). Virion associated shutoff results in the 
disaggregation of cellular polyribosomes (Sydiskis & Roizman 1966, 1967) and 
degradation of host mRNA (Scheie & Bachenheimer, 1985). A mutant virus in 
virion associated host shutoff, v h sl, (Read & Frenkel, 1983) allowed the host 
shutoff function to be mapped to the UL41 gene (Kwong et al. 1988). The UL41 
gene product is predicted to encode a 489 amino acid protein of 58K (Frink et al. 
1981; McGeoch et aL 1988) which is a non-essential structural component of the 
virus (Fenwick & Everett, 1990) and acts in the absence of viral gene expression 
(Fenwick & Walker, 1978; Nishioka & Silverstein, 1978). The host shutoff 
function has been proposed to cause a structural change in mRNA making it 
non-functional (Fenwick & McMenamin, 1984). This function has also been  
proposed to be important in the regulation of viral mRNA in addition to host 
mRNA (Oroskar & Read, 1989).
HSV-2 is generally more efficient at shutting off host cell synthesis than 
HSV-1 (Scheie & Bachenheimer, 1985) and degrades RNA more quickly than 
HSV-1. The efficiency of host shutoff of the virus is also seen to vary between 
strains of HSV. Comparison of the UL41 gene of different viruses reveal 
sequence differences, with the HSV-2 strain HG52 being reported to be deficient 
in host shutoff (Everett & Fenwick, 1990).
Not all cellular genes are shutoff, but some continue to be expressed at 
their normal levels or are even upregulated. This will be discussed in the next 
section.
3 HSV ACTIVATION OF CELLULAR GENE EXPRESSION
Despite the well documented ability of HSV lytic infection to result in the 
shutoff of host protein synthesis, some cellular proteins escape this fate. A 
similar activation of a small num ber of cellular genes is seen to occur with 
several other viruses including adenovirus, Newcastle disease virus, polyoma 
and SV40. Induction of stress response proteins (or heat shock) has been 
reported for HSV (Notarianni & Preston, 1982; La Thangue et al. 1984; Kennedy 
et al. 1985; Yura et al. 1987) although in some situations as elevated temperatures 
were used in the experimental systems, it is difficult to establish if the induction 
of stress proteins is due to HSV infection or the elevated temperatures (Yura et 
al, 1987). Stress proteins have also been reported to be induced following
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infection with Newcastle disease virus (Collins & Hightower, 1982), adenovirus 
(Nevins, 1982), SV40 and polyoma virus (Khandijian & Turler, 1983).
Stress proteins are not the only cellular proteins which escape the 
shutoff function of HSV lytic infection. Histone H3 mRNA transcrip t levels 
remain unchanged following infection (Mayman & Nishioka, 1985) as do the 
small nuclear RNAs, U-snRNA, which remain at a constant level for up to 36 
hours post infection (Bachmann et al. 1986). In both these cases however, the 
presence of mRNA following infection is due to the stability of the mRNA as 
opposed to transcriptional activation. Deadenylation of cellular mRNA occurs in 
the vast majority of transcripts resulting in destabilization of the mRNA 
(Silverstein et al. 1973), however, the above RNAs appear to avoid this fate.
Investigation of cellular gene induction by differential screening 
analysis of RNA levels has lead to the isolation of cDNA clones, whose expression 
is either maintained at the same level or increased after HSV infection (Patel gt 
aL 1986; Kemp et al. 1986a, 1986b). Increased levels of c-fos transcripts have also 
been reported one hour post infection with HSV-2 (Goswami, 1987).
Some cellular proteins are seen to be increased by up to 15 fold following 
HSV infection, including the small RNA binding proteins, Sm, RNP, Ro and La 
(Bachmann et al. 1986). Studies on increased ubiquitin B gene expression  
indicate that HSV induction of cellular genes occurs in a specific manner, as 
neither the ubiquitin A nor C genes are expressed at increased levels following 
HSV infection (Kemp & Latchman, 1988b). Other studies include co-transfection 
experiments involving HSV IE genes and the rabbit beta-globin gene. These 
resulted in the increased expression of the beta globin in transfection studies, 
however when the beta-globin gene was in its normal chromosomal location, 
the increase in gene expression could not be repeated (Everett & Dunlop, 1984). 
Despite this, these experiments suggested a role for IE proteins VmwllO and 
Vmwl75 in the transactivation of cellular genes.
Following the identification of a group of polypeptides which were 
increased after HSV infection, similar proteins were seen to be present in HSV 
transformed cells (Suh et al. 1980; Suh, 1982; Macnab et al. 1985a; La Thangue & 
Latchman, 1988; Hewitt, 1988; Hewitt et al. 1991). This group includes 
polypeptides of molecular weights 90,000 (a doublet) 40,000 and 32,000 which 
can be recognised by antiserum  raised against HSV infected cells, by a 
monoclonal antibody TG7A, raised against HSV infected cell DNA binding 
proteins and by serum taken from tumour bearing animals named TBS (Macnab 
et al. 1985a). The 90,000 molecular weight polypeptide named U90 (Hewitt, 1988; 
Hewitt et a l. 1991) and the 40,000 molecular weight polypeptides have been
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studied in more detail (Hewitt, 1988; Hewitt et a l. 1991; Grassie et al. 1993 and this 
thesis). The studies on the U90 and its induction form the basis of this thesis and 
shall be described in the results and discussion sections.
Transfection experiments have been used to investigate if VmwllO and 
Vmwl75 were involved in such cellular gene induction (Everett & Dunlop, 
1984). Vmwl75 has also been implicated in the induction of ubiquitin B (Kemp & 
Latchman, 1988b) and is either directly or indirectly involved with the 
transcriptional activation of a num ber of mRNAs (Kemp & Latchman, 1988a). 
AP-1 DNA binding activity has been reported to be induced by HSV infection, 
with VmwllO being essential for this induction (Jang et al. 1991). It is claimed 
that HSV infection induces c-jun transcription and AP-1 dependent promoters 
(Jang et al. 1991), however it is interesting to note that the induction of c-fos 
which was previously reported by Goswami in 1987 was not investigated in the 
study of Jang and co-workers.
Another study indicated that a minority of cellular genes induced by HSV 
infection could occur without any viral protein synthesis (Kemp et al. 1986a). 
Later, Vmw65 the virion protein and transducing factor, was implicated with U3 
Sn-RNA transactivation by specifically interacting with the octamer binding 
motif (Kemp & Latchman, 1988c). Vmw63 has also been shown to be required for 
the accumulation of a 40,000 molecular weight polypeptide (Estridge et al. 1989), 
Vmw6 8  required for repression of some transcripts (Kemp & Latchman, 1988a) 
and as indicated previously VmwllO has been reported to be required for the 
upregulation of an AP-1 binding activity (Jang et al. 1991).
No one virus encoded protein has been consistently seen to be implicated 
with cellular gene induction, however, VmwllO and Vmwl75 have been 
reported on more than one occasion to be required for cellular gene induction. 
The properties of Vmwl75 and its effect on cellular polypeptides are outlined in 
this chapter, Section 2:4(b) and the induction of U90 in particular will be 
discussed further in this thesis.
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SECTION 4 : TUMOUR ANTIGENS
This section will discuss tumour antigens, their presence, the potential 
mechanisms by which they become immunogenic to the host and their possible 
function. Although tum our antigens have been given a num ber of names 
including tum our specific polypeptides, tum our specific transp lan ta tion  
antigens and tumour rejection antigens, I shall use the term tumour antigen, as 
this term encompasses all of the above forms. Generally these other names have 
been acquired as a consequence of the circumstances under which a particular 
tumour antigen was first identified.
Tumour antigens may be molecules with a causative role in oncogenesis 
or may represent a difference in the metabolism of the normal and the tumour 
cell. Such tumour antigens have been defined as "chemical moieties associated 
with a tumour in an animal that can elicit an immune response in the host" 
(Levine, 1982). The tumour antigen may reside on the tumour cell surface and 
as such, can be associated with tum our rejection. Alternatively, it may be 
located within the cell where it can be processed to generate peptides fragments 
which may then be presented to the immune response, the result of which can 
be cell death or tissue necrosis.
By characterizing the structure and the immunogenicity of such tumour 
antigens, progress in the field of tumour immunology may be made. To do this 
the immunological relationship between the tum our and the host must be 
understood. Using this knowledge, the host immune response to tumours could 
be utilized for the diagnosis, prophylaxis and immunotherapy of tumours.
1 THE HISTORY OF TUMOUR ANTIGENS
The immunogenic nature of tumours was first reported by Gros (1943) 
who transplanted a sarcoma into a genetically identical, histocompatible mouse. 
The transplanted tumour cells produced nodules which subsequently regressed. 
However, transplantation of a second sarcoma to the same mouse resulted in no 
tumour formation. From these experiments it was concluded that this was a 
result of the mouse becoming immunologically resistant to the transplanted 
tumour cells. A series of studies of this nature have been carried out using 
chemically induced tumours (Foley, 1953; Baldwin, 1955; Prehn & Main, 1957; 
Klein et al. 1960; Old et al. 1962). From these studies it became clear that the mice 
were only immune to the tumour to which they had been exposed, and not to 
any other tumour, even if the tum our was induced by the same chemical 
carcinogen (Prehn & Main, 1957).
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As indicated above, chemically induced tumours have little or no cross 
reactivity. This is most probably explained by the random  nature of the 
mutations which arise from treatm ent with carcinogens. Conversely tum ours 
induced by oncogenic viruses do exhibit cross-reactivity. This is most likely 
because infection with a tumour virus induces the same antigen(s), eg a virus 
encoded protein, on each tumour regardless of tissue type or host species 
(Benjamini & Leskowitz, 1991).
2. A DESCRIPTION OF SOME TUMOUR ANTIGENS
A num ber of tum our antigens have been identified which can be 
classified into two basic groups. These are essentially tumour antigens which 
are host cell encoded but have been altered in some m anner such that they 
become immunogenic to the host, or alternatively tumour antigens coded by an 
infectious agent which have been introduced into the host, for example, by 
virus infection.
A num ber of virus-encoded tum our antigens have been identified 
including SV40 large and small tumour antigens, which generate antibodies in 
hamsters bearing tumours induced by SV40 (Tevethia et al. 1980) and E7 of 
papillomavirus (Chen et al. 1991). In the case of SV40 large T antigen, about 10% 
of the protein is expressed at the cell surface where it plays a role in host 
tum our rejection. The SV40 large T antigen is therefore term ed a tumour 
specific transplantation antigen or TSTA. Esptein-Barr virus also expresses 
tum our antigens known as Epstein Barr virus nuclear antigens (EBNAs), of 
which there are six. Such tumour antigens expressed as a consequence of 
infection with a tumour virus, show extensive cross-reactivity with tumours 
induced in other hosts by the same virus.
The second group of tumour antigens include a large num ber of host 
polypeptides and glycoproteins. These can generate an antigenic response in 
the host for any one of a number of reasons which are outlined below. Foetal 
tum our antigens (Old, 1981) such as the carcinoembryonic antigen (CEA) 
(reviewed by Thomas et al. 1990) and alpha foetoprotein (AFP), (reviewed by 
Deutsch, 1991), are normally only expressed in foetal tissue. If however, these 
proteins are expressed in the adult cell they are recognised as foreign, as they 
have not previously been presented to the immune system, and consequently 
the immune response generates antibodies against them. AFP was first seen in 
foetal sera of humans, then found in anim als with graft-induced  and 
spontaneous hepatomas, and later in hum an patients with hepatom as and 
various other malignancies (Deutsch, 1991). CEA was first described in 1965 and
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subsequently used as a tumour m arker for detecting and monitoring patients 
with colorectal cancer (reviewed by Thomas et al. 1990). However, as more 
sensitive techniques of detection were developed, it was discovered that CEA was 
in fact expressed in low levels in normal tissues and was expressed at elevated 
levels in patients with benign disease. As a result of this discovery Coggins 
(1986) redefined these foetal antigens as differentiation antigens.
Despite the presence of such differentiation antigens in normal cells, CEA 
is still considered to be the best tum our m arker for monitoring colorectal 
cancer. The discovery that CEA was not purely tum our specific initiated 
renewed efforts to identify highly specific tumour markers.
Another group of tumour antigens is thought to become immunogenic to 
the host by the alteration of normal cell surface molecules such that a new 
antigenic determ inant is presented to the host. An example of such a tumour 
antigen can be seen in some adenocarcinomas, where glycolipids can lack the 
term inal glucosamine residue which is present in norm al ganglioside cells 
(discussed in Levine, 1982). The resulting glycolipid is presented to the host in a 
different m anner in an adeno-carcinoma cell compared to the normal cell. 
Alteration of the glycosylation of the surface glycoprotein has also been well 
documented as a method of generating tumour antigens. A number of altered 
normal cell glycoproteins have been identified in gangliosides, melanomas and 
neuroblastomas, for example GD2, GD3, GM2 and GM3, (reviewed by Hakamori, 
1989).
Other mechanisms by which normal cell proteins can become tumour 
antigens include m utation, an increase in the protein concentration or by 
complexing with foreign antigens, resulting in a '‘self’ protein being presented 
to the immune system in a different form. The tumour suppressor protein p53 
has been documented to act in all of the ways described above: antibodies 
targeted against p53 have been seen where tumour cells have increased levels 
of p53 and the p53 protein has been seen to complex with viral tumour antigens 
resulting in its presentation to the immune system in an altered form (Levine, 
1990; Wemess et al. 1990; Levine et al. 1991).
A single point mutation is seen to generate cytotoxic T cell specificity in 
the turn” tumour antigen, P91A, described in a mouse tumour model (Lurquin et 
al, 1989). A single mutation in exon 4 of P91A (DePlean et al. 1988) in mouse 
mastocytoma cells results in tumour rejection when these cells are injected into 
mice. It has also been proposed that the tumour antigen FD and a homologous 
GP95/97 tumour antigen which are present in hum an melanoma cells may 
become antigenic to the host as a consequence of point mutations (reviewed by
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Thurin, 1990). This however, has still to be clarified by sequence comparison of 
the normal and tumour cell proteins.
3. THE POSSIBLE FUNCTION OF TUMOUR ANTIGENS
The tumour antigen GP96 has been studied in some detail and its potential 
function investigated (reviewed by Srivastava & Maki, 1991). GP96 is expressed 
on m ethylcholanthrene induced sarcomas (Meth A, CMS5 and CMS13), 
(Srivastava et al. 1986; Palladino et al. 1987; Srivastava & Old, 1988) and induces T 
cell m ediated immunity. Adoptive transfer of T lymphocytes from GP96 
immunized mice to immunologicaly naive mice can result in the regression of 
pre-existing Meth A tumours in a tumour specific m anner (Palladino et a l. 
1987). This suggests that GP96 acts as a tumour rejection antigen protecting the 
host from tumour development. GP96-like proteins can be detected in a number 
of normal tissues. These however, appear to be immunologically distinct from 
the GP96 isolated from tumours because they do not confer Meth A tumour 
immunity (Srivastava & Maki, 1991).
GP96 has considerable homology with stress proteins, in particular with 
the GRP94 family (Maki et al. 1990). Stress proteins have been proposed to be 
associated with transformation (Nevins, 1982; Khandijian & Turler, 1983) and 
have now been proposed to be tumour specific antigens (Kaufmann, 1990; 
Srivastava & Maki, 1991). Work by Bensuade & Morange (1983), agrees with this 
proposal as they have shown the presence of heat shock proteins in embryonal 
carcinoma cells in the absence of stress normally required for the induction of 
such stress proteins (reviewed by Pelham, 1986; Tanaka et al. 1988).
It has also been proposed that instead of acting as tumour rejection 
antigens (by the normal stress protein becoming altered), stress proteins may 
participate in the processing and presentation of tumour specific epitopes from 
other sources (Kaufmann, 1990; Srivastava & Maki, 1991). If this were the case 
this would account for the limited num ber of stress proteins, but the great 
antigenic polym orphism  present on chemically induced tum ours. As a 
consequence of these properties, stress protein have been likened to MHC 
molecules because of their ability to bind to a num ber of different molecules 
and small peptides with specificity and high affinity (reviewed by Srivastava & 
Maki, 1991).
4. U90. A TUMOUR ANTIGEN
The U90 polypeptide which will be investigated in this thesis fulfils the 
criteria of a tumour antigen, as it could not be detected in normal cells, but was
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seen to be expressed on the surface of tumour cells and elicits an immune 
response in the host (Macnab, 1979). The U90 has also been shown to be 
expressed in primary rat embryo cells generated from embryos of up to 14 days 
(Macnab, unpublished results), suggesting it could be a foetal or differentiation 
tumour antigen. The characterization of the U90 may therefore help to elucidate 
how a normal cell polypeptide could become a tumour antigen.
CHAPTER 2 : MATERIALS
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1. CELLS
(a) RE fibroblast cells were prepared from 16-17 days sibling embryos of 
Hooded Lister rats taken from an inbred colony of rats maintained within the 
Institute. These were used mainly as secondary cultures.
(b) Bn5T cell line was derived from an in vitro culture of a tu m o u r 
induced by injection of Bn5 cells, which are RE cells transform ed by the 
cloned Bgl Iln fragment of HSV-2, strain HG52 (Cameron et aL 1985; Macnab et 
al, 1985).
(c) BHK-21 clone 13, a fibroblastic cell line derived from baby hamster 
kidney cells (Macpherson & Stoker, 1962) was used to grow and titrate virus.
(d) 12-2, a quasi-epithelial mouse cell line was transformed by HPV 16 
and c-fos (Crook et al. 1988), These cells were kindly donated by Dr Lionel 
Crawford (ICRF, London).
(e) Human embryonic lung cells (Helu) were m aintained within the 
Institute but were intially prepared by Dr JCM Macnab.
(f) Human Jurkat cells, a lymphoid cell line grown in suspension was 
kindly donated by Dr John Moore. (Glasgow Vet School).
(g) MCF-7 cells, a human breast carcinoma cell line derived from pleural 
effusion of a breast tumour (Soule et al. 1973), originally obtained from ICRF, 
London and the Department of Biochemistry, University of Liverpool.
(h) PC12, a ra t pheochromocytoma cell line (Sheng et al. 1988), was 
obtained from Dr T McKee, Institute of Virology, Glasgow.
2. CELL CULTURE MEDIUM AND SOLUTIONS
Unless otherwise stated cells were grown and maintained in Dulbecco’s 
minimal essential medium, supplemented with 1% v/v non-essential amino 
acids, lOOunits/ml penicillin and lOOug/ml streptomycin, known hereafter as 
supplemented DMEM, plus 5% newborn calf serum (NCS). BHK C13 cells were 
grown in EC 10, which is Eagles minimal essential medium supplemented with 
lOOunits/ml penicillin, lOOug/ml streptomycin, 7.5% Na bicarbonate, 5% 
tryptose phosphate (TP) bro th  and 10% NCS. PC12 cells were grown in 
supplemented DMEM plus 10% heat inactivated horse serum + 5% NCS, 12-2
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cells grown in supplemeted DMEM plus luM dexamethasone and 5% NCS and 
Helu cells grown in supplemented DMEM plus 5% foetal calf serum. All 
components were supplied by Gibco Ltd, Scotland with the exception of TP 
which was supplied by Difco Laboratories (England) and was prepared in the 
Media department within the Institute of Virology.
Eagles medium without methionine, and Eagles lacking methionine and 
glucose were also prepared in the m edia departm ent in addition to the 
following:
Versene - O.GmM EDTA in PBS containing 0.002% (w/v) phenol red.
Trypsin - 0.25% (w/v) solution of trypsin (supplied by Difco Laboratories, 
England) in tris-saline.
3. VIRUS
Virus stocks were supplied by Mrs Mary Murphy (Institute of Virology, 
Glasgow). Virus strains used included HSV-2 strain HG52 (Timbury, 1971), HSV- 
1 strain 17+ (Brown et al . 1973), HSV-1 isD, HSV-1 tsK and HSV-1 tsT, 
tem perature sensitive mutants of HSV-1 strain 17, the mutations being within 
the gene encoding Vmwl75. Further HSV mutants in the IE genes were used 
including virus m utated in IE12, named HG52X163X12 or 2607, (Brown & 
Harland, 1987), IE63, named 1703 or XD2 (MacLean & Brown, 1987), IE110, 
named dll405 (Stow & Stow, 1986), IE136, named lsl207 (Preston et al. 1984) and 
IE175, named inl411 (Russell et al. 1987b).
4. CHEMICALS
Analytical grade reagents were obtained from BDH Chemicals Ltd, 
England with the exception of; 3 cyelohexylam ino-l-propanesulphonic acid 
(CAPS), (Aldrich Chemical Company Inc., England), Problott m em brane, 
trifluoroacetic acid, (TFA), (Applied Biosystems, California), ammonium
persulphate (APS), N,N'-diallyltartardiamide (DATD), Coomassie brilliant blue 
R-250, gelatin (ElA grade), horse radish peroxidase colour deve lopm en t 
reagen t, N ,N ,N \N '-tetram ethylethylenediam ine (TEMED), FPLC grade 
acrylamide, glycine, SDS, tricine and tris (BioRad Laboratories, California), 
complete Freund's adjuvant, tryptose phosphate (Difco Laboratories, USA), 
acetic acid (glacial), chloroform, hydrochloric acid, methanol, (May & Baker 
Ltd., England), Immobilon-P transfer membrane, (Millipore Coporation, USA),
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Ecoscint A scintillation fluid (National Diagnostics, New Jersey), PCR grade 
ultra pure set of dNTP, (Pharmacia LKB Biotechnology, England), triton X-100, 
10% solution (Pierce, Illinois, USA), HPLC grade acetonitrile  (Rathburn 
Chemicals Ltd., Scotland), nitrocellulose (Schleicher & Schuell, West 
Germany), actinomycin D, cycloheximide, calcium ionophore A23187, pepsin, 
phenylm ethylsulphonyl fluoride (PMSF), tunicam ycin, (Sigma Chemical 
Company, England).
5. ENZYMES
Enzymes were obtained from the following sources:
Ampli Taq DNA polymerase 5units/ul, (Perkin Elmer Cetus, USA) AMV reverse 
transcriptase 20 units/u l, SA 21,600 units/m g (Biolabs, New England), 
proteinase K (Boehringer M annheim) ribonuclease inh ib ito r (hum an 
placenta) 35 units/ul (Amersham International), Staph, aureus V8 protease 
500units/mg (Sigma), T4 DNA ligase 3 units/ul and T4 polynucleotide kinase 2 
un its/u l (Boehringer Mannheim).
6 . RADIOACTIVE COMPOUNDS
[35 s] L-methionine SA 800 Ci/mmol, [y~32P] adenosine triphosphate 
5,000Ci/mmol, [C*4] methylated proteins and Rainbow protein markers both 
14,300-200,000 and 2,350-46,000 mol wt, each 5nCi/ml, all A m ersham  
International Pic., England.
7. IMMUNOLOGICAL REAGENTS
Pansorbin (Calbiochem, California), Mab PR-6 , a rat monoclonal antibody 
against GRP94 (Estes et al. 1987) - a gift from Prof D Edwards (Department of 
Pathology, University of Colorado, Colorado), anti-GRP94 raised against the 
first 20 amino acids of the amino terminus of GRP94 - a gift from Drs Ullrich 
and Appella (NIH, Bethesda, Maryland), anti-endoplasm antibody, a mono- 
specific rabbit antiserum against GRP94 (Koch et al. 1986; Booth & Koch, 1989) 
- a gift from Dr Gordon Koch (MRC Laboratories of Molecular Biology, 
Cambridge).
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CHAPTER 3 : METHODS
1. CELL CULTURE
1(a) PREPARATION OF PRIMARY RAT EMBRYO CELLS
Primary rat embryo cells were prepared from 16-17 day old embryos 
from an inbred colony of Hooded Lister rats which were m aintained by 
brother sister mating over 20 years in the Institute. The colony has no history 
of spontaneous tumours (Macnab, 1979). Embryos from a single litter were 
removed from the uterus of a pregnant rat, washed with versene, eviserated, 
washed again with versene and finely minced. A single cell suspension was 
generated by treating the cells with 0.25% trypsin for 30 minutes (37°C), the 
supernatant removed and the remaining cell clumps treated with trypsin for a 
further 30 minutes. Newborn calf serum (NCS) was added (to 5% v/v) to stop 
the action of the trypsin, and the supernatants centrifuged at l ,0 0 0 rpm for 1 0  
m inutes (4°C) in order to collect the cells. The resulting cell pellet was 
resuspended in Dulbecco’s + 5% NCS and seeded at 2x l0 8 cells per 850cm 2 
burrler. Once sub-confluent the cells were maintained in Dulbecco’s + 2% NCS 
at 31° and fed weekly for up to 4 weeks.
1(b) CELL LINE MAINTENANCE
Bn5T cells and all other cells used (except those stated below) were 
maintained in 850cm2 plastic burrlers at 37°C in Dulbecco’s + 5% NCS + 5% CO2 . 
Once confluent these cells were split 1:5. BHK C13 cells were maintained in  
EC 10 + 5% CO2 in the same manner as Bn5T cells, but were split 1:10. Helu cells 
were treated as the Bn5T cells, but were grown in DMEM + 10% FCS in 175cm2 
flasks + 5% CO2 and split 1:2 when confluent. 12-2 cells were grown in DMEM + 
5% NCS + lf*M dexamethasone + 5% CO2 in 175cm2 flasks, and split. 1:2. PC12 
cells were grown in DMEM + 10% heat inactivated horse serum + 5% NCS + 5% 
CO2.
In all cases the cells were fed every 3 days and cells were split by 
washing twice with versene then once with trypsin/versene (1:4).
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1(c) CELL HARVESTING
Cells were harvested after removing the culture medium by washing with PBS, 
then scraping with a rubber policeman. The cells were pelleted at 2,000rpm 
for 10 minutes (4°C), the supernatant removed and the pellet stored.
1(d) CELL STORAGE
For storage, actively growing cells were trypsinized and centrifuged 
(l,000rpm  for 10 minutes at 4°C), then the medium decanted. The cells were 
then  resuspended in 1ml of m edium containing twice the normal serum 
content + 10% DMSO (v/v). The cells were frozen slowly overnight at -70°C, 
then transferred to liqiud nitrogen (-140°C). To recover the cells they were 
thawed quickly and put in 25cm2 flasks with the appropriate medium. The 
medium was changed the following day to remove any dead cells and DMSO.
2. VIRUS
2(a) VIRUS STOCK PRODUCTION
Stocks of HSV-1 and HSV-2 were produced by infection of 10 and 20 
bu rrlers respectively of sub-confluent BHK C l3 cells at a multiplicity of 
lpfu /300 cells. This was done in a total volume of 40mls and 20mls respectively 
at 31°C for 4-7 days until the cells were rounded and falling off the plastic.
HSV-1 was harvested by shaking the cells off the plastic, collecting the 
cells and medium, centrifuging at 2,000rpm for 10 minutes (4°C) in 250ml MSE 
glass bottles. The pellet was resuspended in 5ml of supernatant to generate the 
cell associated stock. This was checked for sterility and stored at -70°C (stage 
1). The supernatant was then centrifuged at 12,000rpm for 2 hours (4°C) in 
250ml plastic Sorvall bottles following which the pellet was resuspended in 
5ml of the supernatant to generate the supernatant stock. This was then 
checked for sterility and frozen.
Sterility checks were done by streaking virus on blood agar plates which 
were incubated inverted, at 37°C for 5 days. The supernatant stock was 
sonicated once before use, whereas the cell associated stock was sonicated, 
freeze/ thawed, centrifuged at 2,000rpm then resuspended in 5ml of medium. 
This procedure was completed twice before use or aliquoting and freezing at - 
70°C until required.
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HSV-2 stocks were treated as HSV-1 to stage 1, then sonicated, centrifuged 
at 2,000rpm for 10 minutes (4°C) and resuspended in 5ml of medium. This 
extraction was repeated twice before aliquoting the virus and freezing at - 
70°C
HSV-1 m utant stocks of tsK, tsD and tsT were prepared in the same 
manner as HSV-1.
2(b) TITRATION OF VIRUS STOCKS
Serial ten fold dilutions of virus stocks were carried out in EC 10 with 
200ul of the required dilutions being absorbed onto 50mm plates of sub­
confluent BHK C13 cells for 1 hour at 37°C (31°C for ts mutants), overlaid with 
50% EC 10/50% methyl cellulose to prevent secondary virus plaques forming, 
and incubated at 37°C or 31°C for 2 or 3 days respectively until plaques were 
visible. The overlay medium was removed and the cells stained with Giemsa 
stain for 15 minutes. This was gently washed off with water, the plaques on 
each plate counted and the virus titre calculated.
3. ANTISERA
3(a) PREPARATION OF TUMOUR BEARING ANTISERA (TBS)
TBS was produced by subcutaneous injection of 8  week old Hooded Lister 
rats with lxlO 7 Bn5T cells. Tumours formed within 1-2 months at which stage 
the rats were anaesthetized and blood taken by cardiac puncture. The blood 
was kept at 4°C for 24 hours to allow it to clot, centrifuged at 2,000rpm for 10 
minutes (4°C) and the serum supernatant decanted, aliquoted and frozen at - 
20°C
3(b) PREPARATION OF MONOSPECIFIC ANTIBODY AGAINST U90
Using the purification strategy for the U90 polypeptide which I devised 
for this project (which is described in chapter 4 section 4) the U90 was 
purified from HSV-2 infected Bn5T cells by Mr David McNab, electroeluted 
from polyacrylamide gel slices and approximately 2ug of U90 was emulsified 
in Freund's complete adjuvant and injected into a rabbit on three occasions at 
14 day intervals. Following the second boost, blood from the rabbit was tested 
by Dr Joan Macnab by im m unoprecipitation reactions and by western
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blotting. The antiserum was found to be positive in western blots for activity 
against the U90.
4. METABOLIC RADIOLABELLING OF POLYPEPTIDES
4(a) RADIOLABELLING WITH uLU si L-METHIONINE
Cellular polypeptides were metabolically radiolabelled with [35 s] L- 
methionine in vitro by growing the cells in medium lacking methionine for 
at least 1 hour prior to the addition of 50uCi of [35 s] L-methionine/ml of 
medium. Radiolabelling was carried out for 17 hours unless otherwise stated, 
after which the cells were harvested as described previously (section lc).
4(b) PULSE RADIOLABELLING
Pulse radiolabelling was carried out in PBS +5% NCS for either 2 hours 
(50uCi/ml of medium) or 5 minutes (2.5mCi/ml of medium). Cells in both cases 
were starved of methionine for at least 1 hour prior to the addition o f 
radiolabel and harvested as described (section lc).
4(c) PULSE/CHASE RADIOLABELLING
Pulse chase labelling was carried out as described previously for 2 hours 
(section 4b), however after 1 hour (unless otherwise stated) the label was 
removed, the cells washed with PBS A and total medium including cold 
methionine was added for the required chase time before cell harvesting.
5. INDUCTION AND INHIBITION OF CELLULAR POLYPEPTIDES
5(a) HSV INDUCTION OF CELLULAR POLYPEPTIDES
The medium was removed from sub-confluent monolayers of cells and 
the cells infected with virus at a multiplicity of 5-10pfu/cell, the virus being 
absorbed for 1 hour at 37°C in the minimum volume possible (200ul for a 50mm 
plate, 10ml for a 850cm2 burrler). The inoculum was removed and replaced 
with either 2ml or 10ml of medium respectively. If the polypeptides were 
being radiolabelled, [3 5S] L-methionine was added at this stage in methionine- 
free medium. Such infections were carried out for 17 hours unless otherwise 
stated. The cells were harvested by scraping with a rubber policeman, the
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medium and cells pelleted at 2,000rpm for 10 minutes (4°C), the supernatant 
discarded and the infected cell pellet either used immediately or stored -20°C.
5(b) INDUCTION OF CELLULAR POLYPEPTIDES BY TUNICAMYCIN
Tunicamycin was added to methionine starved sub-confluent cells at a 
final concentration of 2 ug/ml in methionine minus medium together with 
50uCi/ml [35s] L-methionine for 17 hours. Following this treatm ent the cells 
were harvested as normal.
5(c) INDUCTION OF CELLULAR POLYPEPTIDES BY CALCIUM
IQNQPHORE
Calcium ionophore A23187 was added to methionine starved, sub­
confluent cells at a final concentration of 6xl0"7M in the presence of 
50uCi/ml of [3 5 S] L-methionine for 17 hours. Following this treatm ent the 
cells were harvested as normal.
5(d ) INDUCTION OF CELLULAR POLYPEPTIDES BY GLUCOSE
STARVATION
Glucose regulated proteins were induced by starving sub-confluent cells 
of glucose by growing in medium lacking both glucose and m ethionine. 
Following the starvation period the cells were radiolabelled for 17 hours and 
harvested as described previously.
5(e) CYCLOHEXIMIDE AND ACT1NOMYCIN D TREATMENT OF CELLS
Cellular protein synthesis was inhibited at the level of translation by 
treating cells with 50ug of cycloheximide/ml of culture medium. Treatm ent 
was maintained for 17 hours, after which the cells were washed five times
with cycloheximide free m edium  to rem ove any rem aining traces of
cycloheximide. Radiolabelling with [3 5 S] L-methionine was performed over a 
period of 2 hours in the presence of 5ug/ml actinomycin D in PBS plus 1% 
serum.
6. PROTEIN EXTRACTION
Cellular polypeptides were extracted from cell pellets using the following 
methods and buffers.
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6 (a) RIPA EXTRACTION
Radioimmunoprecipitation analysis buffer, RIPA (1% triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 150mM NaCl, lOmM tris pH 7.4) modified from 
D ocherty  et al. 1981, was used to p repare  total cell extracts for 
immunoprecipitation reactions. The harvested cell pellet was resuspended in 
RIPA plus protease inhibitors (0.034mg/ml PMSF, 0.03mg/ml benzamidine + 
O.lmg/ml phenanthroline) and the cells sonicated until clear then left on ice 
for 30 minutes. The samples were then centrifuged at 12,000rpm for 10 
minutes (4°C) to remove cell debris, and the supernatant stored at -70°C,
6 (b) CELL FRACTIONATION
Cell fractionation was carried out with three separate buffers to generate 
the cytoplasmic, membrane and nuclear fractions. Freshly prepared  cell 
pellets were resuspended in hypotonic lysis buffer (25mM tris pH 7.5, 5mM 
KC1, 0.5mM MgCl2 ) plus 0.5mM PMSF + ImM DTT, left to swell on ice for 30 
minutes and dounce homogenized with 20 strokes using the B pestle (Wheaton, 
USA) which by the manufacturers definition shears only the cell membrane. 
Centrifugation at 2,500rpm for 10 minutes (4°C) generated the cytoplasmic 
fraction as the supernatant (Burnette & Till, 1971) and a pellet which was then 
treated with nuclear extraction buffer (20% glycerol, 25mM tris pH 7.5, 0.6mM 
KC1) plus ImM PMSF and ImM DTT for 30 minutes at 4°C with rotation. The 
sample was centrifuged at 2,500rpm for 10 min (4°C) and the supernatant 
stored as the nuclear fraction. The resulting pellet was then resuspended in 
mem brane extraction buffer (1% triton X-100 in PBS), sonicated until clear, 
left on ice for 30 minutes, centrifuged at 12,000rpm for 10 minutes (4°C) and 
the supernatant retained as the membrane associated fraction.
6 (c) LARGE SCALE PROTEIN EXTRACTION
The cell pellets were resuspended in hypotonic buffer plus protease 
inhibitors (as described in 6 b) using 1ml of buffer for every 2 x l0 8 cells, the 
cells left to swell on ice for 30 minutes, Dounce homogenized with pestle B for 
20 strokes as above, centrifuged at 2,500rpm for 10 minutes (4°C) to give a 
pellet containing the membrane fraction and supernatant containing the 
cytoplasmic fraction. The membrane pellet was then resuspended in 1ml of
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membrane extraction buffer (1% triton X-100, 0.5mM PMSF and ImM DTT in 
PBS) per 2x108 cells, sonicated until clear and left on ice for 30 minutes. This 
sample was centrifuged at 12,000rpm for 10 minutes (4°C) and the supernatant 
kept as the membrane associated fraction.
6(d) QUANTITATION OF IN C O R P <">R A T u n  [35S1 I-METHIONINE
The amount of radiolabel incorporated in each sample was measured by 
TCA precipitation of lu l of each sample onto a Whatman filter disc. To do this, 
the filters were washed twice in 5% TCA, once in acetone and dried under a 
heat lamp. The discs were then added to 3ml of Ecoscint A scintillation fluid 
and the [3 5S] counted in a scintillation counter.
7. PROTEIN ANALYSIS
7(a) IMMUNOPRECIPITATION REACTIONS
Im munoprecipitation (IP) reactions were carried out based on the 
technique described by Macnab et a l. (1985). A specific am ount of 
incorporated [3 5 S] L-methionine per sample (from 4x l0 6 -4X107 cpm) was used 
in each IP reaction, with the total volume being made up to a defined amount 
(either lOOul or 200ul) with extraction buffer. An appropriate volume of 
antibody was added to the samples for one hour with rotation (4°C), th en  
incubated for 1 hour with 60ul of protein A sepharose (4°C). The immune 
complexes were pelleted by centrifugation at 1 2 ,0 0 0 rpm  for 2 minutes, the 
supernatant discarded and the pellets washed twice with the extraction buffer, 
then once with PBS. This was done by resuspending the pellet in the required 
buffer by pipetting up and down, followed by centrifugation and then 
discarding the supernatant. The final pellet was resuspended in boiling mix 
(see Table 1) and heated to 70°C for 10 minutes to release the antibody/antigen 
complexes from the protein A sepharose. The protein A sepharose was then 
remove by centrifugation at 12,000rpm for 5 minutes, and the IP reaction 
(supernatant) either analyzed by SDS page (section 7b) or stored at -70°C.
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7(b) SDS PAGE
Sodium dodecasulphate polyacrylamide gel electrophoresis (SDS PAGE) 
(Laemmli, 1970) was used to separate polypeptides for analysis, using 7.5% and 
18% discontinuous SDS PAGE. The lower resolving gel was crosslinked with 
2.5% N-N methylene bisacrylamide and polymerized with 0.04% (w/v) APS and 
0.04% (v/v) TEMED then overlaid with butanol. After polymerization the  
butanol was washed off the gel with water, the stacker gel added (12.5% 
acrylamide cross-linked with 0.76% N N diallyl-tartar-diamide DATD) and 
polymerized as before with a teflon comb inserted to form wells. All solutions 
and the relative proportions used for SDS PAGE are outlined in Table 1. Samples 
were loaded on the gel in boiling mix (Table 1) and gels of 220x155mm run at 
70mA, 188x155mm at 35mA (with constant voltage) and the BioRad mini-gel kit 
(102x74) at 200V. The gels were run  until the dye front reached the bottom of 
the gel, the gel removed from the glass plates, fixed and/or stained for 1 hour 
(50% methanol, 7% acetic acid +/- 0.2% Coomassie blue R-250), destained for 1 
hour or as long as required in 10% methanol + 7% acetic acid, then dried 
under vacuum onto 3 mm Whatman filter paper. If the gels contained 
radiolabelled proteins they were exposed to Kodak X-omat S film at -70°C for 
varying lengths of time.
7(c) PEPTIDE MAPPING ANALYSIS
Using a modified version of Cleveland et al. (1977) the relationship of one 
polypeptide to another was compared by the size and num ber of peptides 
generated following total enzymatic digestion by Staph, aureus V8 protease of 
radiolabelled polypeptides. The protein of interest was excised from a dried gel 
by aligning the autorad film with the gel, (by means of radioactive ink spotted 
around the gel), and the slice placed in rehydration buffer (0.5M tris pH 6 .8 , 
5% SDS, lOOmM EDTA + bromophenol blue to colour) for 30 minutes. The gel 
slice was next placed in the well of an 18% gel containing a stacking gel of 
double the normal height and was overlaid with rehydration buffer plus 2 0 % 
glycerol. The tank buffer was added, then 5ug/track of proteolytic enzyme (in 
rehydration buffer + 1 0 % glycerol) and the gel run until the dye front had 
reached 5mm before the resolving and stacker gel interface. At this point, the 
power is turned off for 1 hour to allow digestion to occur and subsequently 
restored to complete SDS page as normal. When the dye front reached the
TABLE 1 : GEL SOLUTIONS
TABLE la
Stacking gel mix (30%) 
Resolving gel mix (30%)
TABLE lb
| Resolving gel buffer 
| Stacker gel buffer
TABLE lc
s
i Tank buffer
I
; Tris-tricine buffer
Acrvlamide DATD Bis-acrvlamide Water 
58.44g 1.56g - 200ml
55g - 5.0g 200ml
Tris_______ SDS_________Water_______ pH
181.5g 4.0g 1,000ml 8.9
59g 4.0g 1,000ml 6.7
Tris________Glvcine Tricine Water
6.3 2g 4.0g - 1,000ml
6.32g - 4.0g 1,000ml
TABLE Id
Acrvlamide mix Buffer APS TEMED Water
Stacker gel 6 ml 9ml 300ul 30ul 21ml
Resolving gel 24ml 24ml 600ul 40ul 48ml
Boiling mix : 30% stacker buffer, 30% glycerol, 12.5% SDS, 15% pmercapto-
ethanol (all v/v)
Fix : 50% methanol, 7% acetic acid, (+/-) 0.2% Coomassie Blue stain in H2 O
Destain: 10% methanol,, 7% acetic acid in H2 O
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bottom of the gel, the gel was treated as described previously (section 7b), but 
after destaining the gel, it was soaked in EN3HANCE for 30 minutes, washed 
with several changes of water over 30 minutes, dried down as described 
previously and then exposed to film, initially for 2 weeks then for up to 3 
months.
7(d) WESTERN BLOTTING
Following SDS-PAGE, polypeptides were eluted from gels onto various 
supports for different purposes. Western blotting was carried out using a 
modified version of Burnette (1981) and a BioRad mini transfer kit. The gel 
was removed from the glass plates after SDS PAGE and soaked in transfer 
buffer (lOmM CAPS p H ll, 10% m ethanol). The transfer sandwich was 
assembled in the order - sponge, 2 sheets of 3mm Whatman filter paper, 
nitrocellulose, gel, nitrocellulose, 2 sheets of filter paper, then sponge. The 
apparatus was filled with buffer and assembled so that the protein was 
transferred towards the anode using a constant current of 120mA for 80 
minutes. Rainbow marker proteins (Amersham, England), were loaded on one 
track of each blotted gel, enabling the efficiency of protein transfer to be 
observed.
After transfer, the nitrocellulose was blocked by incubating with 3% 
gelatin in TBS buffer (20mM tris pH 7.5, 0.5M NaCl) for 1 hour at 37°C, washed 
with TBS buffer to remove the gelatin, reacted with the appropriate dilution of 
the 1st antibody (in TBS buffer, 0.05% tween 20 + 0.05% Na azide) for a 
minimum of 1 hour at 37°C, washed with TBS and incubated with the 2nd 
antibody (1:1000 dilution of horse radish peroxidase (HRP) conjugated to  
protein A for rabbit antibodies and 1:300 dilution of horse radish peroxidase 
conjugated to rat IgG for rat antibodies), both made up in 0.05% tween 20 in 
TBS buffer. The nitrocellulose plus antibody was brought to room temperature 
before removing the 2nd antibody and washed thoroughly with PBS with at 
least 4 changes of buffer in order to remove the tween 20 and Na azide (which 
can interfere with the colour reaction). The protein antibody complexes were 
then visualized by adding a colour developing reagent (60mg of HRP colour 
developer reagent added to 20ml of ice cold methanol, and 6(V1 of H2O2 added to 
100ml of TBS buffer. These solutions were mixed just prior to use). The colour 
reagent was added to the nitrocellulose and shaken at room temperature until
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bands could be visualized. The reaction was stopped at the required stage by 
removing the colour reagent with several changes of water and then the 
filters were air dried.
7(e) ELECTROBLOTTING PRIOR TO PROTEIN SEQUENCING
The electroblotting technique was used prior to protein sequencing to 
transfer protein and peptides as purified and well separated bands onto an 
appropriate support for N-terminal protein sequence analysis. This also 
allowed an approximate quantitation of the total amount of protein present on 
the support by eye following Coomassie blue staining (Matsudaira, 1987).
The protocol for western blotting (section 7d) was followed with the 
exception that Problott, a PVDF membrane was used, and only the highest 
grade of reagents and chemicals were used to avoid the introduction o f 
contaminants. Before use, Problott was soaked in m ethanol but thereafter 
treated as described for nitrocellulose. After transfer the membrane was 
washed with water, saturated with methanol, then stained with 0.1% Coomassie 
blue in 40% methanol + 1% acetic acid for 30 seconds. The membrane was then 
destained until as much Coomassie blue as possible had been removed and the 
protein bands were clearly visible. The membrane was then air dried and the 
bands of interest carefully excised and sent for sequencing.
7(f) ELECTROELUTION
Protein was electrophoretically eluted from Coomassie blue stained gel 
slices onto an anisotropic m em brane contained w ithin an centricon 
m ic ro c o n c e n tra to r  tube (Amicon, UK). This p rocedure allows the 
concentration of protein and exchange of buffers in which the protein is 
contained (LeGendre & Matsudaira, 1990). Using electroelution apparatus, gel 
slices are placed in epindorf tubes with holes pierced in the top and bottom to 
allow contact with the transfer buffer (lOmM CAPS p H ll, 10% m ethanol). 
These were placed in the centricon tubes, the apparatus filled with transfer 
buffer and a current of 30mA applied for a minimum of 3 hours or overnight 
at 5 mA. Care must be taken to avoid bubbles forming in the epindorf tube or 
below the m em brane. After transfer the centricon tube was carefully 
removed and centrifuged in the RC5B SS34 rotor at 5,000rpm (4°C) until the 
dead stop volume is reached (about 30 minutes). The use of higher speeds may
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result in the damage of the centricon membrane. The buffer may be changed 
by repeating the above procedure, and the protein isolated by inverting the 
tube and the electroeluted protein centrifuged from the membrane into the 
collecting vessel.
The centricon tube may also be used to concentrate protein in a sample 
by reducing the volume of the sample buffer to protein ratio. However, in 
doing so, some losses must be expected due to adsorption.
7(g) PROTEIN CONCENTRATION
P ro te in  sam ples were c o n c e n tr a te d  u s in g  c e n tr ic o n -3 0  
m icroconcentrator tubes (Amicon, UK) by adding the sample to the tube 
(maximum volume of 2ml) and spinning the centricon tube in an RC5B SS34 
rotor at 5,000rpm (4°C) until the dead stop volume of approximately 200^1 is 
reached (about 30 minutes). The use of higher speeds may result in the 
damage of the centricon membrane so should be avoided. Addition of a second 
solvent to the tube can be used to exchange buffers in which a sample is 
m aintained in. This requires at least three washes of 2mls with the second 
buffer to be assured that 99.9% of the first buffer has been removed.
7(h) PROTEIN QUANTITATION
The protein content of samples was estimated using the BioRad Bradford's 
protein quantitation kit, which is based on the method described by Bradford, 
(1976). The manufacturer's instructions were followed for the standard assay 
procedure using bovine serum albumin as a protein standard.
7(i) DENSITOMETER SCANNING
Densitometer scanning of autoradiographs and Coomassie blue stained 
gels was carried out using a Shimadzu CS-9000 dual-wavelength flying spot 
scanning densitometer. Autoradiographs were scanned in "transmission photo 
mode" using a wavelength of 485nm and photographs were scanned in 
"reflection mode" at a wavelength of 535nm. In both circumstances zig-zag 
scanning was performed to enable analysis of the entire band in question 
using a "smoothing" value of 11. This results in 11 values for each peak being 
taken, with the mean of these values being given as the final figure. The
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optimum wavelength to use for each condition was determined by performing 
a spectrum scan.
8 PROTEIN PURIFICATION
8 (a) AMMONIUM SULPHATE PRECIPITATION OF PROTEIN
Saturation of a protein solution to different degrees with ammonium 
sulphate results in the selective precipitation or salting out of different 
proteins (Scopes 1987). Ammonium sulphate (0.176g/ml of sample) was added 
slowly over a defined period of time, which was 2 0  minutes, to give a 30% 
saturated solution, and the solution was left to stir on ice for 1 hour. During 
this time a proportion of the proteins precipitated out of solution and were 
subsequently collected by centrifugation at 10,000rpm for 15 minutes with the 
remaining soluble polypeptides being found in the supernatant. The protein 
pellets generated by centrifugation of the 30% saturated sample were collected 
and resuspended in the appropriate buffer (section 8 b).
8 (b) FPLC ANALYSIS
A Pharmacia FPLC system was used with a mono QHR515 column (a 1ml 
anion exchange column) and a "superloop" which enabled up to 50ml to be 
loaded onto the column at once. The mono Q_ column has a maximum capacity of 
20-50mg of protein and care must be taken not to exceed this limit (by 
quantitating the protein content of the sample). Prior to addition of a sample, 
the 2 0 % ethanol storage buffer was removed from the column by washing 
with 5ml of low ionic strength buffer A, (see below), followed by 10ml of high 
ionic strength buffer B, (see below) then equilibrated with buffer A. To clean 
the column it was incubated with lm g/m l of pepsin, 0.1M acetic acid, 0.5M NaCl 
at 37°C for a minimum of 1 hour. It was then washed at least twice with 2M 
NaCl, 2M NaOH, 75% acetic acid until the UV absorption trace (detecting 
protein coming off the column) gave a steady base line.
3 sets of buffers were used :
A.1 (50mM tris pH8 ) B.l (50mM tris pH8 + 1M NaCl)
A.2 (buffer A.1 + 1% triton) B.2 (buffer B.l + 1% triton)
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A.3 (buffer A.1 + 0.1% triton) B.3 (buffer B.l + 0.1% triton)
Prior to loading samples on the column the samples were sonicated until 
clear, the sample was desalted by passing it through a PD10 desalting column 
(Pharmacia, England), which was equilibrated with 30ml of the relevant 
buffer A. Each column had 2.5ml of sample passed over it, which was then 
eluted with 3.5ml of buffer A and centrifuged at 12,000rpm for 5 minutes to 
remove any particulate material which could clog the pre-column filter. The 
sample was then loaded into the superloop, the required programme used and 
lml samples collected.
8(c) MICROBORE HPLC ANALYSIS
Protein separation carried out at picomole levels, was facilitated by the 
use of a reverse phase column on a Applied Biosystems microbore HPLC 
system. The reverse phase column, an aquapore RP300 column (2.1mm in 
diameter and 30mm in length) allowed 50ul to be automatically loaded onto the 
column, however further sample could be added by multiple manual loadings. 
Two buffers were routinely used, buffer A (0.1% TFA in H2 O) and buffer B 
(0.1% TFA in 80% acetonitrile in H2O). Samples were collected manually either 
by collecting protein peaks as indicated by the UV absorbance of a fraction 
coming off the column at any one time, or by collecting samples according to 
the percentage composition of the buffer, i.e 0-100% buffer B.
9. SYNTHETIC OLIGONUCLEOTIDES
9(a) OLIGONUCLEOTIDE PURIFICATION
Oligonucleotides were kindly synthesized by Dr John Maclauchlin on a 
Biosearch 8600 DNA synthesizer using the microscale synthesis process. The 
DNA was eluted from the column by resuspending the beads in lm l of 
ammonia, the solution heated to 55°C for 5 hours, the ammonia removed by 
lyophilization and the oligonucleotide resuspended in lOOul of water. One 
quarter of this solution was used at a time to obtain purified oligonucleotide by 
running the samples on a sequencing gel, i.e. 15% polyacrylamide containing 
7M urea in half strength TBE (90mM tris, 89mM boric acid, ImM EDTA) and 
polymerized with 0.08% APS (w/v) and 0.08% TEMED (v/v). The gels were pre­
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run in 0.5 xTBE running gel buffer for 15 minutes before addition of the 
samples in 50% formamide. A dye mix (95% formamide, 0.05% brom ophenol 
blue, 0.05% xylene cyanol + 20mM EDTA) was run on a separate track to act as a 
marker (no dye was added to the DNA samples as this would prevent the DNA 
being visualized by UV light if the dye and DNA co-migrated). The gel was run 
at 250V until the dye front was two thirds down the gel.
To visualize the DNA, the gel was wrapped in cling film, placed on a thin 
layer chromatography plate and held under short wave UV light. DNA absorbs 
the UV light producing a dark band against the chromatography plate which 
uniformly fluoresces. The DNA band of correct molecular weight was excised 
(so avoiding partially synthesized oligos in the purified sample) and eluted by 
gentle shaking overnight at 4°C in a small volume of TE buffer (lOmM tris 
pH8.0 + ImM EDTA). The DNA was then extracted once with phenol/chloroform 
(1:1), once with chloroform, then precipitated in 3 volumes of ethanol + 0.3M 
Na acetate on dry ice for 30 minutes. The DNA was then  pelleted by 
centrifugation at high speed in a microfuge for 1 0  minutes, the pellet washed 
with 1 0 0 % ethanol, lyophilized and resuspended in 50ul of water.
9(b) OLIGONUCLEOTIDE QUANTITATION
To quantitate the oligonucleotide sample, the optical density (OD) was 
measured at 260 and 280nm. Using the conversion factor of 1 OD (at 260nm) = 
20ug/ml the concentration of the oligonucleotide sample was calculated. To 
calculate the molarity of each oligonucleotide solution the following equation 
was used:
Em=A( 16,000)+G( 12,000)+C (7,000)+T (9,600) 
where m olarity = OP7fo
Em
where A, G C and T are the number of A, G, C and T residues respectively in the 
oligonucleotide.
9(c) 5' END LABELLING OF OLIGONUCLEOTIDES
Oligonucleotide (200ng) was resuspended in 50ul of kinase buffer (50mM 
tris, lOmM MgCl2 , 5mM DTT, O.lmM spermidine, O.lmM EDTA) containing 10 
units of bacteriophage T4 polynucleotide kinase + 50uCi of [ r 3 2 P] ATP and
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incubated at 37°C for 30 minutes (Sambrook et al. 1989). This end labelled DNA 
was used immediately without further purification.
10. cDNA LIBRARY SCREENING USING DEGENERATE
OLIGONUCLEOTIDES
10(a) PREPARATION OF AMPICILLIN PLATES
L-broth agar (1% tryptone, 0.5% yeast extract, 1% NaCl - all w/v, pH 7 
plus 1.5% bacto agar) was melted and allowed to cool until hand hot. Ampicillin 
was added at a concentration of 50ug/ml, the agar poured onto sterile 90mm 
diameter or 20cm2 petri dishes and allowed to set. The plates were inverted and 
dried overnight before being stored at 4°C until required.
10(b) SCREENING LIBRARY
cDNA libraries were plated out on ampicillin plates at approximately 
20,000 plaques per 20x20cm plate. These were incubated inverted at 42°C until 
plaques were visible (after 4-6 hours). The plates were then chilled to harden 
the agarose before asymeterically marked nitrocellulose filters were placed in 
contact with the surface of plate. This was done twice to create duplicate 
filters, the second filter being left on the plate for twice as long compared to 
the first. The filters were then placed in denaturing solution (1.5M NaCl, 0.5M 
NaOH) for 60 seconds, in neutralizing solution (1.5M NaCl, 0.5M tris pH8 ) for 5 
minutes and finally in 2xSSC (0.3M NaCl, 0.3M trisodium citrate pH7) for 5 
minutes, air dried and then baked at 80°C in a vacuum oven for 2 hours.
Before the addition of the end labelled probe the filters were washed in 
50mM tris pH8 , 1M NaCl, ImM EDTA + 0.1% SDS for 2 hours at 42°C followed by 
2-4 hours at 37°C in hybridization buffer (6 xSSC, lxDenhardts, 0.5% SDS+ 
20ug/ml denatured salmon sperm DNA), where Denhardts solution is 0.02% 
polyvinylpyrolidone, 0.02% BSA + 0.02% ficoll. The probe was then added in as 
small a volume as possible of fresh hybridization buffer at 37°C for 16-24 
hours with shaking. Any unbound DNA probe was removed by washing the 
filters 3-4 times in 6 xSSC + 0.05% Na pyrophosphate. This was then repeated 
once at 37°C for 1 hour, then finally at the required tem perature for 10 
minutes. The filters were air dried and exposed to Kodak X-Omat S film using an 
intensifying screen.
Plaques which gave a positive signal on both duplicate filters were 
picked, replated and the entire process of screening repeated until all the 
plaques on any one plate were positive.
11. EXTRACTION OF CELLULAR DNA FROM BN5T CELLS
Cells were lysed in a small volume of TE buffer (50mM tris pH 8.0, lOmM 
EDTA, lOOmM NaCl, 0.4% SDS) plus 200ug/ml of proteinase K, and rotated 
overnight at room temperature. The lysed cells were extracted twice with an 
equal volume of TE saturated phenol, then once with chloroform . The 
chloroform extracted DNA was added to boiled dialysis tubing and dialysed 
against a large volume of TE buffer with frequent changes of buffer during 
the initial stages of the overnight dialysis.
The DNA solution was adjusted to 0.25M Na acetate and 2 volumes of 
ethanol was added and the DNA slowly precipitated overnight at -20°C. The DNA 
was pelleted at 3,000rpm for 10 minutes, the supernatant removed, the pellet 
dried under vacuum and finally resuspended in as small a volume of water as 
possible.
To remove RNA, ribonuclease A (previously boiled for 10 minutes) was 
added to a fincil concentration of lOOug/ml and incubated at 37°C for 3 hours. 
The DNA was then re-extracted in phenol and chloroform as before to remove 
the ribonuclease A, dialysed and quantitated (OD2 6O of 1 = 50ug/ml for DNA).
12. EXTRACTION OF CELLULAR RNA
12(a) CYTOPLASMIC RNA EXTRACTION
Cells were harvested as norm al and resuspended in RNA extraction 
buffer A (0.15M NaCL, 0.01M tris pH7.8, 1.5mM MgCl2, 0.65% NP40), using 250ul 
of buffer for cells harvested from one 80cm2 flask, incubated on ice for 3 
minutes and then centrifuged at 3,000rpm for 5 minutes to remove the nuclei 
and cell debris. An equal volume of buffer B (7M urea, 0.35M NaCl, 0.01M EDTA, 
0.01M tris pH7.8 1% (w/v) SDS) was added to the supernatant, and the RNA 
extracted three times with phenol/chloroform . A final extraction with 
chloroform was carried out before the RNA was precipitated with 3 volumes of 
ethanol + 0.25M NaCl at -70°C and the RNA pelleted at 12,000rpm for 10 minutes.
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The pellet was resuspended in sterile H2O, quantitated (OD2 6 O of 1 = 40ug/ml 
RNA), and stored at -70°C.
12(b) EXTRACTION OF POLY A RNA USING DYNABEADS OLIGO
Dynabeads oligo d(T)25  (Dynal UK Ltd., Ireland), were used to isolate poly 
A RNA from total cell extracts. The cells were harvested as described in the 
Dynabeads protocol, using PBS. The cells were quickly centrifuged out of 
solution at 12,000rpm, then using 12X106 cells, 400ul of the m anufacturer’s 
lysis buffer (lOmM tris HC1 pH7.5, 0.14M NaCl, 5mM KC1, 1% triton-X-100) was 
added for 1 minute on ice. This was then centrifuged at high speed for 30 
seconds and the supernatant transferred to an epindorf containing oligo d(T) 
beads in lOOul of 2X binding buffer (supplied with kit). This was mixed gently 
for 3-5 minutes to allow hybridization. The beads were separated from the 
rem ainder of the sample using the supplied magnet, the beads washed twice 
with 200ul of washing buffer (supplied), lOOul of elution buffer (supplied) 
added, then the sample was heated to 65°C for two minutes. The beads were 
then separated from the polyA RNA (using the supplied magnet) and the 
supernatant containing the purified polyA RNA either used immediately or 
stored at -70°C.
13. POLYMERASE CHAIN REACTION
13(a) cDNA PRODUCTION AND AMPLIFICATION
Based on the method described in Steinthordottir & Mautner (1991), cDNA 
was generated by using an oligonucleotide prim er complementary to the 
message in question in a reverse transcription reaction. PCR was then used to 
amplify this cDNA. Each reaction was carried out in lOul of lx  PCR buffer 
(lOmM tris pH8.3, 50mM KC1, 1.5mM MgCl2 , 0.001% gelatin) containing ImM of 
each dNTP, 100 units RNasin, 10 units AMV reverse transcriptase, l-10ug of 
cytoplasmic RNA (prepared as described in section 9a and quantified as 
described in section 9b) and luM of the first prim er (complementary to the 
mRNA). The sample was then treated at room temperature for 10 minutes, 42°C 
for 15 minutes (variable depending on the size of the cDNA being generated), 
100°C for 5 minutes then quickly chilled on ice. The cDNA produced by this 
reaction was then amplified by PCR in 50ul of lx  PCR buffer, 0.2uM of each
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primer, 1-2.5 units of Taq polymerase, and overlaid with mineral oil to avoid 
evaporation. This was carried out on a Cambio thermal cycler under varying 
conditions and for different numbers of cycles. Aliquots of the resulting 
samples were run on an agarose gel, and the DNA generated visualized with 
UV light.
13(b) PREPARATION OF AGAROSE MINIGELS
Minigels were prepared to visualize DNA products generated in PCR 
reactions. These were prepared using either a 1-2% solution of agarose in TBE 
buffer (0.89mM boric acid, 0.03mM EDTA, 0.89mM tris-HCl pH8.3), or 3% 
Nusieve agarose + 1% agarose in TBE buffer. The agarose solution was heated to 
allow the agarose to dissolve, then ethidium bromide (2ul of a lOmg/ml stock 
solution) was added to 30ml of the agarose solution after it had cooled. The 
ethidium bromide allows the DNA to be visualized under UV illumination.
DNA samples were loaded in 5ul of sample buffer (5X TBE buffer, 10% w/v 
ficoll, 0.2% w/v bromophenol blue + lOOmM EDTA) and the gels were run with 
TBE as electrophoresis buffer at lOV/cm until the sample dye front had 
travelled the appropriate distance through the gel.
13(b) DNA AS A TEMPLATE FOR PCR
In addition to RNA, genomic DNA was also used as a template for PCR. The 
DNA was isolated as described in section 11 and treated in the same manner as 
the synthesized cDNA in section 13(a).
13(c) CLONING OF PCR PRODUCTS
PCR products were run on a 3% NuSieve agarose gel, visualized by UV 
light and the band of interest excised. The gel slice was then melted at 6 8 °C, 
and the DNA extracted twice with phenol, once with chloroform  and 
precipitated in 3 volumes of ethanol + 0.3M Na acetate. The DNA was next 
ligated into the Smal site of M13mp8.
The precipitated DNA was resuspended in lOul of water and added to 50ul 
of kinase buffer (0.5M tris pH7.6, 0.1M MgCl2 50mM DTT, ImM spermidine, ImM 
EDTA) containing 2 units of kinase, 5 units of ATP and incubated at 37°C for 30 
minutes. This was then put on dry ice to inactivate the kinase enzyme, and the 
samples loaded on a 3% NuSieve agarose gel to repurify the DNA. The DNA was
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visualized using long wave UV light as before, the DNA band excised, the gel 
melted and the DNA extracted twice with TE saturated phenol. The DNA was 
then precipitated as before and resuspended in lOul water.
The kinased DNA (20% of the total sample), was next ligated into M13. The 
reaction included 200ng of phosphatased vector + 2 units of ligase in lOul of 
ligase buffer (50mM tris pH7.5, lOmM MgCl2 , lOmM DTT) which was incubated 
for 4 hours at room tem perature. The ligated DNA and M l3 was then 
transfected into competent bacteria.
13(d) PREPARATION OF COMPETENT BACTERIA
Based on the method of Sambrook et al. (1989), a 0.3ml aliquot of an 
overnight standing culture of bacteria was used to inoculate 30ml of 2YT 
buffer. The culture was grown to an OD of 0.4 -0.6 at 630nm at 37°C. A 30ml 
sample of these bacteria were centrifuged at 2,000rpm for 10 minutes then 
resuspended in 2.5ml of ice cold TFB (lOmM MES, lOmM rubidium chloride, 
45mM manganese chloride, lOmM CaCl + 3mM hexamine-cobaltic chloride) and 
left on ice for 15 minutes. Keeping the sample on ice, the following additions 
were made; lOOul of DMSO, incubated for 5 minutes, followed by lOOul of 
2.25mM DDT + 40mM potassium chloride pH 6 left for 10 minutes, then addition 
of lOOul of DMSO for 5 minutes. This resulted in the production of competent 
bacteria.
A 200ul aliquot of competent bacteria was added to a 3ml tube to which 
20ul of the relevant DNA fragment/vector ligation was added and incubated at 
42°C for 3 minutes. To 3ml of top agar (1% bacto tryptone, 0.8% NaCl +0.8% 
bacto agar) 25ul of 2% Xgal in DMF plus 25ul of 2.5% IPTG in water was added 
and heated to 42°C. This top agar mixture was added to the competent bacteria, 
mixed well then poured onto TYE plates (1.5% agar in 2YT). These were left to 
set for 15 minutes then incubated inverted overnight at 37°C.
A white plaque on the bacterial lawn represented  a su c c e ss fu l 
transformation event, with the blue plaques lacking any cloned DNA insert.
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CHAPTER 4 : RESULTS 
AIMS AND BACKGROUND
A set of transformation specific polypeptides have been identified which 
react with sera from tumour bearing rats (TBS), and antisera raised against 
HSV-2 infected cells (Macnab et al. 1985a, Hewitt et al. 1991). These polypeptides 
were also recognised by the monoclonal antibody TG7A, which was raised 
against cellular polypeptides accumulating on HSV-2 infection (La Thangue & 
Latchman, 1988). The transformation specific polypeptides are of molecular 
weights 200,000, 90,000 (a doublet consisting of the upper and lower 90, named 
U90 and L90), 40,000 and 32,000 (Macnab et al. 1985a; Hewitt, 1988). These have 
been shown to accumulate on HSV infection and to be present in the 
transformed cell (Macnab et al. 1985a).
Initial immunofluorescence studies with tumour cells using antisera raised 
against HSV-2 infected cells, showed fluorescence to be located at the cell 
surface and also within the cell cytoplasm and perinuclear area (Macnab, 1979). 
Immunoprecipitation reactions of cellular fractions using TBS subsequently 
confirmed that the U90 was predominantly membrane associated but was also 
located in the cytoplasm (Hewitt et al. 1991).
Analysis of transform ed, immortalized and control prim ary cells by 
immunoprecipitation of radiolabelled cells, indicated that U90 was present in 
the immortalized and transformed cell lines tested, but not in the control cells 
(Macnab et a l . 1985a). In addition to the above, the U90 shows oncofoetal 
expression in up to 14 day old rat embryos (Macnab, unpublished results) and so 
it is possible that the U90 may have a role in differentiation or proliferation in 
the embryo. The aberrant expression of such a protein could therefore be 
strongly implicated in transformation and tumourigenesis.
Previous attempts to characterize the U90 by purification and amino acid 
sequencing resulted in the sequencing of a contaminant protein (Hewitt, 1988). 
This was almost certainly due to the presence of insufficient purified U90. In 
addition, other workers have suggested that the U90 is related to the heat shock 
protein hsp90 (La Thangue & Latchman, 1988). The aims of this thesis were 
therefore to investigate the U90 polypeptide and its expression, in particu lar 
following HSV infection. After the further characterization of the U90 (to aid 
the purification process), the subsequent objective was to purify and obtain 
amino acid sequence of the U90 in order to identify the polypeptide and to allow 
molecular studies to be initiated. The effect of HSV infection on a second cellular 
polypeptide was also investigated.
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The initial observations that a set of transformation specific polypeptides 
existed in tumour cells was confirmed by repeating the im m unoprecipitation 
(IP) reactions with TBS and cells extracted from  [ ^ S ]  L-m ethionine 
radiolabelled Bn5T cells using RIPA buffer. These IP reactions show the 
presence of the transformation associated polypeptides, U90 and L90 in the 
tumour cell line Bn5T, but their absence in the control RE cells (Figure 1). The 
lower molecular weight polypeptides of 40K and 32K cannot be seen under these 
7.5% SDS page conditions.
Unless otherwise stated all IP reactions reproduced in this thesis were 
analysed by 7.5% SDS page, the gels dried under vacuum and exposed to Kodak X- 
omat S film. Each experiment was carried out on a minimum of three separate 
occasions unless indicated otherwise.
• 200K
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•  • L90
•  45K>
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FIGURE 1 : Autoradiograph of IP reactions with TBS of 4X106 cpm each of 
[35S] radiolabelled polypeptides extracted in RIPA from RE cells (track 1) and 
Bn5T cells (track 2). The U90 and L90 are precipitated from Bn5T cells as 
indicated, but not from RE cells. A 200K polypeptide and a polypeptide believed 
to be actin can be seen in both tracks 1 & 2. A further band (of about 45K) 
migrating close to actin is seen to be preferentially precipitated from RE cells.
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SECTION 1 : CHARACTERIZATION OF U90
1. U90 Can Be Detected Bv Im m unoprecipitation Reactions In Cells Of 
D ifferent Lineages And Species
In addition to the tumour cell line Bn5T, cells of different lineages and 
species were radiolabelled with [3^S] L-methionine and IP reactions with TBS 
performed to visualize the tumour specific U90. These studies were carried out to 
establish if any one cell line expressed elevated levels of the U90 polypeptide in 
order to simplify the purification of the U90.
Im m unoprecipitation of both the human fibroblastic cell line human 
embryonic lung cells (Helu), and the transformed mouse quasi-epithelial cell 
line 12-2 (transformed by HPV-16 and c-fos, Crook et al. 1988) resulted in a 
polypeptide highly similar to the U90 being visualized (Figure 2a). Comparison 
of the peptide maps of the 90K polypeptides and the U90 also showed them to be 
indistinguishable (Figure 2b), indicating that the U90 was expressed in 
epithelial and fibroblastic cells, transformed and established cells, in addition to 
cells from different species - human, mouse and rat.
Analysis by IP reactions of a num ber of additional cell lines, including 
human cell lines, showed that a similar 90K polypeptide was also present. These 
included a human lymphoid cell line, Jurkat, a human breast carcinoma cell 
line MCF-7, a ra t adrenal pheochromocytoma line, PC 12, and the ham ster 
fibroblastic line BHK C13. Although the 90K polypeptide migrated slightly 
differently in some of these cells (Figure 3), peptide mapping analysis of the 
90K polypeptide isolated from the Jurkat cell line confirmed that these 
differences were most likely species or cell type specific as a highly sim ilar 
peptide pattern to the U90 was generated. The digestion pattern  of the 9OK 
polypeptide isolated from Jurkat cells could not be photographically reproduced 
due to the low amounts of radioactivity incorporated in this polypeptide. All 
peptides generated following digestion of both U90 and the Jurkat 90K were of 
14K or less and migrated at similar rates.
These results indicated that the U90 could not only be detected in 
immortalized, transformed and tumour cells of rodents (Macnab et al. 1985a), but 
also in human cells and cells of different lineages such as adrenal, epithelial, 
fibroblastic and lymphoid cells. This indicated that the U90 was highly 
conserved and as such was likely to have an important role in the cell. As a 
consequence of these studies the U90 can no longer be termed tumour specific 
as previously thought, (Macnab et al. 1985a) but rather tumour associated.
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FIGURE 2a : Autoradiograph of IP reactions with TBS, using 4X106 cpm each 
of [35S] L-methionine radiolabelled polypeptides extracted from Bn5T cells 
using RIPA buffer (tracks 1 & 3), 12-2 cells (track 2) and Helu cells (track 4). 
This illustrates the presence of U90 in the Bn5T cells and a similar molecular 
weight polypeptide to the U90 in both 12-2 and Helu cells.
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FIGURE 2b  : Autoradiograph of a comparison of the peptide digestion 
patterns of the 90K polypeptide immunoprecipitated by TBS from 12-2 cells 
(tracks 3, 4 & 5) and U90 from Bn5T cells (track 1) by peptide mapping analysis. 
Digestion was carried  out using 5ng of V8 p ro tease /track  in a 18% 
polyacrylamide gel. Tracks 3 & 5 show the 90K band isolated from 12-2 cells 
following HSV-1 and HSV-2 infection respectively with track 4 showing a 90K 
band isolated from uninfected 12-2 cells. Molecular weight markers are shown 
in track 2 and their values in kilodaltons indicated to the left of the photograph.
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FIGURE 3 : Autoradiograph of IP reactions with TBS using 4X106 cpm each of 
[35S] L-methionine radiolabelled polypeptides extracted using RIPA buffer from 
MCF-7 cells (tracks 2, 3 & 4) and Bn5T cells (track 5), illustrating a 90K 
polypeptide in MCF-7 cells of slightly lower molecular weight than U90. Tracks 
3 and 4 show MCF-7 cells following HSV-1 and HSV-2 infection respectively. In 
track 4 precipitation of HSV-1 viral polypeptides of 175K, 155K, 136K and 11 OK 
can be seen and are indicated (•) to the right. This is a feature common in IP 
reactions carried out in the presence of viral polypeptides. The corresponding 
HSV-2 values (track 3) are 182K, 157K and 140K (not shown) respectively. Track 
1 shows molecular weight markers with values indicated to the left of the 
photograph.
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2(a) HSV Infection Increases U90 Expression In Bn5T Cells
The original studies of Macnab et al (1985), showed that after HSV-2 infection,f
| U90 was increased as detected by a monoclonal antibody (MAB) TG7A. This MAB
I however was unable to detect an increase in U90 following HSV-1 infection. The
assumption was therefore made that the U90 was probably more efficiently 
induced by HSV-2 than HSV-1 infection. I firstly addressed this problem  by 
investigating both HSV-1 and HSV-2 infection in BnST cells using TBS. It was noti
| possible to repeat the studies using the TG7A antibody as this antibody was not 
! made available. TBS was therefore used as a substitute.
! HSV-1 and HSV-2 infection of Bn5T cells radiolabelled with [ ^ S ]  l-
| methionine was carried out for a period of 17 hours at a multiplicity of 5-
lOpfu/cell and analyzed by IP reactions using TBS, followed by separation using 
| SDS page. Exposure of the dried gel to Kodak X-omat S film showed that more
i
| radiolabelled U90 was immunoprecipitated in both the HSV-1 and HSV-2 infected
I samples compared to the uninfected samples. Figure 4a shows a representative
I autoradiograph of an IP of HSV-2 infected and uninfected control Bn5T cells and
i
the data from the corresponding densitometer scan can be seen in Figure 4b. 
j Densitometer scanning at a later stage showed the U90 to be increased by 3.1
fold following HSV-2 infection and 5.3 fold following HSV-1 infection after 17 
| hours. The induction of U90 by HSV-2 was initially believed to be of the same
I order as tha t of the induction of U90 by HSV-1, however the subsequent
I availability  of the Shimadzu scanning densitom eter (D epartm ent of
1 Biochemistry, Glasgow University) indicated that this was not the case in the
| gels subjected to quantitative analysis. However, in general HSV-2 does increase
| U90 efficiently.
To ensure that the 90K polypeptide im m unoprecipitated following HSV 
infection was indistinguishable from the U90 as seen in the uninfected cell, 
peptide mapping analysis was carried out using Staph, aureus V8 protease 
(Figure 5). Enzymatic digestion under these conditions was carried out to the 
limit of possible digestion and shall therefore described as total digestion in this 
thesis. Comparison of the resulting total digestion patterns of the U90 isolated 
from infected and uninfected Bn5T cells showed the two polypeptides to have 
indistinguishable digestion patterns.
2(b) HSV Infection Increases U90 In Homan and  Mouse Cells
Infection of the 12-2 and Helu cell lines with either HSV-1 or HSV-2 (5- 
lOpfu/cell for 17 hours at 37°C), also resulted in increased amounts of U90 being 
detected by imm unoprecipitation of [35 s] L-methionine radiolabelled cell 
polypeptides by TBS (Figure 6a), unfortunately the control Helu track was
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FIGURE 4 a  : Autoradiograph of IP reactions with TBS using 4X106 cpm each of 
[35S] L-methionine radiolabelled polypeptides extracted using RIPA buffer from 
Bn5T control cells (track 1), Bn5T cells infected with lOpfu/cell HSV-1 (track 2) 
and Bn5T cells infected with lOpfu/cell HSV-2 (track 3). Cells were infected at 
lOpfu/cell for 17 hours at 37°C. Increased background polypeptides in tracks 2 
and 3 are usually seen and are most probably as a result of co-precipitation of 
viral polypeptides with the immune complexes as discussed previously.
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FIGURE 4b  Quantitation of U90 visualized following IP reaction with TBS in 
Figure 4a. The above data was generated by scanning the resulting U90 bands 
on the autoradiograph using a Shimadzu CS-9000 dual-wavelength flying spot 
scanning densitometer and zig-zag scanning with the resulting data being the 
mean of 11 scans, as detailed in Method 7(i). The resulting error generated was 
insignificant (and too small to be visualized on the above graph). HSV-1 
infection in this experiment resulted in a 5.3 fold increase and HSV-2 infection 
resulted in a 3.1 fold increase. Both HSV types 1 and 2 infection were found to 
result in an increase of U90 on a minimum of 5 occasions, ranging from a 2.5 - 
5.3 fold increase (Hewitt et al. 1991).
FIGURE 5 : Autoradiograph of a comparison of the peptide digestion patterns 
of U90 bands immunoprecipitated by TBS and cut from dried gels. U90 bands 
were isolated from control Bn5T cells (track 4), HSV-1 infected Bn5T cells (track 
3) and HSV-2 infected Bn5T cells (track 2) and compared by peptide mapping 
analysis. Digestion was achieved using 5ng/track of V8 protease in an 18% SDS- 
page system. Molecular weight markers are present in track 1 and their values 
indicated in kilodaltons to the left of the gel.
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FIGURE 6a : Autoradiograph of IP reactions with TBS using 4X106 cpm each of 
[35S] L-methionine radiolabelled polypeptides extracted using RIPA buffer from 
12-2 cells (tracks 2, 3 & 5) and Helu cells (tracks 6 & 7), where U90 is indicated 
by a filled triangle. Tracks 3 & 6 show cells following HSV-1 infection and 
tracks 5 & 7 cells following HSV-2 infection. Bn5T cells IP with TBS are shown in 
tracks 1 & 8 with molecular weight markers in track 4 (whose values are 
indicated in kilodaltons to the left of the gel). All viral infections were carried 
out at lOpfu/cell for 17 hours at 37°C. Unfortunately the control Helu track was 
removed but a comparison of Bn5T and Helu cells can be seen in Figure 2a.
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removed by error, but can be compared with the uninfected Helu cells shown in 
Figure 2a. Densitometer scanning of the resulting autoradiograph of the 12-2 
cells IP reaction confirmed this induction (Figure 6b). It could therefore be 
concluded that HSV infection of not only Bn5T cells, but of other human and 
rodent cells from which the U90 could be immunoprecipitated, resulted in the 
increase of the U90 polypeptide. No cell type however was found which 
expressed greater quantities of U90 than the Bn5T cell line.
3. HSV Infection Increases Total U90 Content In The Cell
The in crease  in U90 following HSV in fec tion , as seen by 
immunoprecipitation of radiolabelled cell polypeptides could occur by at least 
two distinct mechanisms. The increase could either be a consequence of larger 
quantities of the U90 polypeptide being present in the infected cell, or 
alternatively the U90 in the infected cell could incorporate more radiolabel, 
thus generating a stronger U90 band - as seen by autoradiography.
To determ ine which of these two mechanisms was correct, gels with 
rad io labelled  IP reactions of HSV-2 infected and uninfected Bn5T cell 
polypeptides, were stained with Coomassie blue to quantitatively as well as 
qualitatively analyze the amount of U90 in each sample. Coomassie blue staining 
indicated that an order of 8 fold more U90 was present in the infected cell 
compared to the uninfected cell as determ ined by densitom eter scanning 
(Figure 7a), and that the increase in U90 following infection was at least as 
much as was seen by autoradiography. Technical difficulties which occur when 
scanning a Coomassie blue stained gel meant that a photographic reproduction 
of the gel had to be scanned. This might possibly result in a less accu ra te  
quantitation as com pared to scanning an autoradiograph (which was not 
possible), but was not subsequently proven. To illustrate this, the stained gel has 
also been reproduced in Figure 7b.
It was therefore concluded that the increase in the U90 as seen by 
radiolabel incorporation was in fact due to an increase in the total amount of 
U90 in the cell
4. An Earlv Event In HSV Infection Increases U90
To investigate the stage of HSV infection at which the U90 was induced, 
BnST cells infected with HSV-2, at 5-10pfu/cell at 37°C, were radiolabelled with 
[35 s] L-methionine, harvested at regular intervals between 2 and 16 hours post 
adsorption, and imm unoprecipitated with TBS. The result indicated that the 
increase in U90 was clearly visible by 3 hours post adsorption and was therefore 
a consequence of an early event after HSV infection.
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FIGURE 6b : Densitometer scan of U90 in control (uninfected), HSV-1 and 
HSV-2 infected 12-2 cells following IP reactions with TBS and visualization by 
autoradiography. In a similar manner as seen with Bn5T cells, HSV-1 induced 
slightly greater amounts of U90 in the 12-2 cells than HSV-2. The above data was 
generated by scanning the resulting U90 bands on the autoradiograph using a 
Shimadzu CS-9000 dual-wavelength flying spot scanning densitometer and zig­
zag scanning with the resulting data being the mean of 11 scans, as detailed in 
Method 7(i). Error bars cannot be seen due to the very small error produced by 
the scanner.
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FIGURE 7a : Densitometer scan of U90 in control (uninfected) and HSV-2 
infected Bn5T cells after IP with TBS as visualized by Coomassie blue staining. 
The above data was generated by scanning the resulting U90 bands on a 
photographic reproduction of the stained gel as seen in Figure 7b. A Shimadzu 
CS-9000 dual-wavelength flying spot scanning densitom eter was used as 
described previously with the resulting data being the mean of 11 scans, as 
detailed in Method 7(i). Error bars cannot be seen due to the insignificant error 
produced by the scanner.
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FIGURE 7b  : IP reactions with TBS using 500ug each of polypeptides 
extracted using RIPA buffer from control Bn5T cells (track 1) and HSV-2 
infected (lOpfu/cell at 37°C for 17 hours) Bn5T cells (track 2) visualized by 
Coomassie blue staining. The U90 band indicated above (•) was identified by 
overlaying the stained gel with the corresponding autoradiograph of the gel 
which clearly showed the immunoprecipitated U90. The positions of molecular 
weight markers (shown in kilodaltons) are indicated to the right of the figure. 
The additional stained bands are bacterial polypeptides generated by the use of 
Pansorbin [(Calbiochem), a comercial preparation of a suspension of S.aureus 
Cowan 1 strain, which expresses a coat of protein A), as a alternative to protein 
A sepharose.
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This was further investigated by pulse-labelling HSV-2 infected Bn5T cells 
for 2 hours at 1, 3, 5 and 7 hours post-absorption. The am ount of [35 s] L- 
methionine incorporated in the U90 in the infected and uninfected cells was 
quantitated by densitometer scanning of the IP reactions of cells labelled and 
harvested at these time points. Comparison of newly synthesized U90 in infected 
and uninfected Bn5T cells shows that the greatest increase in U90 as a 
consequence of HSV infection, which was 720% of the control cells, occurs 
within 1-3 hours post adsorption (Figure 8). By 7-9 hours post absorption the 
increase in U90 as a consequence of HSV infection has fallen from 720% of the 
uninfected U90 to only 300%. These results confirmed that an event prior to the 
onset of viral DNA synthesis was involved in the induction of 1190, ie either an 
immediate early function of HSV, or an earlier event (ie viral adsorption or 
en try).
5. Identification of HSV Function Involved In U9Q Induction
A selection of viruses mutated in immediate early (IE) genes were used to 
investigate the possibility that an IE event in infection increased the U90. 
Intially t$K (Preston 1981), a tem perature sensitive m utant of Vmwl75 which 
over-expresses Vmwl75 and the other IE genes at its non-perm issive 
temperature (38.5°C) was used. Infection of Bn5T cells with tsK at 5-10pfu/cell at 
both the PT of 31°C for 17 hours and the NPT of 38.5°C for 8 hours, was seen to 
increase U90 (Figure 9a). This suggested as before, that an early event in 
infection increased U90 - ie, either an IE function or an event prior to this, 
such as viral adsorption or entry to the cell. Infection with tsK at the NPT was 
carried out for 8 hours (as opposed to 17 hours) as previous work indicated that 
infection for longer periods of time resulted in a breakdown product of 90K 
being generated (McDonald, 1980).
Experiments carried out by two undergraduate students Helen Ritchie and 
John Yates using various HSV mutants investigated this aspect further. Their 
work confirmed that neither viral adsorption nor entry into the cell resulted in 
the induction of U90. This was done by infecting cells with either UV irradiated 
virus or HSV in the presence of actinomycin D (to inhibit transcription). 
Neither of these conditions resulted in an increase of U90 expression as seen by 
immunoprecipitation.
In order to expand the experiment investigating U90 induction following 
early infection, in addition to tsK infection at the non-permissive tem perature 
(NPT) which resulted in the over-expression of IE genes, the viruses isT and t§D 
were also investigated. Both viruses which contain m utations in Vmwl75
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FIGURE 8 : The amount of U90 expressed in HSV-2 infected cells at 1-3, 3-5, 5-7 
and 7-9 hours post-adsorption is expressed in this graph as a % of the amount of 
U90 in control cells at corresponding time points. Cells were radiolabelled with 
[35S] L-methionine for a period of 2 hours, polypeptides analyzed by IP with 
TBS, the U90 visualized by autoradiography and quantitated in both control and 
HSV-2 infected Bn5T cells by scanning the resulting U90 bands on the 
autoradiograph using a Shimadzu CS-9000 dual-wavelength flying spot 
scanning densitometer and zig-zag scanning with the resulting data being the 
mean of 11 scans, as detailed in Method 7(i). Error bars cannot be seen due to 
the insignificant error produced by the scanner.
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FIGURE 9a : Autoradiograph of IP reactions with TBS of [35S] L-methionine 
labelled polypeptides extracted using RIPA buffer from control Bn5T cells at 
3 7°C (track 1), Bn5T cells infected with tsK at 38.5°C for 8 hours (track 2), 
infected with tsK at 31°C for 17 hours (track 3), control cells at 31°C (track 4) 
and cells infected with HSV-2 at 37°C for 17 hours (track 5). To the right of the 
gel U90 is indicated (•) and molecular weight markers are shown in track 6 and 
their values shown in kilodaltons. All infections were carried out at lOpfu/cell.
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(Preston, 1981) over-express the IE genes at the NPT and were found to induce 
U90.
Bn5T cells were infected with a m utant in l411, which expresses a small 
truncated non-functional Vmwl75 due to the introduction of a stop codon 
between codons 83 and 84 (Russell et al. 1987). Similar levels of U90 were seen in 
the inl411 infected cells as compared to the control Bn5T cells. However, the tsK 
m utant which over-expresses a non-functional Vmwl75 greatly increases U90 
at the NPT. Figure 9b shows the induction of U90 following isK infection at the 
NPT, compared to basal levels of U90 in cells infected with in l411  and control 
Bn5T cells. (The virus inl411 is not a temperature sensitive m utant and as such, 
the control for this virus is infection of Bn5T cells with HSV-1 at 37°C, which 
has been clearly demonstrated previously to induce U90). Infection of Bn5T 
cells with tsK at the PT as indicated in Figure 9a, resulted in an increased U90 as 
would be expected, since tsK at 31°C behaves as wild type. This is similar to the 
induction of U90 seen following infection with tsD and tsT, which also express 
non-functional Vmwl75. This confirms that the induction of U90 by HSV 
infection is independent of the expression of a Vmwl75 polypeptide functional 
for transactivation, which is required under normal circumstances for viral E 
polypeptide induction, but the expression of the first 83 amino acids of Vmwl75, 
as seen in inl411, is insufficient for U90 induction.
It could therefore be concluded tha t certain sequences of Vmwl75 
were essential for the increase in expression of the U90 following HSV 
infection, bu t virus with a m utation rendering Vmwl75 non-functional fo r 
lytic infection was nevertheless capable of inducing U90. How Vmwl75 induces 
U90 is not known. It could act in an indirect m anner by stimulating the other IE 
genes (which was previously thought to be the case in studies on HSV 
replication, Wu et al. 1988), or Vmwl75 could act directly on U90 induction.
6. Does HSV Infection Alter The Half-life Of U90?
The increase in the total amount of U90 present in the cell following HSV 
infection could occur at a num ber of stages during the synthesis of the 
polypeptide. At this point only the possibility that the half-life (or turnover) of 
U90 polypeptide was altered by HSV infection could be investigated as no DNA 
sequence data was available to investigate the levels of U90 mRNA in the cell. 
The experiments to investigate the U90 half life were done by pulse chase 
experiments, as described below.
Pulse chase experiments were carried out on infected and uninfected Bn5T 
cells by radiolabelling, then varying the chase period between 3 and 24 hours. 
IP reactions of each of these conditions indicated that very little difference
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FIGURE 9b : A utoradiograph of IP reactions with TBS of [3$S] L-methionine 
labelled polypeptides extracted using RIPA buffer from Bn5T control cells 
(track 1), Bn5T cells infected with in l411 at lOpfu/cells for 17 hours at 37°C 
(track 2) and Bn5T cells infected by tsK at the NPT of 38.5°C for 8 hours using 
lOpfu/cell (track 3). tsK infection at the PT of 31°C resulted in a characteristic 
increase in U90 as expected of an HSV-1 infection (Figure 9a). Markers in 
kilodaltons are indicated to the left of the gel. This experiment was kindly  
carried out by Helen Ritchie.
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could be seen between the half life of the infected and uninfected U90 (Figure 
10). Due to technical difficulties in achieving incorporation  of sufficient 
radiolabel in the U90, densitometer scanning of the resulting autoradiographs 
was very difficult. The data for this experiment was therefore limited. The data 
available however do indicate that the half life of the U90 in the infected and 
control Bn5T cells are fundamentally the same with the half life of the U90 in 
control Bn5T cells being estimated 10 hours and 4 minutes and 12 hours 54 
m inutes in the infected cells. These figures can can only be taken as 
approximate values due to the limited nature of the data. It should be noted 
however that a similar result for the U90 half life was later obtained by Macnab 
& McNab (personal communication). It was concluded that this difference in the 
half life of the U90 was most probably due to experim ental error as a 
consequence of the limited data which could not account for the 8 fold increase 
in U90 seen at an early stage in infection. Therefore, the increase in U90 in the 
infected cells was not due to a stabilization of the U90 by post-translational 
modification.
7. A lteration Of U90 Location Following HSV Infection
Studies by Macnab & McNab had previously shown that the U90 was 
predominantly located in the membrane associated fraction of uninfected Bn5T 
cells. However, following HSV-2 infection of Bn5T cells, (5-10pfu/cell for 17 
hours a t 37°C), quantitative analysis of the membrane and cytoplasmic fractions 
(generated by cell fractionation) was carried out by western blotting using TBS 
and the monospecific U90 antibody (Methods section 3b). This indicated that 
only one band could be seen in the western blot, the U90, which accumulated in 
the cytoplasmic fraction of the cell following HSV infection (Figures 11a & 11b). 
All western blots in this thesis were reproduced by a combination of laser 
printing and photocopying which ne ither in troduced  no r rem oved any 
background material. The western blot in Figure l i b  was kindly carried out by 
Dr JCM Macnab. Cell fractionation was obtained as described in Methods, Section 
6b, by swelling cells in a hypotonic buffer, dounce homogenization to release 
the cytoplasmic proteins followed by a detergent extraction of the membrane 
proteins.
Purification of the U90 from the membrane fraction had previously been 
found to be very difficult as a consequence of the U90 being m em brane 
associated and also only being present in small amounts (Macnab & McNab, 
unpublished results). The fact that the U90 was present in a soluble form in the 
cytoplasm of infected cells greatly improved the possibility of purifying the
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FIGURE 1 0  : Densitometer scan of U90 in control (uninfected) A and HSV-2 
infected Bn5T cells (•) after 7 hours [35S] L-methionine radiolabel, followed by 
a chase period of either 17 or 24 hours with excess cold methionine. Cells were 
then harvested, extracted with RIPA buffer, IP with TBS, analysed by SDS-page 
| and visualized by autoradiography. Data correspond to the area under the peak 
when the U90 band on the autoradiograph was quantitated  by scanning 
densitometery, as described previously.
The equations of the curves (as determined assuming exponential decay 
using the Apple Macintosh program m e Cricket graph version 1.3.2) are 
illustrated adjacent to the respective curves, which allows the half life of the 
U90 in control Bn5T cells and HSV-2 infected Bn5T cells to be calculated. The 
half life of U90 was found to be 12 hours 54 minutes in HSV-2 infected cells and 
10 hours 4 minutes in control BnST cells. This difference is thought to be due to 
experimental error as a consequence of the limited data which was readable by 
the scanner.
FIGURE 11a : Western blot with TBS of Bn5T cells infected by HSV-2 
(lOpfu/cell for 17 hours), and polypeptides extracted from the cytoplasmic 
fraction (track 1) and membrane fraction (track 2) showing an accumulation of 
the U90 in the cytoplasmic fraction. To visualise, anti-rabbit immunoglubulin 
conjugated to horse radish peroxidase was used with N'chloronapthol.
All western blots were reproduced by a combination of laser printing 
and photocopying which neither introduced nor removed any background 
material. Confirmation of this statement can be seen in Figure 33 where a blot 
has been re-produced using photography (Figure 33b) compared with laser 
printing (Figure 33a).
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FIGURE l i b  : Immunoprecipitation with TBS of polypeptides extracted from  
the cytoplasmic fractions of control (track 1) and HSV-2 infected Bn5T cells 
(track 2) followed by western blotting with U90 monospecific antiserum  
confirms that HSV infection results in the accumulation of the U90 in the 
cytoplasm and that the U90 antibody does in fact recognise the U90. Figure l ib  
was kindly completed by Dr. JCM Macnab.
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U90. It should also be noted, that the alteration of the location of the U90 as a 
consequence of HSV infection, may have a significant effect on the cell.
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DISCUSSION OF SECTION 1: CHARACTERIZATION OF U 90
It was previously reported that the accumulation of the U90 polypeptide 
was a common feature of transformed and immortalized cells, but not of primary 
or secondary cells (Macnab et al. 1985a & Figure 1). It was therefore proposed 
that the accumulation of such a polypeptide is likely to be of importance at the 
level of immortalization of the cell (Macnab et al. 1985a). The U90 polypeptide 
was also seen to be recognised by antisera raised against HSV-2 infected cells, 
indicating that cellular polypeptides accumulating as a consequence of HSV 
infection may be implicated in the initiation of transform ation  by HSV 
infection (Macnab et al. 1985a).
The characterization studies described in Section 1 were carried out to 
provide a better understanding of the U90. In addition, these findings were 
utilized to determine the conditions under which maximal U90 was expressed in 
order to obtain larger amounts of U90 as starting material for the purification 
of the polypeptide.
These studies showed that the U90 polypeptide can be radiolabelled and 
immunoprecipitated using TBS not only from ra t tumour cells but also from 
mouse and human cells. Cells of different lineages also displayed the U90 (as 
seen by IP reactions) which included adrenal, epithelial, fibroblastic and 
lymphoid cells. The presence of the U90 in such a diverse range of cells 
indicated that the U90 is highly conserved and as such, is likely to play an 
important role in the cell.
In these studies the U90 could by detected not only in transformed and 
immortalized cells but also in cells which are neither im m ortalized nor 
transformed but are only capable of passage in cell culture for a finite period of 
time. U90 was not imm unoprecipitated from prim ary and secondary cell 
cultures under similar radiolabelling conditions despite exhaustive attempts. 
This indicated that the ability of TBS to im m unoprecipitate the U90 from 
radiolabelled cells using TBS does not require immortalization of the cell line, 
but is correlated with the ability to passage cells in culture over a considerable 
number of doublings. From these results it was concluded that the change the 
U90 undergoes to enable it to be visualized by radio-immunoprecipitation in 
transformed, immortalized and cells established in culture, is an early stage in 
one of the many steps towards the progression of a "normal” cell to that of a 
cancerous phenotype.
Experiments with HSV infection showed that external factors can alter the 
cell’s control of U90 expression in Bn5T cells. HSV infection with either type 1
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or type 2 virus was found to increase the U90 detected in the cell. In order to 
investigate if the increase in the U90 was an increase in the incorporation of 
radiolabel in the U90 or a real increase in the total amount of U90 synthesized, 
comparative studies using radiolabelling ([35S] L-methionine) and staining for 
total cell protein (Coomassie blue staining) were carried out.
A uto rad iography  of con tro l and  in fec ted  Bn5T po lypep tides 
imm unoprecipitated by TBS showed the presence of a greater total amount of 
radiolabelled U90 in the infected cell compared to the control cell. At least an 
equivalent increase was observed when the gel was stained with Coomassie blue 
(Figure 7b) and analyzed by scanning densitometery. This confirmed that HSV 
infection increased the total amount of U90 polypeptide in the cell as opposed to 
increasing the metabolic turnover of the U90 and hence the am ount of 
radiolabel it incorporated.
The increase in U90 following HSV infection could have been a 
consequence of transcriptional activation or post-translational modification 
resulting in a stabilization of the polypeptide. As no sequence data for U90 was 
available, the levels of the U90 mRNA before and after HSV infection could not 
be investigated. As an alternative, the half life of the U90 polypeptide was 
investigated to establish if HSV infection resulted in a post-translational 
modification which stabilized the polypeptide and thus increased the to ta l 
amount of U90 seen in the cell. The half life of the U90 in the uninfected Bn5T 
cell was found to be in the order 10 hours with the U90 in the HSV infected cell 
having a half life of around 13 hours. This difference in half life, which is most 
likely to be due to experimental error, would not explain the 8 fold increase of 
U90 found in the infected cell immediately after infection. It is therefore 
unlikely that the U90 is increased by a post-translational event but rather a 
transcriptional or post-transcriptional event. Both of these events would result 
in an increased amount of U90 message being present, either by transcriptional 
activation or by increasing the stability of the message.
The investigations with HSV indicated that the U90 was increased as a 
consequence of an early event in viral infection, with the greatest increase in 
U90 synthesis being prior to or at the onset of DNA replication (which is 
detected at 3 hours post-infection). Neither viral adsorption nor viral entry 
were sufficient for this induction of the U90, but expression of immediate early 
genes appeared to be implicated in the U90 induction as over-expression of IE 
polypeptides by tem perature sensitive m utants resulted in increased U90 
expression. Vmwl75 which was functional for transactivation of early gene 
expression however, was not found to be essential for U90 induction. Although a 
m utant in 1411 expressing a non-functional greatly truncated Vmwl75 could not
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induce U90, tsK which over-expresses a non-functional Vmwl75, is still capable 
of U90 induction. Whether Vmwl75 acts in a direct or indirect manner could not 
be determined. Vmwl75 has been previously suggested to act in an indirect 
rather than direct manner in viral replication (Wu et a l  1988). In this study Wu 
and co-workers used transient assays to determ ine the essential functions 
required for viral replication. Vmwl75 has also previously been established as 
having the ability to transactivate gene expression (reviewed in Everett, 1987). 
This could explain the requirem ent for Vmwl75 in U90 induction, how ever 
experiments with transfected Vmwl75 and Bn5T cells completed by both Dr 
J.C.M. Macnab and Helen Ritchie were disappointingly inconclusive.
In subsequent work (Dr J.C.M. Macnab), HSV viral replication was 
inhibited by phosphonoacetic acid (PAA), resulting in an accumulation of U90 
(Grassie et al. 1993). From this it has been postulated that the U90 which is 
increased by viral IE synthesis is depleted by viral replication. This corresponds 
to the observation in this section that the U90 is increased by up to 8 fold 
between 1-3 hours post adsorption, but at later stages in the infection the 
radiolabelled U90 detected falls to a 3 fold increase (compared to control cells).
A further consequence of HSV infection on U90 in the cell was that it 
altered the sub-cellular location of the polypeptide. Previous studies (Hewitt et 
al, 1991), have shown U90 to be primarily located in the membrane associated 
fraction of the cell. However, following HSV infection, these studies showed that 
the majority of U90 was found to be in the soluble cytoplasmic fraction of the 
cell. Analysis of the detergent-solubilized membrane fraction and the nuclear 
fraction also showed a small amount of U90 to be present in these fractions. It 
was impossible however to determ ine if the presence of the U90 in these 
fractions was due to contaminating U90 from the cytoplasm or whether small 
amounts of U90 were also present in both of these fractions. Previous work 
which generated monoclonal antibodies (MAB), raised against DNA binding 
proteins extracted from HSV-2 infected cells and affinity purified by a DNA 
binding matrix, facilitated the isolation of an antibody, TG7A which recognised 
U90 (Macnab et al. 1985a). This indicates that the U90 detected in the nuclear 
fraction maybe a consequence of U90 associating with a DNA binding protein. It 
is also possible, that in fact more U90 is present in the nucleus than the IP 
reaction detected. This could be the case if the U90 were to bind to the DNA or 
become associated with a DNA binding complex, so resulting in a conformational 
change or masking the antigenic site recognised by the antibody such that the 
U90 was not recognised in an IP reaction. The small proportion of the U90 
imm unoprecipitated in the nuclear fraction is probably not complexed with 
other proteins or DNA and hence can react with the antibody in an IP reaction.
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The presence of the U90 in the nucleus could now be investigated by western 
blotting the three sub-cellular fractions, an experiment which could not be 
carried out at the time as an antibody which recognised U90 under western 
blotting conditions was not yet available.
In summary, the work described in this section to characterize the U90, 
showed the U90 was present in a number of cell lines of different types and 
species, including human cells. The total amount of U90 isolated from the cell 
could be increased by HSV-1 and HSV-2 infection in all cells tested, where the 
increase in the total amount of U90 occurred in a manner which did not alter 
the half-life of the polypeptide. An early event in HSV infection was 
responsible for this increase with Vmwl75 playing a essential role. However, 
whether Vmwl75 acts in a direct or indirect manner is uncertain.
Following HSV infection the increased U90 was altered in its location and 
found predom inantly in a soluble form in the cytoplasmic fraction. This 
solubility compounded with the increase in the total amount of U90 offered the 
opportunity to purify the U90 with much greater ease from the cytoplasmic 
fraction of HSV infected Bn5T cells as compared to purifying it from the 
membrane fraction of uninfected Bn5T cells.
These results were used to define the conditions of the starting material to 
give high levels of expression of the U90 and hence optimize the purification of 
the U90. The purification strategy and how it was achieved will be discussed in 
section 3.
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SECTION 2 : HSV-1 INFECTION ALTERS GRP94 EXPRESSION
1. HSV-1 Infection Alters GRP94 Expression
During the characterization of the U90 polypeptide expression in RE and 
Bn5T cells, it was consistently noted that a polypeptide of a slightly higher 
molecular weight than U90 (as seen by SDS page) was immunoprecipitated by 
TBS from HSV-1 infected Bn5T cells and HSV-1 infected RE cells. This section 
outlines the analysis of this polypeptide.
Infection of control RE cells with 5-10pfu/cell of HSV-1 for 17 hours at 
3 7°C resulted in the induction of a polypeptide of approximately 94,000 
m olecular weight, as seen by im m unoprecipitation with TBS of [ ^ S ]  l- 
m ethionine radiolabelled polypeptides and analysis by SDS page. On going 
studies at this time were investigating the possibility that the U90 was a stress 
protein, related to either the heat shock protein hsp90, or the glucose regulated 
polypeptide GRP94. This was possible as TBS had been previously shown to 
possess activity against GRP94 (Amy Lee, personal comm unication). To 
investigate this, GRP94 was induced in RE cells by treating with either 50mM 
tunicamycin, (Olden et al. 1979, Duskin & Mahoney, 1982), 6X10"7M calcium 
ionophore A23187 (Welsh et al. 1983, Drummond et al. 1987) or growing the cells 
in medium lacking glucose (Pouyssegur et al. 1977). Tunicamycin induces GRP94 
as a consequence of the inhibition of glycosylation of cell polypeptides (Olden 
et al. 1979). This has recently been reported to cause the malfolding of 
polypeptides which in turn  induces GRP94 (Kozutsumi et a l. 1988). Calcium 
ionophore A23187 is thought to induce both GRP94 and GRP78 which are 
coordinately regulated (Chang et al. 1989), by depleting intracellular calcium 
stores (Drummond et aL 1987). Hsp90 was induced by heat shocking the cells at 
42°C for 2 hours then transferring them to 37°C where they were radiolabelled 
either immediately, or after 30 m inutes for 6 hours (Hewitt et al. 1991). 
Comparison of the U90 to the induced stress proteins by SDS page showed the 
U90 to be quite distinct (Hewitt, 1988). Peptide mapping analysis and comparison 
of the U90 partial amino acid sequence (discussed later in Results Section 4.6) to 
the published GRP94 and hsp90 sequences also showed U90 to be distinct from 
either of these proteins. However comparison of RE and Bn5T cells infected with 
HSV-1 with cells treated with either tunicamycin (Bn5T cells) or the calcium 
ionophore A23187, showed that the polypeptide of molecular weight 94Kda 
induced by HSV-1 migrated at the same position as GRP94 on SDS page (Figures 
12 & 13a &b respectively).
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FIGURE 1 2 : Autoradiograph of IP reactions with TBS (tracks 1, 3 & 6) and 
Mab PR-6 specific for GRP94 (tracks 2, 4 & 7) using 4X106 cpm each of [35S] L- 
methionine radiolabelled polypeptides extracted using RIPA buffer from 
control Bn5T cells (tracks 1 & 2), tunicamycin treated Bn5T cells - final 
concentration 2ug/ml for 17 hours (tracks 3 & 4) and HSV-1 infected Bn5T cells 
- with lOpfu/cell for 17 hours at 37°C (tracks 6 & 7). GRP94 is indicated by a 
triangle and GRP78 by •. Molecular weight markers are shown in track 5 and 
values in kilodaltons indicated to the right of gel.
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FIGURE 1 3a : Autoradiograph of IP reactions with TBS (tracks 1, 3 & 4) and 
the polyclonal monospecific antibody against GRP94 (tracks 2, 5 & 6) using 
4X106 cpm each of [35S] L-methionine radiolabelled polypeptides extracted 
using RIPA buffer from control RE cells (tracks 1 & 2), tunicamycin treated RE 
cells - final concentration of 2ug/ml for 17 hours (tracks 3 & 6) and HSV-1 
infected RE cells - with lOpfu/cell for 17 hours at 37°C (tracks 4 & 5). GRP94 is 
indicated by a triangle and GRP78 by •. Molecular weight markers are shown in 
track 7 and values in kilodaltons indicated to the right of gel.
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FIGURE 1 3b : Autoradiograph of IP reactions with TBS (tracks 1 & 3) and Mab 
PR-6 against GRP94 (tracks 2 & 4) using 4X106 cpm each of [35Sj L-methionine 
radiolabelled polypeptides extracted with RIPA buffer from tunicamycin treated 
RE cells, 2ng/ml final concentration for 17 hours (tracks 1 & 2) and calcium 
ionophore treated RE cells - at a final concentration of 6 x 1 0 " for 17 hours 
(tracks 3 & 4). Both GRP94 (triangle) and GRP78 (•) can be seen in all four 
tracks as they are coordinately regulated (Chang et al. 1989). In tracks 3 & 4 a 
num ber of forms of GRP94 can be seen due to the varying extent of 
glycosylation induced by the calcium ionophore, GRP94 is not expressed in 
control cells as shown in Figures 13a and 14.
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As in d icated  ab ove TBS had p rev iou sly  b een  show n to have a n t ib o d y  
activity against GRP94 (Amy Lee, personal com m unication). This was confirm ed  
b y a ser ie s  o f im m u n o p rec ip ita tio n  rea ctio n s  o f  tu n ic a m y c in  tr e a te d  
radiolabelled cells using d ifferent antibodies w ith activity against GRP94 after a 
control experim ent was com pleted  to ensure that GRP94 did n ot non-specifically  
bind to Pansorbin p rotein  A com plexes. IP reactions using TBS, a m onoclonal 
an tib o d y  MAb PR-6 aga in st GRP94, a g ift from  Prof. D. Edwards and  a 
m onospecific polyclonal an tibod y raised  against endoplasm in  (ie GRP94, Smith  
& Koch, 1987), a gift from  Dr G ordon Koch, in d icated  that TBS did  in  fact 
recogn ize GRP94 (Figure 14). T hese ob servation s su ggested  that the HSV-1 
induced 94 ,000  m olecular w eight polypeptide m ay in  fact be GRP94.
To investigate this further the GRP94 specific antibodies were used to see if 
th ey  recogn ised  the HSV-1 in d u ced  p olypeptid e. This in clud ed  MAb PR-6, the  
polyclonal an tibod y  raised  against en doplasm in  and an an tipeptide antibody  
raised against the first 20 am ino acids o f the am ino term inal region  o f  GRP94, a 
gift from  Drs Ullrich and Appella (d eta iled  in  Materials: Section 7). IP reactions  
w ere carried out using th ese antisera with RE cells and Bn5T cells radiolabelled  
with P ^ S] L -m ethionine and  treated  w ith  tunicam ycin , calcium  ion op h ore or 
in fected  w ith  HSV typ es 1 and  2. A nalysis o f  th ese  IP reactions by SDS page  
follow ed by autoradiography, resulted  in  the visualization  o f a 9 4 ,0 0 0  m olecular 
w eight polypeptide in  the HSV-1 in fected  cells and the tunicam ycin treated cells  
(Figures 12 & 13a). T his 9 4 ,0 0 0  m olecular w eigh t p o lyp ep tid e  cou ld  n o t be  
im m unoprecip itated  from  eith er  th e control ce lls or th e HSV-2 in fected  ce lls  
(Figure 15). This d ifference in  induction  betw een  HSV-1 and HSV-2 was seen  in  
a m inim um  o f  5 experim ents. In track 2 o f  Figure 15 a reduced  am ount o f  viral 
p o lyp ep tid es can b e seen  suggesting that in fectio n  in  th is sam ple w as less  
effic ien t. T his exp la in s th e  le sser  am ou n t o f  GRP94 in d u ced  u n d er th ese  
con d ition s. From th ese  exp erim en ts it  w as con clu d ed  that HSV-1 in fectio n  
induced a  polypeptide im m unologically  indistinguishable from  GRP94.
To investigate the m echanism  o f  in du ction  o f  th is p o lypeptid e a  series o f  
tem perature sensitive HSV-1 m utants w ere used.
2 In v estig a tio n  O f GRP94 In d u ctio n  U sin g  HSV-1 M utants
In fection  o f  RE ce lls  w ith  tem p era tu re  se n s it iv e  ( is )  m u tan ts o f  th e  
V m w l75  gen e  at th e p erm issive (PT) and non-perm issive tem peratures (NPT) 
resulted in  the induction  o f GRP94 to  various extents. Infection w ith HSV-1 isD , 
ISK and isT , all o f  w hich  are m utated  in  th e  im m ediate ear ly  gen e V m w l7 5 , 
resulted  in  the induction  o f GRP94 at their PT (31°C ) as exp ected  how ever at 
their NPT (38.5°C ), tsD and IsT induced  GRP94 to a  sm all degree, whereas tsK did
1 2 3 4 5 6 7
GRP 94
FIGURE 14 : Autoradiograph of IP reactions with TBS (tracks 2 & 5), polyclonal 
monospecific antibody against GRP94 (tracks 3 & 6) and Mab PR-6 specific for 
GRP94 (tracks 4 & 7) using 4X106 cpm each of [35S] L-methionine radiolabelled 
polypeptides extracted with RIPA buffer from control RE cells (tracks 2, 3 & 4) 
and tunicamycin treated RE cells - final concentration of 2ug/ml for 17 hours 
(tracks 5, 6 & 7). Molecular weight markers are shown in track 1 and values in 
kilodaltons indicated to the left of the gel.
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FIGURE 1 5 : Autoradiograph of IP reactions with TBS using 4X106 cpm each 
of [35S] L-methionine radiolabelled RE cell polypeptides extracted with RIPA 
buffer from control cells (tracks 5), cells infected with HSV-1 (tracks 2 & 4) and 
HSV-2 (track 3). Cells were infected at lOpfu/cells for 17 hours at 37°C. GRP94 is 
less abudant in track 2 compared with track 4 because track 2 is less well 
infected as assessed by the presence of IE polypeptides. This is thought to be due 
to the reduced efficiency of HSV-1 infection in this sample as less viral 
polypeptides (175, 155 & 136 as denoted by •) are present. The corresponding 
molecular weights of HSV-2 IE polypeptides are 182K, 157K and 140K 
respectively. Molecular weight markers are shown in track 1 and values in 
kilodaltons indicated to the left of the gel.
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not (Figure 16). Two possib le explanations for this observation  are proposed; (1) 
a functional w ild type (WT) VmwT75 m ay be necessary' for GRP94 induction . At 
the NPT no functional WT V m w l75  should  b e expressed  by any o f these three  
viruses, how ever tsD  and tsT w hich  are m utated  at the carboxy term inus of
V m w l75 are less effic ien t at preventing early  and late viral p rotein  syn th esis  
(Preston, 1981) and induce som e GRP94. This w ould suggest that the n eed  for a 
functional V m w l75  is n o t an appropriate explanation  for GRP94 induction . (2) 
An alternative exp lanation  is that a later stage in  viral in fection  than IE g en e  
expression  is essen tia l for GRP94 in du ction . All three v iru ses over-exp ressed  
the IE genes, but tsD and tsT differ slightly from  tsK in that th ey  allow  partia l 
expression  o f early  and late genes (Preston, 1981). This w ould suggest that the  
induction  o f GRP94 occurs after im m ediate early  gene expression.
3 D oes HSV-1 In fectio n  In crease  T he A b so lu te  A m ou n t O f GRP94?
Q uantitative an a ly sis  o f  GRP94 in d u ctio n  b y  HSV was carried  ou t by  
w estern  b lotting. This in vestiga ted  th e total am ount o f  GRP94 recogn ised  by  
MAb PR-6 rather th an  th e  to ta l am ou n t o f  n a t iv e  r a d io la b e lle d  GRP94 
recogn ized  in  IP reactions (w hich is a fu n ction  o f h a lf life) as was p rev iou sly  
investigated. The sam e total num ber o f cells w ere used  w hen control RE cells or 
RE cells in fected  by HSV-1 w ere analyzed. W estern blotting was carried out with  
these sam ples and the antibody MAb PR-6. Using 50|ig and 25fig o f each sam ple, 
the optim al p rote in -an tib od y  con cen tration  cou ld  be determ in ed  in  order to  
com pare th e rela tive am ounts o f GRP94 in  th e control and in fected  sam ples  
(Figure 17). T hese b lots con firm ed  that HSV-1 in fectio n  resu lted  in  e leva ted  
levels o f GRP94 being present in  the RE cells w hen  com pared to control RE cells. 
C onstitu tively  exp ressed  GRP94 cou ld  also b e d etected  in  control RE cells by  
w estern  b lotting as the levels o f background p rotein  seen  in  such b lots w ere  
co n sid era b ly  le ss  th an  th o se  see n  in  IP reaction s. T he w estern  b lo ttin g  
ex p er im en t in d ic a te d  that th e  to ta l am ou n t o f GRP94 is in creased  as a 
con seq u en ce o f HSV-1 in fection . This shows that the increase in  GRP94 as seen  
by radio-im m unoprecipitation is unlikely  to b e due to an increased rate o f [35S] 
m ethion ine incorporation , a lthough alteration in  the h alf life or stability  o f  th e  
protein cannot b e excluded.
Northern and slot b lot experim ents w ere carried out by Carol Sievwright (a  
post-graduate student in  the lab .), to investigate if  HSV-1 induced  GRP94 at th e  
level o f transcription. RNA was extracted from  control RE cells, RE cells treated  
w ith calcium  ion op h ore (w hich  is know n to in d u ce  GRP94) or in fected  w ith  
HSV-1 (for 6 hours at 37°C). The extracted RNA was run on  a form aldehyde gel, 
b lo tted  on to  n itroce llu lose  th en  prob ed  w ith  a fragm ent o f  the GRP94 cDNA
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FIGURE 16 : Autoradiograph of IP reactions with TBS using 4X106 cpm each of 
[35S] L-methionine radiolabelled polypeptides extracted with RIPA buffer from 
control RE cells (track 1), RE cells infected with HSV-1 at 37°C for 17 hours 
(track 2), tsK at 38.5°C for 8 hours (tracks 3 & 5), t§K at 31°C for 17 hours (track 
4), isT at 31°C for 17 hours (track 7), tsT at 38.5°C for 8 hours (track 8), tsD at 31°C 
for 17 hours (track 9) and t§D at 38.5°C for 8 hours (track 10). Molecular weight 
markers are shown in track 6 and values in kilodaltons indicated to the left of 
gel. GRP94 is indicated by a triangle.
FIGURE 17 : Western blot with polyclonal monospecific GRP94 antibody and 
polypeptides extracted from a total cell extract of control RE cells (tracks 2 & 4)
and HSV-1 infected RE cells using lOpfu/cell for 17 hours at 37°C (tracks 1 & 3).
Tracks 1 & 2 represent 50pg  and tracks 3 & 4 represent 2 5pg  of  cellular 
polypeptides as quantitated using the Bradford's method. To visualise, an ti­
rabbit  im m unoglubulin  conjugated to horse radish peroxidase was used with
N 'chloronapthol. As stated previously western blots were reproduced  by a 
combination o f  laser printing and photocopying which neither introduced nor 
removed any background material.
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called p4A3. This 1.75Kb probe was generated following a Bam Hl/Sal 1 digestion 
of a cDNA encoding GRP94 and was kindly supplied by Dr Amy Lee. The probe 
was then radiolabelled with «32P by random priming (to a high specific activity 
of greater than 2X108 cpm). To confirm that equivalent quantities of RNA were 
loaded on each track, a ribosomal RNA probe (Barbu & Dautry 1989) was used to 
reprobe the northern blot.
From the slot blot (using 2(Vg/track) it was seen on three occasions that 
similar levels of GRP94 are present in RE cells both before and after HSV-1 
infection, but the levels of GRP94 are increased following calcium ionophore 
treatment as expected (Figure 18). The results from the northern blots also show 
that levels of GRP94 mRNA were not increased as a consequence of HSV-1 
infection. Figure 19 shows that when the total amount of RNA loaded on each 
track is corrected for rRNA, as a consequence of HSV induced shutoff, less 
GRP94 message per ug of total RNA is present in the HSV-1 infected cells. In 
these blots 5, 10 and 15ng of RNA were probed with the GRP94 insert, and the 
resulting autoradiograph scanned as described previously. The GRP94 present 
in each sample was then corrected for the total rRNA present in each sample 
(by scanning the autoradiograph of the same northern  after it had been 
hybridized with a rRNA probe). Taken together these results indicated that HSV- 
1 infection does not increase GRP94 by transcriptional activation but rather 
that the increase in GRP94 must occur at the level of translation or post­
translation.
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FIGURE 18 : Densitometer scan of autoradiograph of slot blot where 15pg of 
RNA extracted from control RE cells, HSV-1 infected RE cells (lOpfu/cell for 6 
hours at 37°C) and RE cells treated with calcium ionophore (6X10-7M) were 
loaded on each track and the GRP94 cDNA (p4A3) used to probe the blot. Data 
corresponds to the area under the peak when quan tita ted  by scanning 
densitometery (an average of 11 scans), as described previously. This slot blot 
was kindly probed by Carol Sievwright.
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FIGURE 19 : Densitometer scan of autoradiograph of northern blot where 5, 10 
and 15ng of RNA was extracted from control RE cells and HSV-1 infected RE cells 
(lOpfu/cells for 6 hours at 37°C) and probed with the GRP94 cDNA (p4A3) probe. 
The blot was re-probed using a rRNA probe to ensure that similar quantities of 
RNA were loaded on the appropriate control and HSV-1 tracks. Data corresponds 
to the area under the peak when quantitated by scanning densitometery and 
corrected for rRNA. This northern blot was kindly probed by Carol Sievwright.
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DISCUSSION OF SECTION 2 : HSV-1 INFECTION ALTERS
GRP94 EXPRESSION
An interesting but complex observation is reported in this section. During 
the investigation of U90 expression in Bn5T and RE cells, a 94Kd polypeptide was 
consistently found to be induced by HSV-1, but not by HSV-2 infection. This 
polypeptide has been characterized as GRP94, which is a major structural 
component of the endoplasmic reticulum (ER) and the most abundant calcium 
binding protein in the ER (Koch et al. 1986). GRP94 is constitutively expressed at 
low levels in the cell and has enhanced expression following glucose 
deprivation, inhibition of glycosylation (Pouyssegur, et al. 1977; Chang et al. 
1987), and pertubances of intracellular calcium stores (Welch et a l. 1983; 
Drummond et al. 1987; reviewed in Lee, 1987). GRP94 is also thought to be 
induced by the presence of malfolded proteins in the ER (Kozutsumi et al. 1988). 
GRP94 together with a coordinately regulated glucose regulated polypeptide 
GRP78 (Chang et al. 1987) have been reported to regulate protein transport 
through the ER by their calcium binding capacities (Li & Lee, 1991).
GRP94 is a member of the stress protein family which is comprised of heat 
shock proteins and glucose regulated proteins. These polypeptides show a 50% 
homology with each other at the amino acid level (Mazzarella & Green, 1987; 
Sorger & Pelham 1987). This family of polypeptides has been previously 
implicated with HSV infection. Notarianni & Preston (1982) and N otarianni, 
(1986) reported the induction of stress proteins following HSV infection in 
chick embryo cells, La Thangue et al. (1984) reported the accumulation of heat 
shock proteins following HSV infection, Kennedy et al. (1985) reported the 
accumulation of heat shock proteins on acute HSV infection of cultured human 
neural cells and La Thangue & Latchman (1988) reported the induction of a 
hsp90-like polypeptide following HSV infection.
At the time of these investigations the m utant HSV-1 viruses tsD, tsK and 
tsT were being utilized to investigate the induction of U90. Experiments using 
these mutants were carried out to determine if IE gene expression was sufficient 
for GRP94 induction. Using immunoprecipitation techniques and TBS which has 
activity against GRP94 (Amy Lee, personal communication) immediate early  
expression seen with tsK at 38.5°C was found to be insufficient for GRP94 
induction. As indicated in the previous Result Section 2.2, tsD and tsT do allow 
partial early and late gene expression at 38.5°C (Preston, 1981). This suggested 
that either early or late viral gene expression must occur for the alteration of 
GRP94 expression, or that some additional difference between tsK and tsD & tsT 
which is as yet undetermined is involved in GRP94 induction. This area could
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not be expanded as I decided to concentrate on the induction of the U90 by HSV 
infection, which was transformation associated.
The northern  blot results indicate that the increase in GRP94 is not a 
consequence of transcriptional activation or an increase in mRNA stability as 
measured during the first 6 hours after infection. The observed increase in 
GRP94 must therefore either be due to increased rate of translation of the mRNA 
or a post-translational modification which results in the stabilization of the 
protein, eg phosphorylation, glycosylation, sulphation or lipid modifications. In 
order to investigate if the total amount of GRP94 expressed in the cells was 
increased following HSV-1 infection or if the metabolic rate of [35S] methionine 
incorporation was increased, western blots using a GRP94 specific an tibody  
were carried out. Comparison of the results obtained in the western blot and  
those obtained following IP studies indicated that the increase seen in the radio- 
immunoprecipitated GRP94 corresponds to the increase in the total amount of 
GRP94 seen in the western blot. From these experiments it could be concluded 
that an increase in the total GRP94 translated occurred ra ther than a n  
increased in radiolabel incorporation and turnover of the protein.
It can be clearly seen that HSV-1 but not HSV-2 infection increases GRP94. 
This further confirms that differences exist between the two viruses and their 
host cell interactions. It may be a distinction such as this ability or lack of 
ability to induce GRP94 that plays a role for example in the association of HSV-2 
with certain tissue types, and HSV-1 with others. It can be concluded from this 
section that an interesting distinction between HSV types 1 and 2 host cell 
in teraction  has been uncovered, and fu rther investigations may y ie ld  
important results with regard to the differences which exist between HSV types 
1 and 2 host cell interactions.
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SECTION 3 : PARTIAL PURIFICATION OF U 90
Partial purification of the U90 was initiated to enable the isolation of 
sufficient U90 as a discrete protein band, following western blotting, in order 
that N-terminal amino acid sequencing could be carried out. To purify the U90, 
10 burlers of Bn5T cells infected with HSV-2 at 5-10pfu/cell were used to give 
maximal U90 expression. In addition to the increase in the total amount of U90 
following HSV infection, the U90 was found in greater abundance as a soluble 
polypeptide in the cytoplasm of the cell. This greatly simplified the purification 
process. In developing the purification strategy, using HSV infected Bn5T cells 
to purify the U90 resulted in the elimination of a num ber of steps and so 
reduced the inevitable protein losses which occur at every stage in a 
purification scheme.
STEP 1 : Optimizing Protein Extraction
Ion exchange chrom atography and selective protein precipitation (or 
salting out) methods were used to purify the U90 polypeptide. The buffers used 
to extract the U90 from the cells therefore had to be compatible with these 
purification techniques and were chosen, or developed with this in mind.
Previously general analysis of cell polypeptides was carried out using 
radio-im m unoprecipitation (RIPA) buffer (Macnab et al. 1985a; Hewitt et al. 
1991) as described in the Methods, Section 6a. Although RIPA buffer was very 
efficient at solubilizing cell polypeptides (including the U90), it contained the 
ionic detergent SDS which was incompatible with autom ated ion exchange 
chromatography using a mono Q. column and therefore RIPA could not be used. 
This was as a consequence of irreversible binding of SDS to the mono Q. column. 
The detergent SDS is almost impossible to remove from a protein sample once it 
has been added, although a method has been devised which claims to remove the 
vast majority of SDS (Fischer et al. 1989). After using this method however, it 
cannot be determ ined if all the SDS has been removed. Furthermore, this 
procedure also requires the sample to be passed over a "fast desalt" column 
(Pharmacia, England) to remove excess urea, an extra step which would also 
increase the loss of material.
An alternative buffer lacking SDS, had to be developed which was suitable 
for use on the different chrom atography systems, but was still able to 
efficiently extract the small quantities of U90 present in the cell. Several non­
ionic detergent containing buffers were analyzed for their ability to extract the 
U90. These included M ichelson's buffer, (50mM tris pH7.4, ImM beta 
mercaptoethanol, 2mM EDTA, 1% NP40, 1% sodium deoxycholate, O.lmM PMSF,
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ImM DTT), Toft's buffer (50mM tris pH7.4, lOmM EDTA, 50mM NaF, +/-10mM 
NaMo0 4 ) and PBS A plus 1% triton-X-100. This last buffer was found to give very
good extraction of the U90 from whole cells (Figure 20), and would allow the U90 
to be extracted from uninfected Bn5T membranes. In addition to triton-X-100 the 
efficiency of two other detergents (NP40 and octyl glucoside) at extracting U90 
was investigated by Dr J.C.M. Macnab. To determine if either NP40 or octyl 
glucoside were better at solubilizing the U90, IP reactions were carried out and 
comparison of the total amount of U90 immunoprecipitated and the amount of 
background protein present in each reaction investigated. Of the three, triton- 
X-100 was found to give the best results with the least background protein being 
present at around 90K in IP reactions (Macnab, unpublished results). Triton-X- 
100 was therefore chosen to be used as a 1% solution in PBS A in the purification 
strategy.
In order to reduce the number of proteins in the starting material it was 
decided to fractionate the cells by using various combinations of hypotonic 
buffer (25mM tris pH7.5, 5mM KC1, 0.5mM MgCl2 , 0.5mM PMSF, ImM DTT), dounce
homogenization (using pestle B to break the cell membrane which was followed 
by pestle A to break the nuclear mem brane), sonication and addition of 
detergent containing buffers such as Michelson's, Toft's or triton-X-100 buffer 
(1% triton in PBS A). These were used to generate the cytoplasmic, nuclear and 
membrane fractions of harvested cells (Method 6b). The U90 was detected by IP 
reactions of Bn5T cells extracted in all the buffers investigated, however when 
IP reactions were carried out considerable differences in the am ount of 
background protein and the total U90 extracted from the cell was seen 
depending on which buffer was used.
The most efficient cell fractionation method for the isolation of U90 
(described in Method 6b) used hypotonic buffer (as above) to swell the cells (on 
ice for 30 minutes) which were then lysed by dounce homogenization with 
pestle B to break open the cell membrane and release the soluble cytoplasmic 
fraction. The nuclear and membrane associated proteins were then removed 
from the cytoplasmic sample by centrifugation (3000rpm for 10 minutes at 4°C) 
generating a pellet which was then extracted using the nuclear extraction 
buffer (20% glycerol, 25mM tris pH 7.5, 0.6mM KC1 plus ImM PMSF + ImM DTT) 
for 30 minutes at 4°C and followed by dounce homogenization with pestle A. The 
centrifugation was repeated and finally the resulting pellet was treated with 
the membrane extraction buffer which contained the detergent triton-X-100 
and sonicated to disrupt the cell membranes and release membrane associated 
polypeptides.
FIGURE 20 : Autoradiograph of IP reactions with TBS using 4X106 cpm each of 
[^5S] L-methionine radiolabelled polypeptides extracted from Bn5T cells using 
either 1% triton X-100 in PBS (tracks 1 & 2) or RIPA buffer (tracks 3 & 4). 
Control Bn5T cells can be seen in track 1, HSV-2 infected cells in tracks 2 and 3 
and HSV-1 infected cells in track 4. Virus was added at lOpfu/cell for 17 hours at 
37°C.
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In order to increase the speed of cell fractionation, and in doing so reduce 
the possibility of protein degradation, the above method was modified. This 
modified version which was used for the large scale extraction of the U90 from 
HSV infected and control cell membranes is described Methods 6c. This method 
differs from the cell fractionation described above as one step is removed. In 
the large scale extraction the nuclear fraction is not generated, but instead the 
membrane associated U90 is extracted from a sample which contains both the 
membrane and nuclear fraction. This had very little effect on the amount of 
background polypeptides in the membrane fraction, as seen in IP reactions, nor 
did it affect the total amount of U90 recovered, but most importantly the speed of 
the fractionation  process was increased considerably  by using this 
modification.
STEP 2 : Ammonium Sulphate Precipitation of U90
Following cell fractionation, the first step in the purification of the U90 
was the "salting out" or selective precipitation of proteins by ammonium 
sulphate (AS) saturation of the cytoplasmic fraction of the HSV infected Bn5T 
cells (Method 8a). AS was gradually added at a consistent rate to the sample 
containing U90 over a period of 30 minutes to give a 30% saturated solution. This 
was then stored on ice with agitation for 1 hour, which resulted in the 
precipitation of the U90 together with a number of other cellular polypeptides. 
The addition of the AS was carefully monitored to ensure that it was added to the 
sample in an identical m anner in each experiment. This was necessary as a 
change in the rate of addition of AS could result in an altered set of polypeptides 
being precipitated due to the different conditions.
The precipitated U90 was then isolated from the 30% AS saturated sample 
by centrifugation at 10,000rpm for 15 minutes (4°C). The pellet containing the 
U90 was then resuspended in a detergent containing resupsension buffer 
composed of 1% triton-X-100 in PBS A.
At this stage the partially purified U90 was found to form highly insoluble 
aggregates if detergent was not included in the resuspension buffer. This may 
have been as a consequence of the AS precipitation disrupting protein-protein 
interactions which may have stabilized the U90 in its native form. For this 
reason, all buffers from this stage onwards contained a minimum of 0.1% triton- 
X-100 to prevent the U90 forming aggregates and precipitating out of the 
sample.
86
STEP 3 : Purification Bv Ion Exchange Chrom atography
As indicated above the AS precipitated U90 was resuspended in 1% triton-X- 
100 in PBS A. This was stored on ice for a minimum of 30 minutes then sonicated 
until clear to disrupt any protein aggregates which had formed. The sample was 
then desalted (to remove the AS) by passing it over a PD10 sephadex G-25 
column and the protein eluted into running buffer A (50mM tris pH8 +/- 1% or 
0.1% triton-X-100) which was to be used on the FPLC, as described in Method 8b. 
If the samples were not injected onto the FPLC column immediately after 
desalting, they were sonicated again just before use. Prior to loading the sample 
onto the automated FPLC ion exchange system (Pharmacia, England) the sample 
was centrifuged for 5 minutes at 12,000rpm to remove any particulate material 
which might clog the filters within the FPLC system. The supernatant was then 
ready to be injected onto a 1ml anion exchange column, (mono Q HR5/5,  
Pharmacia, England) using a "superloop" which enabled a volume of up to 50ml 
to be loaded at one time onto the column. This proved extremely useful as when 
the precipitated U90 was resuspended in a small volume of buffer, the recovery 
of the polypeptide was found to be reduced. The superloop therefore allowed the 
protein to be resuspended in a larger volume and still be injected onto the 
column in one run.
After desalting the sample and prior to injection onto the column, the total 
protein content of the sample was determined. This was done using the Bradford 
method of protein quantitation (Method 7h) and was used to ensure that no more 
than approximately lOmg of protein was ever loaded on the column, as the 
column could only accommodate a maximum of 20mg of protein.
Three different sets of buffers were used in the FPLC system throughout 
the period in which the purification strategy was being developed, as detailed 
in Method 8(a), The first set, A.l (50mM tris pH8) and B.l (50mM tris pH8 + 1M 
NaCl) contained no detergent and was used in the initial attempts to purify the 
U90.
In initial experiments the U90 sample was injected onto the mono Q, column 
in buffer A.1 and eluted using a 17ml linear gradient of 0-100% buffer B.l with 
lm l samples being collected. SDS page analysis of the samples, which contained 
a small proportion of [35 s] L-methionine radiolabelled polypeptides followed by 
autoradiography revealed a 90K protein to be eluted from the column between 
76-94% buffer B, when the gradient was run over 17 minutes at a flow rate of 
lm l buffer/per minute (Figure 21).
A very faint 90K polypeptide isolated from the mono Q column in fractions 
20 and 21 (tracks 11 & 12 of Figure 21) reacted with TBS in IP reactions and 
migrated on SDS gels at a similar rate to the U90 (Figure 22). However, such a
FIGURE 21 : Autoradiograph of 7.5% SDS page of Bn5T polypeptides extracted 
from 10 burlers of HSV-2 infected cells (1 burler of cells radiolabelled with 
lOO^Ci of [35S] L-methionine) which were fractionated and treated as described 
in the text. A 30% AS precipitation reaction was completed on the cytoplasmic 
fraction, this sample resuspended in 1% triton/PBS, desalted, centrifuged (12K) 
to remove any particulate material, then injected onto the column in a volume 
of 7ml. lm l samples were collected off the mono Q, column. Fractions 1-7 
represent the flow through with fraction 8-25 corresponding to a 0-100% 
gradient of buffer B (50mM tris, 1M NaCl). One tenth of each sample was 
analysed by 7.5% SDS-page. Track 1- fraction 1, track 2- fraction 2, track3- 
fractions 3-5, track 4- fractions 6-9, track 5- fractions 10-13 track 6- 14, track 7- 
15, track 8- IP of Bn5T with TBS showing U90 (indicated by a filled triangle), 
track 9- fractions 16-17, tracks 10-17 corresponds to fractions 18-25 
respectively. Track 18 shows m olecular weight m arkers, with values in 
kilodaltons indicated to the side of the gel. • denotes the area in which 90K 
polypeptides migrate.
► #
FIGURE 22 : Autoradiograph of IP reactions with TBS using 4X106 cpm of [^5S] 
L-methionine radiolabelled samples isolated from the FPLC mono Q, (Figure 21) 
in which a 90K polypeptide corresponding to the U90 may have been present. 
Tracks 2-9 represent IP reactions of samples run in tracks 10-17 of Figure 21. A 
total cell extract of radiolabelled Bn5T cells IP with TBS is seen in track 10. 
Molecular weight markers can be seen in track 1 and their values indicated in 
kilodaltons to the left of the gel. A filled triangle denotes the area where a faint 
band at 90K can be seen in track 4, and where the U90 is in track 10.
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small am ount o f protein  was recovered  from  these sam ples that insufficient 35S 
was incorporated  in to  the p rote in s to a llow  v isu a liza tion  follow ing p ep tid e  
m apping analysis. The stronger 90K band seen  in  fractions 22-24 did not react 
with TBS. Compared to the total am ount o f protein  added  to the colum n, on ly  a 
very small proportion o f the U90 was recovered. This indicated that on ly a small 
proportion  o f the U 90 load ed  on to  the colum n w as in  this 76-94% buffer B 
sam ple. A second  problem  was encou n tered  w ith th ese experim ents in  that on  
the addition  o f the sam ple, the colum n becam e blocked very  quickly resulting  
in the bu ild  up o f v ery  h igh  back-pressure. This back-pressure e v e n tu a lly  
prevented  the elu tion  o f the sam ple o ff the colum n from  being com pleted  and  
also caused the colum n to be very  d ifficu lt to clean. The reason  for this m ay  
have b een  that once rem oved from  detergent containing buffer, the U90 form ed  
aggregates w hich  then  precip itated  out o f solution  and eventually  b locked  the  
colum n and its filters. Enzymatic d igestion  w ith  pepsin  ( lm g /m l pepsin  in  0.1M  
acetic acid, 0.5M NaCl) at 37°C for a m inim um  of 1 hour, was required to unblock  
the colum n after every  experim ent. This was then  follow ed by careful w ashing  
o f th e co lu m n  w ith  a co m b in a tion  o f  h igh  salt an d  acid  fo llo w e d  b y  
equilibration with buffer A (M ethod 8b). Using the buffer cond itions described  
above, the colum n usually had to be cleaned  after every experim ent.
To reso lve  th is p rob lem , d e terg en t w as in tro d u ced  in to  th e running  
buffers A.2 and  B.2, w hich w ere id en tica l to A .l and  B .l except that th ey  also  
contained 1% triton-X-100. The addition  o f detergent to the running buffers had  
a dramatic effect on  the U 90 polypeptide, its interaction with the m ono d  colum n  
and its subsequent purification.
The addition  o f detergent to the running buffers altered the U90 such that 
it no longer bound to the colum n but in  fact was iso lated  in  the colum n’s vo id  
volum e referred to hereafter as th e flow  through. The flow  through contained  
polypeptides w hich  did  n ot bind to the colum n, and so were w ashed through the  
colum n b y  buffer A prior to the com m encem ent o f the salt gradient. In the flow  
through , o n ly  a sm all n um ber o f  o th er ce llu lar p ro te in s w ere p resen t in  
addition to the U90, which allow ed the U90 to be isolated  as a discrete band, w hen  
the sam ples w ere analyzed  b y  SDS page and v isualized  by both  Coom assie b lue  
staining and autoradiography (Figures 23 & 24 respectively). V isualization o f  
the p olypeptid es in  the flow  through by silver staining resulted  in  no fu rth er  
proteins being seen . This technique o f protein  staining was not used  routinely, 
as u n less th e U 90 cou ld  b e ea sily  v isu a lized  b y  C oom assie b lu e  sta in in g  
in su ffic ien t m ateria l was p resen t to  ju stify  con tin u in g  tow ards am ino acid  
sequencing experim ents.
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FIGURE 23 : Coomassie blue stained 7.5% SDS page showing Bn5T polypeptides 
extracted from 10 burlers of HSV-2 infected cells which were fractionated and 
treated as described in the text. A 30% AS precipitation reaction was completed 
on the cytoplasmic fraction, this sample resuspended in 1% triton/PBS, desalted, 
centrifuged (12K) to remove any particulate material, then injected onto the 
mono Q column in a volume of 5ml. lm l samples were collected off the column, 
with lOOul of each of the flow through samples being analysed on a Coomassie 
blue stained 7.5% polyacrylamide gel. Flow through samples 1-5 can be seen in 
tracks 1-5 when 1% triton detergent was added to both buffers A and B. Track 6 
contains Bn5T cells immunoprecipitated with TBS however, insufficient U90 is 
present to be visualized. Molecular weight markers are shown in track 7 and 
values in kilodaltons indicated to the right of the gel. U90 is indicated by •.
FIGURE 24 : Autoradiograph of gel shown in Figure 23, ie lOOul of each of the 
mono Q, flow through samples of cytoplasmic fraction of HSV-2 infected Bn5T 
cells when 1% triton detergent was added into the FPLC buffers A and B. Flow 
through samples 1-5 are seen in tracks 5-1 respectively. Values of molecular 
weight markers are shown to the left of the gel. U90 is indicated by •.
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The addition  o f detergent to a colum n chrom atography system  is b elieved  
to alter the capacity and selectiv ity  o f the colum n. This is a consequence of the 
proteins in  the sam ples b ein g  su rrounded  by d etergen t and w eakening the 
in teractions w hich w ould norm ally occur betw een  the protein  and the colum n  
m aterial (Yanagita & Kagawa, 198 6 ). It was this p h en om en on  w hich greatly  
aided the purification o f the U90.
To confirm  that th e 90K p o lyp ep tid e iso lated  in  the flow  through was in  
fact the U 90, the sam ples w ere first reacted  with TBS in an IP reaction (Figure  
25) and the resulting 90K bands in  each flow  through  sam ple w ere p eptide  
m apped with V8 protease to ensure that they had an identical d igestion  pattern  
to the U90 (Figure 26). These experim ents confirm ed that the 90K polypeptide  
isolated in  the flow  through was indistinguishable from  the U90.
A representative trace o f b efore the sam ple was in jected  into the m ono d  
and a trace o f the proteins eluted  from  the m ono Q. colum n and the conditions in  
w hich this was carried out are illustrated in  Figures 27 & 28 respectively.
S tep  4  P u rifica tion  B ased On H v d ro p h o b ic itv
To further purify and concentrate the U 90 isolated  from  the flow  through  
sam ples, reverse phase chrom atography was attem pted. This was done using an  
Applied Biosystem s m icrobore HPLC system  using a 2.1m m X30m m  aquapore RP- 
(reverse phase) 300  colum n. This system  separates proteins on  the basis o f th e  
distribution o f  the solute betw een  a polar m obile phase and an organic phase  
fixed to the matrix. The buffers used  were A, (0.1% TFA in H2 O) and B, (0.1% TFA, 
80% aceton itrile  in  H2 O) with a gradient o f 0-100%  buffer B being run with a 
flow  rate o f 5 0m l/m in  over a defined  period  time. The length  o f tim e over w hich  
the gradient was run was varied betw een  15 and 60  m inutes in  order to obtain  
maxim um  separation o f eluted  polypeptides.
The starting m ateria l for th is p u rifica tion  was lm l o f sam ple o f  the  
partially purified  U90 isolated  in  the flow  through o f the FPLC m ono Q  run. The 
flow  through sam ples w ere reduced  in  volum e b y  approxim ately 50% by partial 
lyophilization  in  a "speedi-vac”, then  loaded  onto the reverse phase colum n by  
m ultiple m anual loading This was essen tia l as on ly  a 50^1 in jection  loop  was 
available. Initial studies using th is system  w ere unsuccessfu l as the U90 was not 
retained  on  the colum n, but in  a sim ilar m anner to the m ono Q  the U 90 was 
found in  the flow  through. Analysis o f th ese  sam ples elu ted  from  the HPLC was 
carried  o u t by e ith er  e lec trob lo ttin g  on to  PVDF (p o ly v in y l d in itr o f lu o r o )  
m em branes fo llow ed  by visualization  w ith either Coom assie b lue or b y  w estern  
blotting onto  n itrocellu lose. This was n ecessary  as the sm all am ount o f m aterial 
p resen t w ould  be d ifficu lt to d etect by SDS page analysis. In ad d ition  as a
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FIGURE 25 : Autoradiograph of IP reactions with TBS using 80ul of a lm l 
sample isolated as the mono Q_flow through samples (as seen in Figures 22-24). 
Fraction 2 is seen in track 2, fraction 4 - track 3 and fraction 7 - track 4. 
Molecular weight markers are seen in track 1 and their values in kilodaltons 
indicated to the left of the gel. U90 is marked •.
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FIGURE 26 : Autoradiograph showing a comparison of the peptide digestion 
patterns of U90 polypeptide immunoprecipitated by TBS from the flow through 
fractions of the mono Q. run, after the cytoplasmic fraction of HSV-2 infected 
Bn5T cells had been passed over it. This was carried out by peptide m apping 
analysis and 18% SDS-page. Digestion was carried out using 5ng of V8 
protease/track. The U90 bands were cut from an IP reaction similar to those 
seen in Figure 25. Fraction 2 is seen in track 1, fraction 4 - track 2 and control 
U90 band from an IP reaction using total Bn5T cell extract in track 3. Molecular 
weight values in kilodaltons are indicated to the left of the photograph.
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FIGURE 27 : FPLC trace generated when buffer A alone was injected onto the 
mono Q. - - - - represents the buffer B concentration - 0% buffer B for 7
minutes initially (flow through), 0-100% linear gradient over a period of 17 
minutes, 100% for 3 minutes, returning to 0% buffer B for final 5 minutes. Flow 
rate =lml/minute. Full scale deflection sensitivity = 0.5 Aufs
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FIGURE 28  : FPLC trace generated when 7ml of sample generated from the 
desalted 30% AS precipitated cytoplasmic fraction of HSV-2 infected Bn5T cells 
(10 burlers) was injected onto the mono Q column in buffer A (1% triton-X-100, 
50mM tris pH 8). Using a flow rate of lml/minute, the sample was injected and 
0% buffer B run for 7 minutes followed by a linear gradient of 0-100% buffer B 
over a period of 17 minutes, 100% buffer B for 3 minutes and returning to 0% 
buffer B for 5 minutes. Peak 1 corresponds to U90 as determined by Coomassie 
blue staining (Figure 23), IP reaction (Figure 25) and peptide mapping analysis 
(Figure 26). - - - - represents buffer B concentration, solid line represents
eluted protein. Full scale deflection sensitivity = 2.0 Aufs
considerable am ount o f m aterial was required in  order to progress to this point 
(taking ap p roxim ately  3 m on th s to g en era te  th e m ateria l - in clu d in g  the  
propagation and titration o f virus), blotting the eluted  sam ples onto PVDF m eant 
that the sam ple could  b e sen t for p rotein  sequencing if  sufficient was present. 
However, in  contrast to the situation  fou n d  with th e FPLC m ono Q. colum n, it 
appeared that a ll the protein in  the sam ple was in the flow  through o f the HPLC 
system , i.e. n on e o f th e U 90, nor the contam inating proteins had  bound to the  
colum n (Figure 29). A small proportion o f th is unbound m aterial m ay have b een  
a consequence o f the 50fil injection loop, how ever the vast m ajority o f unbound  
sam ple was attributed to the large am ount o f  triton in  the sam ple, as th e FPLC 
buffer A.2 in  w hich  th e U 90 was iso la ted  in  th e flow  through con ta in ed  1% 
triton-X -100. This m eant that fo llow ing con cen tration , the U 90 sam ple w ould  
contain  a m inim um  o f  2% triton. By changing the FPLC buffers to A.3 and B.3 
w h ich  o n ly  co n ta in ed  0.1% triton-X -100 and  red u cin g  th e  sam p les u s in g  
c e n tr ic o n -3 0  m ic r o -c o n c e n tr a to r  tu b e s  (A m icon , UK) as o p p o se d  to  
lyophilization , the final concentration  o f the triton in  the sam ples loaded  o n to  
the HPLC was m aintained at 0.1%. Centricon tubes desa lt and concentrate sm all 
volu m es b y  ultrafiltration through a hydrophilic  m em brane. Centrifugal forces  
(5 ,000g) drive th e so lven t and low  m olecular w eight solutes (o f less than 30K) 
through  th e  m em brane. This resu lts  in  a d ecrea sed  sam p le v o lu m e an d  
increases th e so lu te concentration . A second  buffer can also b e in troduced  to 
th e sam ple u sin g  th is system , a llow ing th e sam ple to  b e recovered  in  a  new  
so lven t.
Even after reducing the U 90 sam ple b y  this m ethod, the U 90 w ould still not  
bind to th e  colum n and further attem pts to rem ove even  m ore o f  the triton w ere  
m ade as the detergent was still p resen t at greater levels than its critical m isceU e  
concentration o f 0.01%. These are described  below .
To rem ove as m uch as possib le o f  the triton-X-100 from  the sam ple, th e U90  
sam ple was concentrated  in  a  centricon  tube, then  w ashed  w ith  3 X 2m l o f the 
HPLC buffer A. D espite th e fact that th e m anufacturers o f  th e centricon  tubes  
claim  that th e m em branes in  th ese  tubes h ave low  adsorption  properties, th is  
was n ot found to be the case w hen  sm all quantities o f the U 90 were used . It was 
n oted  that a  large am ount o f the U 90 was lost in  the centricon  tube and it was 
consequently  accepted  that in  using the centricon  tubes betw een  20-50% o f the  
U 90 cou ld  b e  lo st through ad sorp tion  o n to  th e  m em brane. D esp ite th is the  
centricon tube d id  have the advantage o f all m anipulations being carried ou t in  
the on e tube and so th e inevitab le loss o f  som e protein  due to adsorption  onto  
the side o f an y  vessel u sed  was m inim ized. To com pensate for the loss o f protein
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FIGURE 29 : Samples recovered from the reverse phase column on the HPLC 
after the injection of one flow through fraction of partially purified U90 
(volume reduced by 50%). Samples recovered from the HPLC were run on a 7.5% 
mini-gel, electroblotted onto PVDF and stained with Coomassie blue. Tracks 1 & 2 
represent the flow through, where almost 100% of the eluted protein can be 
seen, tracks 3-8 are samples recovered corresponding to a linear 0-100% buffer 
B gradient. Over-exposure was required in order to visualize the very small 
quantities of protein stained by Coomassie blue. Molecular weight markers are 
seen in track 9 and values in kilodaltons indicated to the right of the gel.
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due to m em brane adsorption, a larger quantity o f U90 was therefore required as 
starting m aterial.
W ashing the sam ple three tim es with buffer A in  a centricon tube rem oved  
su ffic ien t tr iton-X -100 to en ab le  th e U 90 to b ind  to  the colum n. By using  
m ultiple m anual loading o f the TFA w ashed U 90 sam ple, up to lOOpmoles o f  the  
U90 was estim ated to have been  loaded  onto the colum n. Multiple m anual loading  
was required as on ly  a 50^1 loading loop  was available for this m achine.
Several d ifferen t n on -lin ear grad ients o f buffer B w ere used to find  the  
optim um  m ethod  o f eluting the U 90 as a d iscrete peak representing the purified  
polypeptide. As the U 90 was the m ajor com pon en t o f the sam ple ad ded  to th e  
reverse phase colum n, its p o in t o f e lu tion  should  have b een  obvious w ith  the  
largest peak corresponding to e lu tion  o f  the U90. The largest peak thought to  
correspond to U90 appeared betw een  80-90%  buffer B (Figure 30), and  so the 
gradient was extended  over th is range. Sam ples w ere co llected  m anually  either
at regular in terva ls or to corresp on d  to th e p o in t at w h ich  th e  U 90 h ad
\
p rev io u sly  b een  th ou gh t to  e lu te . F ollow ing co llec tio n , th e  sam p les w ere  
analyzed by SDS page, electroblotted  onto  Problot PVDF m em brane and  protein  
visualized b y  Coom assie b lue staining (this m ethod, as opposed to  silver staining, 
disclosed  w hether th e elu ted  sam ple con sisted  o f  su fficien t protein  for protein  
seq u en c in g ).
W hen th e grad ient was ex ten d ed  betw een  80-90%  buffer B, th e  U 90 was 
thought to  e lu te  at 80-82.5%  b uffer B (Figure 31). H owever, th e  U 90 was n o t  
isolated  in  o n e  single sam ple, but trace am ounts could  b e found  in  a num ber o f 
sam ples iso la ted  at h igher buffer B con cen tration s later in  th e grad ien t - as 
visua lized  by C oom assie b lu e  sta in in g  o f a  PVDF m em brane (Figure 3 2 ). In 
addition , a peak  corresponding to th e  U 90 was a lso  seen  betw een  80-82.5%  
buffer B from  the colum n w hile it was being clean ed . Even b y  exten d in g  the  
gradient for  30  m inutes at th e p o in t w here U 90 started  to  b e  e lu ted  from  the  
colum n, som e U90 still rem ained uneluted  in  th e in itial run and a peak could  be  
seen  at this p oint i f  the n m  was repeated  w ithout the ad d ition  o f  an y  further  
sam ple. Several w ash runs w ere requ ired  to  rem ove a ll the p rote in  from  the  
colum n. This in ab ility  to iso late th e U 90 from  the reverse p hase colum n as a 
single sharp peak resu lted  in  fu rth er lo sses  o f th e  U 90 in  th e  p u r if ic a t io n  
process.
As seen  in  Figure 32 , th e  ge ls  con ta in in g  th e sam ples taken  from  th e  
reverse phase colum n also  had  a  num ber o f  additional proteins p resen t in  the  
sam e fraction as th e  U 90. T hese w ere v isua lized  b y  C oom assie b lue staining o f  
the PVDF m em brane fo llow in g w estern  b lottin g  o f  th e  p o lyacry lam id e gels  
con ta in in g  th ese  sam ples. Extension o f th e  grad ien t at th is stage w ould  n ot
FIGURE 30 : HPLC trace of elution profile following injection of an estimated 
lOOpmoles (equivalent of 9ug) of U90 isolated in the flow through of  the FPLC.
Large peaks between 80-90% buffer B are thought to correspond to the U90.
Flow rate used was 50ul/minute with the following gradient: time 0-3 minutes
0% buffer B, 3-20 minutes linear gradient of 0-80% buffer B, 20-25 minutes 80-
88%, gradient held for 1 minute , 26-30 minutes 88-92%, 30-43 minutes 92-100%, 
gradient held at 100% for 2 minutes then reduced from 100-0% from 45-60 
minutes. Full scale deflection sensitivity = O.lAufs
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FIGURE 31 : HPLC trace of the elution profile following injection of an 
estimated lOOpmoles (equivalent of 9ug) of U90 isolated in the flow through of 
the FPLC onto an HPLC reverse phase column. The gradien t was extended 
between 80-90% buffer B. Flow rate used was 50ul/minute with the following 
gradient: time 0-3 minutes 0% buffer B, 3-20 minutes linear gradient of 0-80% 
buffer B, 20-30 minutes 80-85%, 30-40 minutes 85-90%, 40-50 minutes 90-100% 
then reduced from 100-0% from 50-55 minutes. Full scale deflection sensitivity = 
0.1 Aufs
FIGURE 32 : Samples recovered from the reverse phase column on the HPLC 
after the injection of an estimated lOOpmoles of partially purified U90. 25% of 
each sample recovered from the HPLC was run on a mini-gel electroblotted onto 
PVDF and stained with Coomassie blue. Track 1 =flow through, 2=0-20%, 3=20- 
40%, 4=40-60%, 5=60-80%, 6=80-82.5%, 7=82.5-85, 8=85-87.5%, 9=87.5-90%, 10=90- 
95% buffer B. Protein can be detected in tracks 6-8, with the band which is 
believed to be U90 indicated by a closed triangle. Over-exposure was required 
due to the very small quantities of protein eluted from the reverse phase 
column.
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separate the U90 from  these polypeptides, nor could it be explained from  where 
they orig inated . W hen the sam ples w ere an alyzed  by SDS page th en  w estern  
blotted using the U90 m onospecific antibody in  addition  to TBS, not only did  the 
m onospecific antibody confirm  that th e protein  o f m olecular weight 9 0 ,0 0 0  was 
the U90, b ut it also recognised  th e proteins o f low er m olecu lar w eight p resent 
in the sam ple (Figure 33 ). This w estern  b lot and all others in  this thesis w ere  
rep rod u ced  by a  com b in ation  o f  la ser  p rin tin g  and  p h o tocop y in g  w hich  
n eith er in tro d u ced  nor rem o v ed  an y  s ign ifican t b ack grou n d  m ateria l. A 
p hotographic rep rod u ction  o f tracks 1 & 2 o f Figure 33a  are also show n in  
Figure 33b  to confirm  this. By com paring the sam ple before washing w ith TFA 
(to rem ove triton), and  the e lu ted  sam ple, th e m ost likely  exp lanation  o f the  
peptides origin  was that they w ere breakdow n products o f the U90. These were 
thought to be generated  b y  proteolytic d igestion  by TFA w hich was p resen t in  
the buffer A u sed  to w ash  th e U 90 sam p le w h en  rem oving the triton-X -100. 
Comparison o f th e sam ple before in jection  on to  the reverse phase colum n and  
the sam ples co llected  from  the co lu m n  after b ein g  e lu ted  in  TFA b y  w estern  
blottin g  using th e  m on osp ecific  U 90 a n tib o d y  sh ow ed  that a ll th e  lo w e r  
m olecular w eight protein s w ere p resen t both  before and after elu tion  from  the  
colum n. However, greater protein  degradation  can be seen  in  the elu ted  sam ple  
(Figure 3 4 ). This suggested  that th e U 90 was n ot stab le in  0.1% TFA and that 
prolonged contact w ith TFA resulted  in  U 90 degradation.
As a  con seq u en ce o f th ese  breakdow n products th e U 90 iso lated  from  the  
HPLC reverse p hase colum n cou ld  n o t b e used  for sequence analysis since the  
U90 was n o t iso lated  in  su fficien t am ounts n or as a d iscrete protein . Had tim e  
allowed, th is m ight have b een  overcom e b y  altering the buffer used  to w ash  the  
sam ple to  rem ove th e  tr ito n -X -1 0 0 , fo r  ex a m p le , to  lOmM am m on iu m  
bicarbonate (instead  o f  a  buffer contain ing TFA). T hese changes still m ight not 
have allow ed the U 90 to  b e sequenced  d irectly  from  the HPLC, as at least 50% o f  
the m aterial ad ded  to  th e  co lum n p rev iou sly  was n o t recovered  in  th e  final 
sam ple, y ield ing insufficient m aterial for the U 90 to be sequenced. The lost 50% 
m ay be accounted  for in  th e breakdow n products v isu a lized  fo llow ing w estern  
blottin g .
As the FPLC flow  through sam ples con ta in ed  n o  contam inating p rotein s at 
90K, these sam ples were used to attem pt to sequence th e N-term inal o f the U 90  
without the use o f  the HPLC.
STEP 5 : U 9 0  C on cen tration
The proposed m ethod  for determ ining th e N-term inal am ino acid  sequence  
o f the U 90 w as b ased  on  that p rop osed  b y  M atsudaira, (1 9 8 7 ). This tech n iq ue
A•U 90
•U 9 0
FIGURE 33a : A western blot of U90 sample eluted from HPLC reverse phase 
column (tracks 2 & 3) visualised with anti-rabbit immunoglubulin conjugated to 
horse radish peroxidase and developed with N'chloronapthol, compared to U90 
in the FPLC flow through sample prior to washing with TFA (track 1). TBS was 
used in the blot containing tracks 1 & 2, and U90 mono-specific antibody used in 
blot containing track 3. The western blots were reproduced by laser printing 
and photocopying. This did not alter the background as compared to a 
photograph of the blot (Figure 33b). This technique was subsequently used for 
all western blots. U90 is indicated by •  with lower molecular weight bands 
believed to be U90 breakdown products caused by the presence of TFA.
FIGURE 33b : Photographic reproduction of tracks 1 & 2 seen in Figure 33a.
FIGURE 34 : Western blot of U90 sample prior to injection onto the HPLC 
reverse phase column (track 1) and U90 eluted from HPLC reverse phase 
column (track 2) using the monospecific U90 antibody, visualised with anti­
rabbit immunoglubulin conjugated to horse radish peroxidase and developed 
with N'chloronapthol. The increased number of immunoreactive bands in track 
2 is due to TFA degrading the U90 polypeptide. U90 is indicated by •  and 
molecular weight markers are indicated in kilodaltons to the right of the blot.
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involves SDS page followed by electroblotting of the electrophoresed proteins 
onto a polyvinyl dinitrofluoro (PVDF) membrane. The proteins are then 
visualized by Coomassie blue staining and the required band(s) excised. The 
PVDF sections are then placed in the reaction chamber of the protein sequencer 
and the protein of interest eluted from the membrane and sequenced.
The size of the reaction chamber is the limiting factor in the process, as it 
can only accommodate up to the equivalent of 8 tracks in a Biorad mini gel 
system. The sequencing reaction itself requires between 10-100 picomoles of 
protein, and it is also found to be more efficient if the protein in question is 
blotted onto as small an area of m em brane as possible. The protein for 
sequencing, which was run on the gel and electroblotted onto the PVDF 
membrane therefore had to be as concentrated as possible to enable it to be 
loaded onto a small number of lanes on the gel.
Unfortunately insufficient U90 was isolated in the flow through of a single 
FPLC run to obtain 10-100 picomoles. This meant that samples containing the 
U90 had to be reduced in volume to enable more U90 to be loaded on the gel at 
the one time. This concentration of U90 was approached using two different 
methods.
The first method involved reduction of the sample volume from 1ml to 
0.1ml by partial lyophilization. This however, also concentrated the triton-X-100 
in  the sample resulting in up to 10% (v/v) of triton in sample which then 
dramatically affected the mobility of the U90 on SDS page. This effect was so 
great that the U90 could no longer be isolated as a discrete band by SDS page. To 
try  to overcome this, the samples were reduced in volume using an Amicon 
centricon tube which concentrated the protein sample by allowing the buffer 
including the triton-X-100 to pass through the membrane within the tube, but 
not the protein (Method 7g). Unfortunately, the U90 was found to bind to the 
membrane, resulting in a large percentage of the U90 being lost during this 
procedure.
The solution found to this problem of excess detergent, was to once again 
change the FPLC running buffers to a third version of the original buffers, A.3 
and B.3. These buffers still contained 50mM tris pH8 +/- 1M NaCl, but contained 
only 0.1% triton-X-100 (instead of 1%). As the critical miscelle concentration of 
triton-X-100 is between 0.01 and 0.001%, the detergent was still present in excess 
in the samples, and therefore in theory should give the same results. Using 
uninfected Bn5T cells and the purification method described in this thesis, Mr 
David McNab confirmed that these buffers containing 0.1% triton-X-100 did in 
fact give similar yields of U90 in the flow through.
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The buffers A.3 and B.3 were then incorporated in the purification 
strategy of the U90, which enabled the flow through samples to be reduced ten 
fold in volume by lyophilization and still m aintain the triton-X -100 
concentration at levels of 1% (v/v) or less. This method was found to be the most 
suitable for the purification of U90 and so was incorpora ted  in to  the 
purification strategy which is summarized in Figure 35.
FIGURE 35: SUMMARY OF PURIFICATION OF U 90
4X109 Bn5T cells (20 burlers) infected with 
HSV-2 at 5pfu/cell for 17 hours at 37°CI
Cells harvested 
\
Cell fractionated by hypotonic swelling of cells 
and dounce homogenization
Soluble cytoplasmic fraction (Insoluble membrane
^  associated fraction)
30% AS precipitation
t
Pellet resuspended in buffer A and sonicated
t
Sample desalted on a PD10 column
t
Centrifugation at 12K to remove any particulate material
t
Sample injected onto mono Q,column
t
Flow through samples collected
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DISCUSSION OF SECTION 3: PARTIAL PURIFICATION OF U 90
The main objective in purifying the U90 was to enable partial amino acid 
sequencing to be obtained and hence allow molecular studies of the U90 to 
commence. In order to proceed with the N-terminal amino acid sequencing an 
order of KMOOpmoles of protein, void of all contam inating factors was 
required. Despite this, the purification of the U90 did not in fact require the U90 
to be purified to 100% homogeneity' but to a degree of partial homogeneity that 
allowed the polypeptide to be resolved as a discrete isolated band following SDS 
page and subsequent electroblotting.
The polypeptide characterization studies described in Section 1 determined 
the optimal starting conditions for the purification of U90. An im portant 
disclosure from these studies was that HSV infection of Bn5T cells resulted in 
increased U90 being isolated in a soluble form in the cytoplasm. This was of 
particular relevance as previous work to purify the U90 from the membrane of 
Bn5T cells had failed. This was because purification of the U90 had proved too 
difficult due to the small quantities present and the insoluble nature of the 
polypeptide in the membrane fraction. The cytoplasmic fraction of HSV-2 
infected Bn5T cells was therefore used as the starting material to purify the U90.
To obtain sufficiently pure U90 with as little loss of material as possible it 
was aimed to keep manipulations of the sample to a minimum. By using the 
cytoplasmic fraction as starting material, ie with no m em brane or nuclear 
proteins present, a large proportion of cellular protein was removed from the 
sample before the purification procedure had started.
The first step in the purification strategy was to selectively precipitate 
protein by increasing salt concentration. Although this technique is very 
crude, it allowed the removal of a considerable num ber of contaminating cell 
polypeptides. The use of ammonium sulphate precipitation in this system was 
established by J.-F. Lucasson, a post-graduate student within the laboratory who 
showed that the proteins precipitated in a 30% ammonium sulphate saturated 
sample of Bn5T cell polypeptides contained the U90.
This work was then applied to the HSV-2 infected Bn5T cells, and it was also 
found to be the case that when the cytoplasmic fraction of HSV-2 infected cells 
was saturated to 30% with ammonium sulphate, the U90 was precipitated from 
the sample. Further investigations showed that when 25%, 30% and 35% 
ammonium sulphate saturated samples were run on the FPLC mono Q. and the 
subsequent flow through samples analyzed, the 25% saturated samples also 
contained a small amount of U90, as did the precipitated proteins in the 35% 
ammonium sulphate samples. The FPLC trace of protein eluted from the monoQ.
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after injection of the 35% AS cut showing a peak corresponding to the U90 in 
the flow through, can be seen in Figure 36. However analysis of these samples 
by SDS page showed that in comparison with the total amount of U90 isolated in 
the flow through of the 30% cut sample, the U90 found in the 25% and 35% cut 
was only a small proportion of the U90 found in the 30% cut. In addition, the 
num ber of background polypeptides seen in the flow through of the 35% cut 
was greater than the 30% cut, and therefore the 30% cut was used.
After the U90 had been selectively precipitated by saturating  salt 
concentrations, it was found that the polypeptide was no longer in a soluble 
form and addition of detergent was required to solubilize the protein. Following 
the resuspension of the precipitated polypeptide a further step of sonication 
was included to disrupt protein aggregates which had formed. The insolubility 
of the U90 after selective precipitation may be a consequence of the U90 under 
normal circumstances being complexed with additional polypeptides which 
enabled it to remain in solution. The increased salt concentration and selective 
precipitation of the U90 may have disrupted such interactions resulting in the 
insoluble U90 forming aggregates and precipitating out of solution. Addition of 
detergent to the sample and sonication to disrupt any protein aggregates 
overcame this problem. It was in fact this hydrophobic nature of the U90 which 
helped in the partial purification of the U90 by FPLC.
Some time was devoted to trying to isolate the U90 as a single polypeptide 
eluted from a reverse phase column on a microbore HPLC, in order that the 
polypeptide could be sequenced directly without further manipulations. To 
achieve this, considerably more time would have had to be spent on this 
particular aspect to overcome a problem of protein degradation by TCA which 
was encountered. To sequence the U90 under the conditions which it was eluted 
from the HPLC, the sample would have still needed to be run on a gel, then 
blotted onto a PVDF membrane. No advantage was therefore obtained by using 
the HPLC compared to using U90 isolated from the flow through of the FPLC 
where conditions for isolating partially purified U90 were already well defined. 
As a consequence of this, it was decided to use the U90 isolated from the FPLC in 
attempts to obtain N-terminal amino acid sequencing.
100% B ->
CO
0% B ->
FIGURE 36 : FPLC trace generated when 7ml of sample generated from the 
desalted 35% AS precipitated cytoplasmic fraction of HSV-2 infected Bn5T cells 
(10 burlers) was injected on to the mono Q column in buffer A (1% triton-X-100, 
50mM tris pH8). Using a flow rate of lml/minute, the sample was injected and 
0% buffer B run for 7 minutes followed by a linear gradient of 0-50% buffer B 
over a period of 4 minutes, 50-100% over the following 13 minutes, 100% buffer 
B for 3 minutes and followed by 0% buffer B for 5 minutes. Peak 1 corresponds 
to U90 as determined by Coomassie blue staining. - - - - represents buffer B 
c o n cen tra t ion , solid line represen ts  e lu ted  pro te in . Full scale  de flec tion  
sensitivity = 1.0 Aufs
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SECTION 4 : N-TERMINAL AMINO ACID SEQUENCING 
OF THE U90
Amino acid sequencing of purified U90 was carried out on an ABI 477A 
pulsed-liquid protein sequencer using the Edman degradation reaction. This 
reaction which is outlined in Figure 37 consists of a coupling reaction of 
phenylisothiocyanate (PITC) to the N-terminal amino acid of the protein to be 
sequenced followed by a wash step, to remove excess reagents, a cleavage 
reaction which generates a PTC derivative and a thiazolinone incorporating the 
original N-terminal amino acid. The thiazolinine is then converted to a more 
stable phenylthiohydantoin for identification by HPLC (Yarwood, 1989). Amino 
acid analysis was carried out on an ABI 420H amino acid analyzer, Amino acid 
sequencing and amino acid analysis were carried out by Drs Gordon Currie and 
Maggie Cusack in the Department of Geology, University of Glasgow.
1 U90 Isolated From the Cytoplasm of Infected Bn5T Cells
Using approximately 2X10^ HSV-2 infected Bn5T cells, U90 was purified 
from the cytoplasmic fraction which had been passed over the FPLC using 
buffers A.3 and B.3 containing 0.1% triton-X-100, and the flow through samples 
containing the U90 concentrated 10 fold by lyophilization. These samples were 
then loaded onto a 7.5% SDS mini-gel using a comb which produced one large 
deep well, almost the full length of the gel and a second smaller well in which 
marker proteins were run. This large track enabled more material to be run on 
the gel at the one time, so concentrating the U90 further in a single band. This 
gel was run  as normal then transferred by electroblotting onto Problot (Applied 
Biosystems, England), a PVDF membrane (Method 7e). Following transfer, the 
U90 was visualized by Coomassie blue staining (0.1% w/v Coomassie blue, 10% 
methanol, 1% acetic acid) for 30-60 seconds, then quickly destained (10% 
methanol, 1% acetic acid), with several changes of buffer. If the U90 band was 
stained strongly enough with Coomassie blue such that it was easily visible 
within 3 minutes of destaining, it was predicted that a minimum of lOpmoles of 
U90 was present. (Coomassie blue staining will visualize a minimum of 
approximately 200ng of protein on a PVDF membrane (Matsudaira, 1990) where 
900ng of U90 is equivalent to lOpmoles.)
To confirm the quantity of U90 present, a known proportion of the band 
was sent for amino acid analysis (in general 10% of the total U90 was analyzed). 
This accurately determined the total amount of protein which was present in a 
sample. If this analysis indicated that at least lOpmoles of U90 was present in
Coupling
iHCO-R2-R,
PTC - Paptid*
NH2CH R - j  CO - R2' - R-
Paptid*
N = C=
Coupling
PITC
Cleavage
Shortened  P«ptid«
NH
Conversion
PTH-Am ino Acid Thiazolinona
FIGURE 37 : Schematic representation of the Edman degradation reaction 
used in amino terminal protein sequencing (Yarwood, 1989). PTC= phenyl 
thiocyanate, PITC = phenylisothiocyanate.
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one sample in total, (the lower limit for amino acid sequencing), amino acid 
sequencing was carried out. Ideally 25-100 pmoles of polypeptide was required.
This experiment was completed on 4 separate occasions with amino acid 
analysis being completed on three different occasions revealing that quantities 
between 60 and 88pmoles of U90 were present on the membrane sections sent 
for sequencing. This indicated that sufficient material was present to allow 
detection of the individual amino acids eluted from the HPLC after sequencing. 
However, when the samples were sequenced, on all 4 occasions, only 4-8pmoles 
were detected to be eluted from the HPLC following sequencing and hence no 
readable sequence was obtained. From this it was concluded that the amino 
terminus of the U90 isolated from the cytoplasmic fraction of HSV-2 infected 
Bn5T cells was "blocked".
Blockage occurs as a result of a modification of the amino terminus (eg 
acetylation), in such a m anner that the Edman reaction used in N-terminal 
amino acid sequencing is inhibited preventing amino acid sequence from being 
obtained. This modification of the N-terminal can either occur naturally by 
post-translational modification, or it can occur as a consequence of chemical 
modification during the purification procedure. As a large number of proteins 
which have been isolated from eukaryotes to date are blocked (Driessen et al. 
1985), it was possible that the U90 was also naturally blocked. Steps were taken 
to minimize the possibility of blockage occurring during the preparation and 
purification of the U90, and attempts to sequence the U90 were repeated.
2 Prevention o f N-Termitial Blockage
Several factors can prevent a successful Edman reaction. Some of these 
factors were eliminated and if this was not possible, the length of time during 
which the protein to be sequenced was in contact with such a blocking agent 
was minimized. Potential blocking factors are discussed below and the method of 
minimizing inhibition of the sequencing reaction by them presented:
(1) acrylic acid present in polyacrylamide gels may react with the side 
chains of the protein to be sequenced. To minimize this only the highest purity 
acrylamide was used, which was treated with amberlite (an ion exchange resin) 
to remove oxidising factors which could produce acrylic acid. The smallest and 
thinnest possible gels were used to minimize the amount of acrylamide which 
the protein came in contact with. The gels were pre-run, ie the gels were run as 
norm al before the stacker (and the samples) were added so eluting any 
unpolymerized acrylamide through the gel. Reduced glutathione was also added 
to the tank buffer while the gel was being pre-run, (0.7g per 250ml of buffer) 
to react with acrylic acid or any free reactive sites and finally gels were
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"matured" by storing at 4°C for a minimum of overnight (Ullrich, personal 
comm unication).
(2) oxidising agents present in the polymerized gel could also give rise to 
blockage of the protein. A free radical scavenger (3ul of thioglycolic acid, free 
acid/ 250ml of buffer) was added to the upper buffer to mop up any oxidising or 
reducing agents while the gel was being run  (U llrich , p e rso n a l 
communication).
(3) contam inants in the gel solutions were minimized by using on ly  
chemicals and water of highest purity (FPLC grade), and were stored where 
possible in sterile plastic containers and not glass containers which may have 
had contaminants adsorbed to the glass as a consequence of the detergent 
containing fluids used during cleaning.
(4) the tank buffer was changed from the standard glycine buffer to a tris- 
tricine buffer (Methods, Table 1). This was necessary as the glycine in the 
buffer previously contaminated the protein sample and the resulting sequence 
had  an artificially  high glycine con ten t (Curry & Cusack, personal 
comm unication).
Even after incorporating these conditions, the U90 was still found to be 
blocked. It was therefore accepted that the U90 was most probably naturally 
blocked, and so an alternative method for obtaining amino acid sequence of the 
U90 had to be found.
3 U90 Isolated From The Membrane Of Infected Bn5T Cells
As the U90 could also be isolated from the membrane fraction as well as the 
cytoplasmic fraction of Bn5T cells, the amino terminus of the U90 was purified 
from the membrane fraction. This was investigated in the hope that the U90 
polypeptide contained a membrane signalling peptide which was removed once 
the U90 became associated with the m em brane. Such signal peptides are 
normally 10-20 amino acids in length and  situated at the amino te rm in a l 
(Einfeld & Hunter, 1991). It was therefore anticipated that if such a peptide was 
removed from the U90 on its insertion into the membrane, an unblocked N’ 
terminus might be exposed and sequencing therefore become possible.
The membrane sample was treated as described for the cytoplasmic sample, 
with the exception that 10 times more starting material was used. The purified 
U90 was electroblotted onto Problot membrane with at least lOpmoles estimated 
to be present, as determ ined by the intensity of staining by Coomassie blue. 
Amino acid analysis revealed that sufficient material was present for successful 
sequencing to be carried out, but in a similar manner to the cytoplasmic isolate 
of U90 no amino acid sequence was obtained from the purified U90 isolated from
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the membrane fraction of HSV-2 infected Bn5T cells. The experiment was also 
repeated using U90 purified from control Bn5T cells, but no readable sequence 
was obtained from these attempts.
4 Attempts To Unblock the U90 Amino term inus
The majority of eukaryotic polypeptides which cannot be sequenced are 
blocked as a result of acetylation of the terminal amino acid. It has been claimed 
that treatment of such polypeptides with TFA will remove the blocked terminal 
amino acid from the polypeptide so leaving second amino acid free to be 
sequenced (Hulmes et al 1989). U90 isolated on ProBlot membrane was treated 
with TFA using a modification of the procedures outlined by Hugli (1989) 
Method, Section 8c. A 20% solution of TFA in water was added to the bottom of a 
small glass bottle containing U90 immobilized on the Problot membrane. This 
was made air tight and the TFA left to evaporate to produce gaseous TFA. The U90 
was left in the gaseous TFA for either 10 days at room temperature or 2 days at 
42°C. Following this treatment the U90 was sequenced.
No readable sequence was obtained from either of these two preparations 
as the TFA not only digested the terminal amino acid but also the U90 itself. This 
resulted  in breakdown products creating background sequences and so 
prevented a single readable sequence from being obtained.
5 In ternal am ino acid sequencing
As no amino acid sequence of the U90 could be obtained using the 
conditions defined above, experiments were progressed to try to obtain internal 
amino acid sequence by enzymatically digesting the polypeptide then 
sequencing the N-terminal of each fragment. To obtain internal amino acid 
sequence U90 purified as described previously was digested using Staph, aureus 
V8 protease within a gel system in a similar m anner to that described for 
peptide mapping analysis (Method, Section 7c). The major difference between 
the procedure to obtain internal sequence as opposed to amino term inal 
sequence was that an absolute minimum of 10 times more material was required 
for internal amino acid sequencing. This was to ensure that at least lOpmoles 
was present in each digested fragment to enable a readable amino acid sequence 
to be obtained. The U90 was therefore required to be further concentrated after 
the flow through samples had been reduced in volume by partial lyophilization. 
This was done by running the concentrated flow through samples on a 7.5% gel, 
using a large comb consisting of one well which ran almost the entire length of 
the comb and a second small well for protein markers. The U90 was then
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visualized with Coomassie blue stain, the gel dried and the U90 band carefully 
excised from the dried gel.
One large U90 band the length of the gel was produced by this step, which 
was then cut into smaller pieces to enable it to be placed into the wells of a 
second 7.5% gel. The bands were rehydrated in the wells with tricine tank 
buffer (methods section, Table 1) then run into the gel as normal. Once the dye 
front had run the length of the gel, the gel was stained with Coomassie blue, 
dried, then the highly concentrated bands of U90 were cut out and digested 
within a third gel using the peptide mapping technique.
The gel used for the digestion varied from that of a normal peptide map in 
that it had  a much larger stacker and so required  larger gel plates 
(188x250mm). The peptide mapping gel used wells which were twice as deep as 
normal wells, and because of the depth of the wells the stacker gel was made 
larger than normal (approximately 150mm in length). The larger stacker gel 
was also necessary to enable the material being loaded onto the gel to form a 
tightly stacked band. If the protein did not form a tight band before it reached 
the interface of the stacker and resolving gel, it was found that only a 
proportion of the U90 was completely digested as the remainder of the protein 
ran behind the enzyme on the gel. If this happened the rem ainder of the 
sample which was only partially digested, produced protein smears the length 
of the gel, preventing discrete bands of digested peptides from being isolated. 
By using a larger stacker this was avoided.
Once the U90 had stacked together to form a tight band and had reached 
just above the interface of the two gels, the power was switched off for one 
hour to allow the digestion to take place. The power was then returned and the 
samples run as far as possible down the gel to give the maximum separation of 
peptides. These peptides were then transferred to Problot membrane as before 
by electroblotting, visualized by Coomassie blue staining, then carefully excised 
(using a scalpel blade) ensuring no smears of contaminating protein were 
included in the band. Figure 38 shows the electroblotted V8 protease digested 
U90 peptides as visualized by Coomassie blue staining prior to being excised and 
sent for sequencing.
The N-termini of 7 independent peptides in total were successfully 
sequenced over a period of three experiments the sequences of which are 
presented in Table 1. The sequences are represented by the single letter code 
for amino acids (which is outlined in Table 2). Four of the seven peptide 
sequences were confirmed at least twice. To ensure that the Staph, aureus V8 
protease had not been mistakenly sequenced, all peptides were checked for
1 2 3
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FIGURE 38 : U90 purified from the cytoplasmic fraction of an estimated 2X1010 
HSV-2 infected Bn5T cells using the purification strategy as described 
previously (Figure 35). The U90 was digested with V8 protease using the 
modified version of the peptide mapping technique as described in the text. Half 
of the U90 was loaded into each of tracks 1 & 2 together with 50ug of V8 
protease/track and digestion carried out as described previously. The 18% SDS 
gel was then electroblotted onto a PVDF membrane which was then stained with 
Coomassie blue. The approximate molecular weights of the resulting peptides 
are indicated to the left of the membrane, with m olecular weight markers 
present in track 3 and their values in kilodaltons indicated to the right of the 
membrane.
TABLE 1 : A m ino acid seq u en ces o f  U 90 peptid e fragm ents
Amino acid sequences of the U90 peptides are listed below using the single 
letter code (see table 2), bold letters correspond to the sequence finally  
determined after careful comparison the different sequence data obtained and 
analysis of the amino acid elution profiles generated (where appropriate).
Size (Kd) Sequence Quantity (nmoles)
4 VGYLWYGEWP 43
4 VGYLWYGEKP STFLRAGP YSHW 33
VGYLWYGEWP STFLRAGP YSHW
6 SWWVTSDKNM RSDAQ. 16
8 FQWYKEGNRV 25
8 FEEYKAGDRV TINWKTLDKA 47
8 FEEYRAGDRV TINWN 16
FEEYKAGDRV TINWNTLDKA
12 KIYPTLADEN GQEKV 47
14 KGYIKAADEN VQPHV 40
16 VGYWFYGTDP AWFFS 21
16 VGYWWYWWR 8
VGYWFYGTDP AWFFS
20 VIKINAQFYE 12
20 WIKISANFYE 23
20 7ILINANFYE 8
VIKINANFYE
TABLE 2 : Single and three letter  code for am ino acids
THREE LETTER 
CODE
ALA
ARG
ASN
ASP
CYS
GLN
GLU
glycine GLY
histidine HIS
isoleucine ILE
leucine LEU
lysine LYS
m ethionine MET
phenylalanine PHE
proline PRO
serine SER
threonine THR
tryptophan TRP
tyrosine TYR
valine VAL
AMINO
ACID
alanine
arg in ine
asparagine
aspartic acid
cysteine
glutamine
glutamic acid
SINGLE LETTER 
CODE
A
R
N
D
C
0 .
E
G
H
I
L
K
M
F
P
S
T
W
Y
V
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homology with the known amino acid sequence of the enzyme using the 
computer software described below.
6 Comparison of the U90 to docum ented sequences
The seven internal amino acid sequences of U90 were compared to the 
sequences entered in the NBRF databases using the Genetics Computer Group 
(GCG) Sequence Analysis software package version 7. The programmes 
Wordsearch and FastA were used, which both search for sequence similarity by 
either a Wilbur & Lipman (1983) or Pearson & Lipman (1988) style search 
respectively. No significant homology to any protein sequence entered in the 
database was found. This will be considered further in the following discussion 
section
The programme Backtranslate was also used to produce the nucleic acid 
sequences of the peptides, which were then compared to the nucleic acid 
sequences entered in the Gen EMBL databases. No significant homology was 
found with any of the nucleic acid sequences (including hsp90 or GRP94), 
suggesting that the U90 is a novel tumour associated polypeptide.
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DISCUSSION OF SECTION 4 : Amino Acid Sequencing of the 
U90 N-terminus
The development of PVDF membranes and automated protein sequencing 
has enabled the sequencing of the N-terminal amino acids of many proteins. By 
electroblotting a partially purified polypeptide onto such a membrane, limited 
amino acid sequencing of an unknown polypeptide can be obtained, without the 
need for a 100% homogeneous sample of protein. The acquisition of such 
sequence data, even though it be potentially very small, facilitates further 
investigations of the protein in question using such techniques as PCR, cDNA 
library screening, northern and Southern blotting. The aim of the p ro te in  
sequencing studies described in this section was therefore to obtain sufficient 
sequence of the U90 to allow some of these techniques to be applied to the 
expression of U90 in tumour cells and compare this with HSV infected tumour 
cells, infected RE cells and control RE cells.
Initial attempts to sequence the U90 used the most abundant source of 
material available, U90 isolated from the cytoplasm of HSV-2 infected Bn5T cells. 
Following the protein’s partial purification and electroblotting onto a PVDF 
membrane the amount of protein on the membrane was estimated and then sent 
for amino acid sequencing. Despite deliberately under estimating the total 
amount of U90 on the PVDF membrane (by Coomassie blue staining) to be in the 
very least 20 pmoles of protein, the results generated by amino acid sequencing 
indicated that less than 4 pmoles of protein were present. This suggested that 
either the estim ation of protein present by Coomassie blue staining was 
somewhat inaccurate or that the protein was in fact blocked. The former which 
was subsequently disproved by amino acid analysis of the sample, will be 
discussed below.
Blockage can occur for example by the presence of a formyl group, a 
methyl group, a pyroglutamyl group or an acetyl group on the terminal amino 
acid, where the addition of a pyroglutamyl or acetyl group occurs more 
frequently. Considerable work has been done investigating acetylation and has 
been reviewed by Driessen et al (1985). It is thought that acetylation can occur 
shortly after the initiation of translation while the protein is still being 
translated. It has been proposed that a general function of N-acetylation may be 
to protect proteins from proteolytic degradation by amino peptidases (Jomvall, 
1975) although contradicting evidence has been presented (Mauk et al. 1976).
In the first protein preparation to be sequenced, it was not known if the 
blockage in the N-terminal was a naturally  occurring modification of the 
term inal amino acid or if the modification occurred as a result of protein
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manipulation. To ensure blockage did not occur during the handling of U90 
every possible precaution was taken to remove any "blocking factors" and 
minimize contact with those blocking factors which could not be removed. 
Before further amino acid sequencing was attempted an amino acid analysis of 
the sample was used to quantitate the total amount of U90 present on a small 
portion of the PVDF membrane. Approximately 10% of the total piece of PVDF 
membrane to be sequenced was analyzed and unless the amino acid analysis 
predicted that at least 25 pmoles of U90 was contained on the remaining 90% of 
the membrane, sequencing was not attem pted. On the three occasions that 
amino acid analysis was completed the amounts of amino acids seen were 
between 60-88pmoles, but following sequencing the amino acid levels generated 
by the Edman degradation reaction and detected by HPLC were never found to be 
significantly above background levels. From this data it was concluded that the 
N-terminal of the U90 was blocked.
By varying the source of U90 starting m aterial it was hoped that an 
unblocked form of the U90 could be isolated and amino term inal sequence 
derived. Alternative sources of U90 included membranes of infected Bn5T cells 
(a small amount of U90 was detected in this fraction) or membranes from 
control Bn5T cells. It was hoped that the membrane-associated form of the 
protein would contain a membrane targeting signal which would be cleaved 
from the N-terminus of the U90, once it had become associated with the 
membrane. Such signal peptides are thought to have a general pattern of amino 
acids (which is outlined below) as opposed to a specific consensus sequence.
+ + hydrophobic region more polar mature polypeptide
 \ ________________ \ _________cleavage -> |________________
1-5 a£l 5-15 a.a. 3-7 a.a.
If this were the case, the possibility existed that U90 isolated from the 
membrane associated fraction of the cell may have a number of its N-terminal 
am ino acids cleaved and therefore  expose an unblocked te rm in u s .  
Unfortunately the membrane associated U90 isolated from HSV-2 infected Bn5T 
cells was also found to be blocked.
The final attempt to obtain N-terminal amino acid sequence was to apply 
the U90 purification strategy to control Bn5T cell membranes to overcome any 
modification which might occur within the U90 following HSV infection. 
Although characterization studies suggested that it was unlikely that HSV-2 
infection resulted in the stabilization of the U90 by post-translational 
modification (Results Section 1.6) the introduction of the virus to the cell may
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still have resulted in some modification of the polypeptide which could have 
prevented the Edman degradation reaction from being completed. U90 was 
purified from uninfected Bn5T cells (by using considerably more starting 
material than used previously) - but still the U90 was found to be blocked.
The alternatives available at this point in the project were to either try to 
unblock the N-terminal or to digest the protein in order to generate "new" N- 
termini of internal peptide fragment.
Attempts to unblock the amino terminal with TFA using a modification of 
methods described by Hugli (1989), not only removed the N-terminal amino acid 
but also cleaved the polypeptide in a num ber of places resulting in the 
generation of additional peptide fragments. The most viable option left was to 
try to generate internal peptide sequence by proteolytic digestion of the 
protein followed by electroblotting of the peptide fragm ents onto PVDF 
membrane which were then sequenced.
In order to obtain internal amino acid sequence of the U90, peptide 
fragments were generated by proteolytic digestion using V8 protease. This was 
completed by using a modification of the protocol as described for peptide 
mapping analysis. The modifications introduced aimed to increase the total 
quantity and purity of each peptide finally recovered and sequenced after 
electroblotting from the SDS gel to the PVDF membrane. In order to sequence 
the individual peptides, the Coomassie stained bands were carefully cut from the 
PVDF membrane.
The dimensions of the gel itself were modified for two different reasons. In 
order that maximum efficiency of transfer was achieved a "thin" gel of 0.75mm 
thick as opposed to the normal standard 2mm gels was used. This was necessary 
as it was discovered that electroblotting of a 2mm thick gel in the BioRad mini 
gel system at 120mA (constant voltage) for 1 hour resulted in at least 20% of the 
protein remaining in the gel, as seen by Coomassie blue staining, compared to 
almost no visible protein remaining in the gel when a 0.75mm gel was used. Due 
to the small quantities of peptides that were being dealt with, achieving 100% 
transfer could mean the difference between obtaining just sufficient material 
for amino acid sequencing or providing a little more than the m inim um  
required and hence generating much more reliable sequence data.
The second change to the dimensions of the gel was required in order that 
a larger stacker region of the gel could be generated. This was necessary as the 
purified U90 polypeptide was loaded into the wells of the gel in the form of 
strips of dried acrylamide cut from 7.5% gels containing partially purified U90. 
As a result of the large amount of material required to be loaded in each well, 
the protein was rehydrated in the wells of the gel (as opposed to prior to
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addition to the gel) and then electrophoresed through the 7.5% strips into the 
stacker of the 18% peptide mapping gel. In order that more gel slices could be 
loaded onto each track, the wells were made twice the depth as normal and 
therefore the remainder of the stacker had to be increased in length so that it 
was at least twice the length of the wells. This was necessary to allow all the 
protein which was eluted from the gel slices to "stack” correctly before 
entering the resolving gel. If this "stacking" process did not occur properly 
before the protein entered the resolving gel, a smear of protein was seen by 
Coomassie blue staining which ran  the length of the track. This was a 
consequence of the different rates of migration of the polypeptides due to the 
very slightly earlier time at which the protein at the leading edge of the 
protein band entered the resolving gel compared to protein behind the leading 
edge.
A nother modification introduced to the system was the addition of 
considerably more enzyme to each well containing U90 gel slices. 50ng of V8 
protease was used for each track of the gel (as compared with 5jig which was 
used previously). It was estimated that up to at least 10 times more material was 
being digested under these conditions and as 5^g per track was in vast excess 
previously, it was anticipated that digestion to completion would be obtained 
using 50fig of enzyme per track.
The pH of the enzyme digestion buffer was altered from pH 6.8 (which 
allows digestion of peptide bonds on the C-terminal side of glutamate residues, 
cleavage of aspartyl bonds and some non-specific cleavage), to pH 8.1. This 
change restricted peptide bond cleavage prim arily to glutam ate residues 
(Aitken et al. 1989). By reducing the num ber of peptides generated during 
proteolysis, it was anticipated that some larger fragments would be obtained 
which would be able to be separated more easily than a num ber of small 
peptides of similar molecular weight.
During SDS page, the dye front was run  as far as possible down the gel 
(without the loss of any low molecular weight peptides) to obtain maximum 
separation, the gel was electroblotted, quickly stained and destained using 
staining and destaining solutions containing only 1% acetic acid (Method 
Section 7e), to allow the peptide fragment to be visualized. The individual 
peptides were carefully excised using a scalpel blade, then sent for amino acid 
sequencing.
The resulting fragments seen in Figure 38, visualized by Coomassie blue 
staining appear different to digestion pa ttern  of U90 when visualized by 
autoradiography of [35S] labelled peptides. This is due to two factors, (1) the 
different digestion pH conditions and (2) the different m ethod used for
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visualizing the peptides. [35S] L-methionine may be incorporated in some 
peptides, but others may contain no methionine residues resulting in some 
peptides not being visualized by autoradiography even though they were 
present. The different digestion conditions should also generate fewer cuts and 
therefore fewer peptides.
In total seven different peptides were isolated sifter V8 protease digestion, 
with the sequences for four of these peptides being generated on at least two 
occasions. The sequences from the other four peptides were only generated on 
one occasion due to the difficulties in obtaining sharp discrete bands on the 
PVDF membrane. This problem occurred because some of the peptides migrated 
very close to each other on the gel, ie the 12K, 14K and 16K peptides. A similar 
problem was obtained with the 6K peptide since the 4K and 8K peptides migrated 
below and above it on the gel, potentially "contaminating" the area around the 
6K peptide. Due to the cost of sequencing each peptide, only bands isolated on 
the PVDF membrane which were free from contaminating smears of protein 
from above or below them were sent for sequencing.
As can be seen from Table 1 some variations in the sequence were obtained 
on different occasions. Despite more than adequate material being registered by 
the system as being present, the quality of the amino acid sequence obtained 
was not ideal. The sequence was determined by analysis of the HPLC amino acid 
elution profiles following Edman degradation by the inbuilt programme of the 
Applied Biosystems 477A protein sequencer. This compared the total amounts of 
individual amino acids as they were eluted from the HPLC system. Each amino 
acid is characterized by the length of time which they are retained on the 
column, eg serine is retained for 6.37 minutes with lysine being retained for 
23.58 minutes. However, it was discovered that the system did not always 
accurately interpret this analysis (Curry & Cusack, personal communication) 
and therefore every elution profile had to be carefully analysed manually by 
comparing the picomoles of each amino acid eluted after every cycle in the 
Edman degradation reaction.
Disparity between the manually and  com puter predicted amino acid 
sequence occurred when the levels of more than one amino acid were elevated. 
Under these circumstances the best fitting sequence for these elution profiles 
were predicted manually. In some cases these were later modified when more 
sequence data became available and comparison with the second (or third) set 
of sequence data suggested that one amino acid was more likely to be correct 
than another for that particular position. This was particularly relevant when 
two amino acids were eluted from the HPLC at similarly increased levels, with no 
indication which was the most probably correct. These manual predictions also
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took into account the lag period seen when proline was eluted from the column, 
which results in increased levels of proline in the system for several 
subsequent degradation reactions (Curry & Cusack, personal communication).
Analysis of the seven proposed amino acid sequences showed that some 
similarity existed between the 4K and the 16K peptides and also between the 12K 
and 14K peptides, as illustrated below (identical amino acid residues shown in 
bold). As the 12K and 14K peptides were only sequenced on one occasion, the 
possibility existed that the 14K peptide was derived from the same region of the 
U90 polypeptide as the 12K, but the 14K had not been fully digested. This was 
very unlikely as the proteolytic enzyme was added in vast excess and therefore 
digestion should have gone to completion and additionally, although th e  
peptides were of similar molecular weights, it was certain that the peptides were 
not mistakenly identified as the alternative peptide since the sequences were 
generated from two very distinct bands isolated from one track on a single piece 
of PVDF membrane with the peptides being electroblotted after being separated 
on a 18% polyacrylamide gel.
4K V G Y L W Y G E W P  S T F L R A G P Y S H W
16K V G Y W F Y G T D P  A W F F S
12K K I Y P T L A D E N  GQ. EKV
14K K G Y I K A A D E N  VQ. PHV
It is therefore proposed that the similarities that arise between the 4K and 
16K peptides and the 12K and 14K peptides are a consequence of repeat elements 
within the U90 polypeptides itself. These repeat elements may represent some 
functional domains within the protein. However, as the sequence data is limited, 
what these particular regions may be is impossible to predict.
The amino acid sequence of the seven peptides were compared to the 27,711 
protein sequences entered in the NBRF data bases using two d if fe re n t  
programmes - Wordsearch and FastA which align regions of homology within 
two sequences. These use slightly different methods of alignment, but bo th  
indicate not only homology but will indicate conservative changes of amino 
acids and introduce spaces in one sequence in order to produce a better 
alignment of the sequences.
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Each individual sequence was compared to the sequences entered in the 
database NBRF. Using the Wordsearch and FastA programmes discussed above, 
different levels of stringency were applied in order to identify homologous 
sequences to the U90 within the database. The stringency was varied by altering 
the num ber of "mismatches" which could be tolerated during the search. When 
only one or no mismatches were allowed, no sequences were identified as being 
homologous to the U90 peptides sequences. This suggested that the U90 had not 
been previously sequenced and therefore the searches were repeated allowing 
up to four mismatches in order to search for a sequenced protein which 
displayed homology with the known sequences of the U90.
When such low stringency searches were completed, a large num ber of 
entries in the database were found which met the search criteria. However the 
homologies found were very limited and only occurred over a small number of 
amino acids, the statistical significance of such homologies is very low, as the 
shorter the stretch of amino acids is, the greater the probability that such 
sequence will occur elsewhere. In order to assess if any of these hom ologies 
were significant, proteins which showed any degree of homology, no m atter 
how small, to more than two of the U90 peptide sequences were analysed in 
greater detail
One sequence was found to have a small degree of homology with the 
peptides 4K and 16K. This sequence was derived from NADH dehydrogenase 
(ubiquinone) chain 1 which is 318 amino acids in length, isolated from the 
mitochondrial genome of the Norweign rat, accession numbers 504747 and 
501954 (Gadaleta etal, 1989).
It should be noted that the 4K and 16K peptides themselves exhibit some 
degree of homology with 3 out of the first 5 amino acids being the same (see 
above) and it is possible that it was a consequence of this, that the alignment of 
NADH dehydrogenase was found to have homology with two of the peptide 
sequences. Further comparison of the U90 (taking all seven peptide sequences 
into account) with NADH dehydrogenase showed no other homologies to suggest 
that the U90 was in fact related  to NADH dehydrogenase. By carefully 
considering conserved amino acid changes (eg lysine to valine or tryptophan to 
arginine) conserved motives were searched for - once again no homologies 
were found.
In fu rther attem pts to determine if the U90 was similar to any other 
proteins entered in the database not already searched the nucleotide data base 
GenEMBL was screened. In order to do this the seven peptide sequences had to 
be "Backtranslated" to predict their DNA sequences (using the GCG programme 
"Backtranslate"). This used the human foetal globin codon usage as determined
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by Shen et al. (1981), analyzed by Smithies et al. (1982) and adopted for use in 
the Backtranslate programme by Dr J.C.M. Macnab. No entries were found that 
displayed any significant homology with two or more of the peptide sequences.
Comparison of the U90 sequences derived from the digested polypeptide to 
the documented sequence of V8 protease sequence confirmed that the enzyme 
had not been mistakenly sequenced. Further comparison of the sequences was 
also made to the published sequences of hamster GRP94 (Mazzarella & Green, 
1987), with no homology being found. The predicted DNA sequences of the 
peptide fragments were also compared to the DNA sequence of hsp90 generated 
by Farrelly & Finkeslstein (1984), and later Jendoubi & Bonnefoy (1988). No 
homology was found confirming that the U90 was indeed distinct from both 
GRP94 and hsp90. This also agrees with subsequent work by Dr J.C.M. Macnab in 
collaboration with Goldberg (Harvard Medical School) who showed that the 
purified U90 did not cross react with antibodies raised against the La protease 
(hsp90 equivalent in E.coii), nor did the monospecific U90 antibody react withi
purified La protease. This is in contrast to the reported findings of La Thangue 
& Latchman (1988).
Throughout this section of the work, a considerable number of problems 
were encountered which could neither be avoided nor overcome by me. A 
num ber of technical problems were reported to have arisen with the protein 
sequencer itself, including one particular problem  with the injector. This 
resulted in the complete loss of two of my peptide samples (which took up to 2 
months to prepare). Despite the fact the the sequencing facility were aware that 
problems existed, 4 o ther peptides samples were sequenced under these 
circumstances without my knowledge and out with my control, resulting in 
very poor quality sequence data, further more, technical problems which arose 
with the sequencer resulted in considerable delays between a sample being sent 
to the Geology Department and the sample being analysed. An additional 
problem encountered was that of spurious peaks on the HPLC trace, generated 
during the sequencing. These peaks could have been caused by a "dirty" 
column, which should have been avoided by extended washing of the column - 
an point which I could not anticipate nor have any control over.
To ensure that the sequence data given by the Geology Department was as 
accurate as possible the amino acid profiles of every piece of sequence data 
were discussed at great length with Drs Cusack and Currie. This was particularly 
im portant when determining the relevance of dual amino acid peaks eluted 
from the column. These could be explained by an amino acid lag period seen 
after the initial elution of particu lar amino acids (eg proline). As a 
consequence, every piece of sequence data generated was discussed with the
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protein sequencers in the Geology Department. A considerable time and effort 
that was therefore invested in every sample sent for sequencing, and the 
sequence data that was received, no m atter how little, was very carefully 
analyzed not only by myself but also by Dr Maggie Cusack, Dr Joan Macnab and 
Mr David McNab. Amino acid analysis of the U90 provided no relevant 
inform ation about the composition of the U90 because of the size of the 
polypeptide. This information could have been useful if it were obtained for the 
small peptide fragments generated by V8 digestion, however such small 
quantities of peptides were available tha t all the m aterial generated was 
required to obtain amino acid sequence.
Based on the assumption that the sequence data eventually generated by 
Drs Curry and Cusack was correct it can be concluded that the U90 is a novel 
tumour associated polypeptide with no significant sequence homology to any 
sequence entered in the data bases to date.
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SECTION 5 : UTILIZING THE U 9 0  AMINO ACID SEQUENCE
1.Utilizing amino acid sequence for cDNA lib ra ry  screening
Dr J.C.M. Macnab had previously generated cDNA libraries of the Bn5T cell 
line in the expression vector XgTl l .  With the information obtained from the 
amino acid sequencing data, this library could now be screened. Although this 
expression vector was originally designed for screening cDNA libraries with 
antibodies, oligonucleotide probes have also been successfully used (Huynh et 
al, 1985). The experiments described in this section were not completed due to 
the short period of time remaining for this project.
Before em barking on any m olecular biology experim ents certain  
assumptions had to be made: firstly that the amino acid sequence data was 
correct in order to generate probes for the U90, and secondly that the cDNA 
library (generated by Dr JCM Macnab) contained the cDNA for the U90. Neither 
of these assumptions could be substantiated and due to the short period of time 
left to identify the U90 gene the sequence data had to be accepted as a close 
representation of the U90 and the cDNA library accepted as expressing the U90.
To generate synthetic oligonucleotides corresponding to the U90, the 
internal amino acid sequences were backtranslated to nucleic acid sequences 
using the eukaryotic codon usage of human foetal globins G and A gamma genes 
(Shen et al. 1981 , Smithies et al. 1982) and the GCG Sequence Analysis 
Backtranslate programme as detailed in Table 3. This resulted in either a 
"bestfit" sequence, which predicted the most likely codon usage for each amino 
acid, or a degenerate sequence which included all possible nucleotide sequences 
for that particular peptide's 5' amino acid sequence. Unfortunately none of the 
amino acid sequence generated had low redundancy which resulted in the 
necessity to synthesize degenerate probes.
The most reliable peptide sequences (ie where there was least ambiguity), 
were analyzed to determine which part of the U90 peptides contained the least 
degeneracy and these regions were chosen to generate oligonucleotides. By 
reducing the num ber of degenerate  sites, all degeneracies could be 
incorporated into the nucleic acid sequences of the 4K and 8K peptides and used 
to produce synthetic oligonucleotides. In all circumstances oligonucleotide 
sequences were checked by at least one other person and the suitability of the 
particular sequence for PCR confirmed others who were experienced in PCR 
primer design (Dr Bill Carman, Institute of Virology). The degenerate synthetic 
oligonucleotides which were kindly made by Dr John Maclauchlan and their 
derivation is illustrated in Figure 39. At the time of synthesis of the initial 
oligonucleotides only one set of amino acid sequence data had been obtained and
TABLE 3: Eukaryotic cod on  usage
Eukaryotic codon usage as derived from the human foetal beta globins G and A 
(Shen et al. 1982; Smithies et al. 1982).
A m in o c o d o n % a m in o c o d o n %
a c id d i s t r i ­ a c id d i s t r i ­
b u t io n b u t io n
Gly GGA 46 Asn AAT 40
GGC 46 AAC 60
GGT 1
Met ATG 100
Glu GAG 50
GAA 50 lie ATA 25
ATC 75
Asp GAT 63
GAC 38 Thr ACC 50
ACT 30
Val GIG 69 ACA 20
GIT 15
GIG 15 Trp TOG 100
Ala GOC 55 Cys TOT 100
GCT 27
GCA 18 Tyr TAC 100
Arg AGG 67 Leu CIG 71
AGA 33 CTO 18
TIG 12
Ser TOC 45
TOT 18 Phe TIC 63
AGT 18 Trp 38
AGC 18
Gin CAG 100
Lys AAG 83
AAA 17 His CAT 57
CAC 43
Pro CCT 50
END TGA CCA 25
GOC 25
FIGURE 3 9  : D erivation o f  syn th etic  o ligon u cleo tid es 4a  & 4b  and
8a & 8b.
The amino acid sequences and corresponding DNA sequences of the 4K and 
8K peptides are shown below. The arrows indicated the DNA sequences from 
which the synthetic oligonucleotides originated. This data was generated 
from initial amino acid sequence data and used for cDNA library screening 
and PCR. As at this time only one set of sequence data had been obtained, 
oligonucleotides were directed against the most "reliable" sequences which 
were at the amino terminus of the peptides. Positions of degeneracy are 
indicated by showing the alternative base(s) in brackets.
4K PEPTIDE
Val Gly Tyr Leu Trp Tyr Gly Glu Trp Pro
4a 5’— — 3 ’
GIG GGA TAC CIG TGG TAC GGA GAG TGG OCT
GTT GGC CIC GGC GAA CCA
GTC TIG GOC
4b 3' — —— — — — '
la
5' GTG(T,C) GGA(C) TAC C(T)TG(C) TGG TAC GG 3’
4b (com plem entary to RNA in region indicated bv arrows)
5' CC GTA CCA C(G)AG(A) GTA T(G)CC C(A,G)AC 3'.
8K PEPTIDE
Phe Gin Trp Tyr Lys Glu Gly Asn 
8a 5' — 3'
TIC CAG TGG TAC AAG GAG GGA AAC
TIT AAA GAA GGC AAT
GGT
8b 3'— — — — — -  5'
8 a
5' TTC(T) CAG TGG TAC AAG(A) GAG(A) GG 3’
8b (com plem entary to RNA in region indicated bv arrows)
5' G(A)TT T(GA)CC C(T)TC C(T)TT GTA CCA CTG
Arg Val
AGG GIG 
AGA GTT 
GTC
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therefore the amino acid sequence used to generate the probes does not exactly 
correspond to the final sequence present in Table 1. The 4a and 8a 
oligonucleotides were then used to try to identify any cDNA in the Xgjtl 1 
libraries containing the U90 message.
As indicated cDNA libraries were constructed in an expression vector 
allowing both oligonucleotide and antibody probes to be used to screen for the 
U90 cDNA. For this reason, in conjunction with the degenerate oligonucleotide 
screening, Mr David McNab also used an antibody probe (the monospecific U90 
antibody and TBS) to screen the library. This m eant that any positive clone 
isolated could be confirmed by both an antibody and an oligonucleotide probe.
Up to 80,000 plaques were screened in total using end labelled probes 
(Method 9c) derived from both the 4K and 8K peptide fragment sequences and 
duplicate filters. A number of clones gave positive reactions. However, when 
these were isolated and grown up they were found to be non-specific positives. 
Repeating the experiments using duplicate filters and the two probes separately 
still resulted in no positive clone being consistently identified. Screening with 
the antibody probe also resulted in the isolation of several positive clones 
(McNab, unpublished) but disappointingly in a similar m anner to the clones 
isolated by the oligo probes, none of these were found to be positive following 
plaque purification and further antibody screening.
A num ber of technical difficulties arose during these e x p e rim e n ts  
including false positives. This particular problem  was removed by using 
duplicate filters. Other problems included high non-specific background and 
difficulties in determining the optimal hybridization temperature of the probes 
(due to their degeneracy). These problem s could only be overcome by 
synthesizing new probes using nucleotide sequences which would hybridize 
100% with the cDNA of the U90. This could only be done by obtaining DNA 
sequence directly from the gene or the cDNA, ie sequence which was not 
inferred by the amino acid sequence which may have contained inaccuracies.
The other possible reason for not being able to identify the U90 cDNA could 
have been that either the cDNA construct expressing the U90 had been lost, that 
it was present in such low amounts that insufficient clones had been screened 
to allow its detection or that expression of the U90 was toxic to the bacteria such 
that any positive clone when it was attempted to be amplified, died. It is also 
possible that the cDNA for the U90 was not included in the library at the time of 
synthesis. This may have occurred if the message for the U90 had a long polyA 
tail. As a result of this the resulting large cDNA may not have been isolated 
intact. If time had not been a limiting factor, I would have liked to generate
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further cDNA libraries using not only Bn5T cells, but also Bn5T cells infected 
with HSV and control RE cells.
In order to obtain some highly homologous DNA sequence and overcome 
these problems the oligonucleotides were used in polymerase chain reactions 
(PCR) to amplify either mRNA which was reverse transcribed into cDNA or 
genomic DNA, both of which were isolated from different sources as described 
below.
2 Utilizing Amino Acid Sequence For Polymerase Chain Reaction
Studies using the polymerase chain reaction (PCR) can be divided into two 
sections - either using DNA as a template or RNA as a template (from which 
cDNA was synthesized). These two conditions were then further divided 
depending on the primers used - either a set of primers derived from two 
different internal peptide sequences (Figure 39) or a set of primers derived 
from either end of a single peptide sequence (Table 4).
2(a) BnST DNA As A Template
DNA was isolated from 6x10^ Bn5T cells as described in Method 11, 
quantitated by optical density (OD260)> then used as a template in PCR reactions 
using degenerate synthetic oligonucleotide probes. Prior to PCR, the primers 
were purified on a 15% urea/acrylam ide gel (Method 9a) then the molarity of 
the prim er samples determ ined using their OD2 6 O in the equation below 
(Steinthorsdottir, personal communication), where A=the num ber of adenine 
nucleotides, C=cytidine, G=guanine, T=thymidine.
Em = A( 16,000) + G( 12,000) + C(7,000) + T(9,600) 
where Molarity M = OP? 60
Em
PCR was carried out using 15-30ug of Bn5T DNA, 0.2jiM of each of the two 
primers, 0.125mM of each of the four nucleotides and 2 units of Ampli Taq 
polym erase/ reaction in PCR reaction buffer as described in Method 13(b) 
containing 4mM MgCl2 .
As the primers were derived from the amino acid sequence of two different 
internal peptides of U90, the orientation of the sequences with respect to one 
another was not known. To determine this orientation two complementary sets 
of primers were used to accommodate both possibilities (Figure 40a) using the 
synthetic oligonucleotides described in Figure 39. The amplification using both 
sets of primers was carried out in a total volume of 50ul, for 35 cycles, using the 
following tem peratures - denaturation at 95°C for 6 minutes in the first cycle
TABLE 4  ^D erivation o f  syn th etic  o ligon u cleo tid es 4.1 & 4 .2  and 8.1 &
8.2.
Synthetic oligonucleotides generated from revised amino acid sequence data to 
enable PCR products the length of the known peptide sequence to be generated. 
Oligonucleotides were directed at the extremes of the known amino acid 
sequences in order to generate as large a PCR product as possible. In these 
oligonucleotides inosine (I) is used at positions where degeneracy is greater 
than two, and the arrows correspond to the regions against which the 
oligonucleotides were directed.
4 . 1  5' -— — — — — — — 3'
Val Gly Tyr Leu Trp Tyr Gly Glu Trp Pro Ser
Thr Phe Leu Arg Ala Gly Pro Tyr Ser His Trp
4 . 2  3' — — — — — — — 5'
4 . 1
5’ GTI GGI TAC C(T)TG(C) TGG TAC 3’
4. 2  (com plem entary to RNA at position indicated bv arrows)
5’ CCA A(G)TG G(A)G(C)A(T) GTA IGG ICC 3’
8.1 5f— — — — — — — — — 3’
Phe Glu Glu Tyr Lys Ala Gly Asp Arg Val Thr
lie Asn Trp Asn Thr Leu Asp Lys Ala
8 . 2  3 — 5 ’
8.1
5’ TTC(T) GAG (A) GAG(A) TAC AAG(A) GCI GG 3’
8. 2 (com plem entary to RNA at position indicated bv arrows)
5’ GC C(T)TT A(G)TC C(G)AG(A) IGT G(A)TT CC 3’
FIGURE 40: Determining the relative orientations of the 4K and 8K 
peptides.
Figure 40a and 40b differ with regards to the oligonucleotides used. In 
Figure 40a the oligonucleotides were derived from only 10 amino acids of 
sequence and therefore represent the vast majority of the peptide sequence and 
are partially complementary. In Figure 40b, the oligonucleotides were derived 
from peptides of at least 20 amino acids in length and therefore are derived from 
the amino and carboxy ends of each peptide sequence.
Figure 40a
[1] 4.a >
.4K peptide /  /  8K peptide.
< 8.b
[2]
8.a.............. >
 8K peptide /  /  4K peptide__
<--............4.b
Figure 40b
[1] 4.1 >
.4K peptide /  /  8K peptide.
8.2
[2] 8.1
8K peptide /  / _______ 4K peptide.
< 4.2
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and 1 minute thereafter, hybridization at 45°C for 1.5 minutes, and extended 
polymerization at 72°C for 4 minutes. The low hybridization temperature of 45°C 
was used to enable hybridization of low specificity to occur. This was essential as 
the oligonucleotides used were not 100% homologous to the U90 DNA. One tenth 
of the resulting samples were analyzed on agarose gels and DNA products 
visualized by UV illumination.
Using DNA as a template and primers from separate internal peptide 
sequences no DNA could be visualized by UV illumination. This may have been 
because insufficient DNA was present to be visualized or alternatively the 
reaction may not have worked for a number of reasons which are discussed 
below.
There was no way of determining how far apart the primers were on the 
U90 gene as it was impossible to predict the size of any potential PCR product 
when DNA was used as a template. This also made the PCR reaction itself more 
difficult as it was not known how much time should be assigned to the 
elongation period of each cycle. If the elongation period was too short, a full 
length product would not be made, but if it was too long the activity of the Ampli 
Taq polymerase would be unnecessarily reduced. Another problem with using 
DNA as a template was the possibility that introns existed between the two 
primers on the U90 gene. If this were so, the result would be the amplification 
of a DNA fragment which included an intron and hence would be too large to 
expect the PCR reaction to be successful. It was therefore concluded that the two 
probes were most probably too far apart on the DNA to expect a successful PCR 
reaction. However, the inability to isolate a product may have been due to 
insufficient cycles being com pleted or the  oligonucleotides being too 
degenerate to permit efficient hybridization.
An alternative approach was taken using primers both of which were 
derived from the sequence of a single peptide fragment (Figure 40b). This was 
only possible because more amino acid sequence of the 4K and 8K peptides had 
been obtained. As a result of the additional sequence which had been generated 
alterations were made to the predicted DNA sequence (inferred from the 
corrected amino acid sequence) and new oligonucleotides made (Table 4). These 
were also modified to include inosine (Patil & Dekker, 1990), in positions where 
three or more different nucleotides were required due to degeneracy of the 
sequence. This m eant that the orientation of the primers with respect to each 
other was known and the size of product could be predicted assuming an intron 
did not fall in the middle of the known amino acid sequence. Using primers 4:1 
and 4:2 for one reaction and 8:1 and 8:2 (Table 4) for a second reaction, the PCR 
was repeated as before using 1 and lOug of Bn5T DNA, 500uM dNTPs, ImM of each
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primer, 2.5 units of Tap polymerase and either 1.5 or 2.5mM MgCl2 . 45 cycles 
were completed using a hybridization temperature of 48°C for 1 minute and an 
extended polymerization temperature of 72°C for 1 minute. Following the first 45 
cycles no DNA product could be visualized therefore 10% of each of the 
amplified samples were re-amplified for a further 20 cycles. Analysis of these 
samples revealed DNA products in the samples using primers 8:1 and 8:2 at a 
MgCl2 concentration of 2.5mM. A representative line diagram and photograph 
of the resulting DNA products can be seen in Figure 41. The resulting DNA 
product of less than lOObp in size, as estimated by DNA markers run on the gel, 
was seen on two occasions. This corresponds to the expected size of the DNA 
generated using the 8.1 and 8.2 primers (17 bases between the primers plus 34 
bases for 8.1 plus 31 bases for 8.2 ~ 82 bases in total), assuming no intron falls in 
this region The DNA bands seen running at approximately 40bp in tracks 6 and 
7 are thought to be due to primer-dimer formation which is frequently seen 
(Carman, personal communication).
The reamplified DNA in the sample was purified on an low melting agarose 
gel and cloning into M l3 was attempted by blunt end ligation (Method 13c) to 
allow the amplified DNA to be sequenced. The ligation reaction was attempted on 
3 occasions and transform ed into E.coli. however no positive clones were 
isolated by blue/white X-gal selection.
2(b) Bn5T RNA As A Template
To overcome the problems encountered when DNA was used as a template 
for PCR (ie the possibility of introns being present within the target DNA or the 
DNA product defined by the primers being too large to realistically expect the 
PCR to be successful), RNA was isolated from cells and used as a template. The 
RNA isolated was produced using two different methods and from cells either 
infected or uninfected by HSV-2. The two latter conditions were used to help 
determine if the U90 was transcriptionally activated by HSV infection.
(a) Cytoplasmic RNA was isolated from Bn5T cells as described in Method
12a.
(b) Poly A RNA was isolated using Dynabeads oligo (dT)25  selective for the 
poly A tail of mRNA (Dynal, Ireland) as described in Method 12b. The Dynabeads 
which bind poly A tails of the mRNA were isolated from the sample by 
magnetism and the mRNA eluted from the beads using buffers supplied and 
conditions described by the m anufacturer’s protocol. This m ethod of RNA 
isolation was used with both infected and uninfected Bn5T cells.
Once the RNA was isolated and quantified the RNA was reverse transcribed 
as described in Method 13 a (Steinthordottir & Mautner 1991) using the primer
1 2 3 4  5  6 7
1 2 3 4 5 6 7
369bp 
246bp 
1 23bp
Primer-
dimers
FIGURE 41 : Ethidium bromide stained agarose gel (3% nusieve, 1% agarose), 
containing PCR products generated using the primers 4.1 & 4.2 (tracks 4 & 5) 
and primers 8.1 & 8.2 (tracks 6 & 7). Track 1 shows DNA markers whose values 
are indicated to the left of the gel in bp, track 2, a negative sample and track 3, a 
positive sample of an expected size of lOObp. Tracks 4 & 6 used 1.5mM MgCU, and 
tracks 5 & 7 used 2.5mM MgCl2. 10ug of Bn5T DNA was used as a template, 2.5 
units of Taq polymerase, ImM of each prim er and 500uM dNTPs in each 
reaction. Initially 45 cycles were completed in a total volume of 50ul (94°C 
denaturation for 1 minute, 48°C hybridization for 1 minute, 72°C extension for 1 
minute), and 1/10 of the final sample was removed. A 20 further cycles were 
carried out on this material using the same conditions - after new primers, 
enzyme and dNTPs had been added. 5ul of each sample can be seen in the above 
gel. A DNA product (indicated by an arrow), of <lOObp can be seen in track 7. A 
representative line diagram is shown.
1 1 6
which was complementary to the RNA to initiate cDNA synthesis. This first
strand cDNA was then used as a template for the PCR reaction.
Various conditions were used over a number of experiments by changing 
the following parameters:
Starling m aterial - 1 and 5ug of RNA was used to produce cDNA 
The num ber of cycles used - 35 cycles were used initially. This was
increased to 40 followed by a further 20 cycles to reamplify the product. 
Denaturation tem pera tu re  - this was maintained at 95°C for a period of 5-6 
minutes in the first cycle and 1 minute in all other cycles
Hybridization tem perature - this was kept low due to the degeneracy of the 
primers, between 45-54°C.
Extension tem perature - maintained at 72°C
Time allowed for extension - this varied depending on the tem plate and 
primers used, between 1 minute and 4 minutes. The larger the expected DNA 
product, the longer the extension period had to be, thus in reactions using 
primers derived from two different peptide fragments the extension was carried 
out over 4 minutes, and over 1 minute if the primers were derived from either 
end of the one peptide fragment.
Ampli Taq enzyme concentration - this was used successfully at 2.5 units 
per reaction.
MgCl2 concentration - this was varied between 1 and 4mM with success most 
often at 4 mM.
Using the two sets of primers (4.1 + 8.2 and 8.1 + 4.2) derived from peptides 
4 and 8 (Table 4) the orientation of the peptides with respect to each other was 
investigated. To determine which was the correct location of the 4K and 8K 
peptides with respect to each other as illustrated in Figure 40b, two different 1st 
strand cDNA synthesis experiments followed by PCR were completed.
In order to investigate the situation where the 4K peptide is located to the 
amino end of the 8K peptide (ie to the left) primer 4.1 was used in the 1st strand 
cDNA synthesis reaction (seen in Figure 40b [1]), and 8.1 was used for 1st strand 
cDNA synthesis, to investigate the opposite situation (ie the 4K peptide lying to 
the carboxy or right side of the 8K peptide) seen in Figure 40b [2]. In this 
experiment 1 or 5ug of RNA was used for 1st strand cDNA synthesis, (isolated as 
described in Method 12a). Conditions used were 1.5mM MgCl2 , ImM dNTPs, 10 
units of RNasin, 10 units of AMV reverse transcriptase and luM of the relevant 
primer (in lOul). The sample was incubated at room temperature for 10 minutes 
followed by 30 minutes at 42°C, 5 minutes at 100°C then placed immediately on 
ice (modified from Steinthordottir & Mautner 1991). To proceed with PCR more
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of each prim er was added to a final concentration of 0.2uM, 1 unit of Taq 
polymerase and the volume made up to 50ul. Using a hybridization temperature 
of 50°C and 36 cycles were completed and 10% of each sample analyzed on a 1.5% 
agarose gel as seen in Figure 42 (which also includes a diagramatic 
representation of this gel). It demonstrated on three separate occasions that 
orientation dictated by the primers 4.1 and 8.2 was correct, as only these 
primers gave any DNA products following amplification. The DNA amplified 
under these conditions included non-specific DNA products due to the low 
stringency of the primer hybridization temperature.
Attempts to reamplify the above PCR products to provide more material to 
allow shot gun cloning into M l3 to be completed was unsuccessful. This was 
most likely due to the same prim ers being used in the reamplification as 
opposed to nested PCR being attempted with a second set of primers. This was not 
possible as insufficient sequence was available to synthesize further primers to 
carry out nested PCR.
A repeat of these experiments using mRNA isolated using Dynabeads oligo 
(dT )25  was unsuccessful. The PCR reaction itself was successful as shown by the 
positive control, however it appears that the mRNA isolated using these 
conditions was not suitable for PCR. This may have been a consequence of the 
final buffer the RNA was isolated in, as it contained EDTA, or alternatively, the 
U90 mRNA may not have been isolated because the poly A tail was hidden, or, in 
a similar manner to histone DNA, the U90 may not have a poly A tail.
1 2  3  4  5  6  7 8
4-3
1 2 3 4 5 6 7 8
4.3Kb
2.3Kb
2.0Kb Representing non- 
specifc DNA products
0.12Kb
Prim er-
dimers
FIGURE 42 : Ethidium bromide stained agarose gel (1.5% agarose), containing 
PCR products generated using the primers 4a, 4b, 8a & 8b. Track 1 contains DNA 
markers, indicated to the left of the gel, track 2 a positive sample of an expected 
size of around 2Kb, track 3 - a negative sample. Tracks 4-6 used 5ug of HSV-2 
infected Bn5T RNA as a template, and tracks 7 & 8 used 5 and lug respectively of 
uninfected Bn5T DNA. Track 4 used the primer 8a to generate cDNA, followed by 
8a & 4a in PCR, with tracks 5 & 6 using primer 4b to generate cDNA, followed by 
primers 4b & 8b in PCR. Conditions for PCR were 1.5mM MgCU, 2.5 units of Taq 
polymerase, ImM of each primer and 500uM dNTPs in each reaction. 40 cycles 
were completed in a total volume of 50ul (94°C denaturation for 1 minute, 50°C 
hybridization for 1 minute, 72°C extension for 3 minutes), and 10% of the final 
sample analysed. The reverse transcription reaction where appropriate used 20 
units of reverse transcriptase at room temp for 10 minutes, 42°C for 30 minutes, 
100°C for 5 minutes and cooled quickly on ice. The PCR reaction was then 
carried out. A representative line diagram is shown.
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DISCUSSION OF SECTION 5 : Utilizing the U90 am ino acid  
se q u e n c e
This section outlined the molecular experiments initiated to utilize the 
information generated from the amino acid sequencing of the p ro teo ly tic  
peptide fragments of the U90. The long term aim of this work is to be able to 
obtain the complete amino acid and DNA sequence of the U90, either by isolating 
cDNA encoding the U90, by screening cDNA libraries, or by accumulating 
sequence data generated by PCR. On establishing the sequence of the U90, the 
data bases could be rescreened to search for other polypeptides which might 
contain functional domains which display a degree of homology with the U90. If 
this was achieved, progression towards elucidating the functional role of the 
U90 in the cell could be made. As stated previously these experiments depended 
on the accuracy of the amino acid sequence data generated by others and the 
presence of a cDNA representing the U90 in the cDNA library.
To screen the kgTl l  cDNA library of Bn5T cells, which was previously 
generated by Dr J.C.M. Macnab, synthetic oligonucleotide probes were made. 
Using the sequence data of the 4K and 8K peptides, mixed oligonucleotides that 
encompassed all degenerate sequence possibilities were made, as described by 
Girgis, et al (1988). This increased the chance of the most homologous probe 
possible, which was complementary to the U90 cDNA being present. The amino 
acid sequence against which the oligonucleotides were made was chosen such 
that the number of degenerate sites in the probes were minimized (in order to 
reduce the total num ber of different probes required in the mixed oligos). 
Where possible this was done by choosing a region of amino acid sequence 
which incorporated the least amount of degeneracy, eg sequence containing 
tryptophan, tyrosine, methionine, cysteine and glutamine.
The mixed oligo probes were also to be used as primers in PCR experiments 
and so further considerations had to be taken into account when designing 
these probes. In PCR the most important region of the primer is the 3' region. 
When selecting the region of amino acid against which to make the probes, any 
large area of degeneracy was avoided in the 3f area and it was essential to select 
a region where there was no dubiety in the amino acid sequence. The length of 
primer should aim to be around 20 bases and where possible end in a guanine or 
cytosine. Latterly deoxyinosine was incorporated into the primers at points of 
degeneracy. Finally once these conditions have been met, the primer should be 
checked for obvious complementarity within itself to prevent hairpin bends 
forming. Most importantly, complementarity with the second primer should be 
minimized, as if this does occur prim er dimers will occur and reduce the
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number of primers in the sample free to align with the target DNA. Before 
selecting the probes to be synthesized these conditions were carefully applied, 
the sequences of the probes checked by at least one other person and the design 
of the probes confirmed to be suitable by Dr Bill Carman.
Two probes were used to screen the available cDNA library, one derived 
from the 4K peptide and the second derived from the 8K peptide. The use of two 
different probes proved to be a considerable aid, as screening of the 
nitrocellulose filters with degenerate oligos produced a large am ount of 
background. By using two independent probes and duplicate filters it was 
possible to select regions on the duplicate filters which gave positive signals 
with both probes. As the cDNA of the U90 was thought to be of low abundance in 
the cells (Macnab, unpublished), it was possible that only a very sm all 
proportion of the library would correspond to the U90. To increase the chance 
of isolating U90 cDNA, as many colonies as possible were screened on any one 
occasion by plating the library out at a high number of colonies per plate. Any 
regions on the plates which were found to be positive with both probes were 
then picked, grown overnight and plated out at a lower density in order that 
single colonies could be isolated. However when these colonies were rescreened 
no positive colonies were found, suggesting that the original colonies were just 
background contamination. Despite attempts to remove the background by 
introducing more stringent washes, no positive colonies could be isolated.
The inability to isolate positive colonies could have been due to the low 
representation of the U90 in the library, the absence of U90 in the library or 
potentially inaccuracies in the original amino acid sequence. Low levels of U90 
cDNA (or none at all) may have occurred if the U90 expression was found to be 
toxic to the bacteria. Efforts were then concentrated on trying to obtain more 
sequence data by generating a PCR product, cloning it into M l3 and sequencing 
it.
Several different experim ents were attem pted using the synthetic 
oligonucleotide probes with both DNA or RNA as a template. Initial PCR 
experiments were unsuccessful when DNA was used as a template to try to 
amplify the DNA sequences lying between the 4K and 8K peptide fragments. 
However, as the relative location of the 4K and 8K peptide fragments to each 
other on the U90 gene were unknown, the size of any potential DNA product 
could not be predicted. It is probable that this product would have been too large 
to expect a successful amplification reaction, as the chance of introns being 
present between the two peptides was also possible.
Once further amino acid sequence had been obtained, primers of a known 
distance apart from each other were used by synthesizing oligos corresponding
1 2 0
to the beginning and the end of the sequence data of a single peptide. Some 
success was obtained using this approach as a small DNA product (Figure 41), of 
the expected size could be visualized when primers from either end of the 8K 
peptide were used.
To reduce the size of any potential DNA product when primers from the two 
different peptides were used, RNA was used as a template as opposed to DNA. 
These experiments allowed the relative positions of the 4K and 8K peptides on 
the U90 gene to be determined. This was done by using a primer complementary 
to the RNA to enable the reverse transcription of the mRNA, followed by PCR 
using the two prim ers from the 4K and 8K peptides to amplify up th e  
synthesized cDNA.
A num ber of background bands were seen when the samples were 
analyzed by gel electrophoresis which were probably  generated as a 
consequence of partial reverse transcription of the RNA (producing truncated 
products), and /o r due to the low stringency of the annealing conditions as a 
consequence of the degenerate nature of the oligos.
Attempts to clone the DNA products generated by the different PCR 
experim ents were unsuccessful. This may have been due to insufficient 
material in the ligation reactions or possibly incorrect conditions to increase 
the chance of the ligation reaction being successful. The ligation reactions 
were attem pted on three different occasions using material isolated from low 
melting agarose gels. As the reaction depended on a blunt end ligation reaction 
being successful, perhaps if more material had been available repeating the 
experiment several more times would have resulted in the successful cloning of 
the amplified DNA.
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SECTION 6 :CHARACTERIZATION & PURIFICATION
OF U 90  IN PRIMARY RE CELLS
1 U9Q Visualized In Control RE Cells bv Coomassie Blue Stain
When control RE cell polypeptides are radiolabelled  with [3 5 s] L- 
methionine, immunoprecipitated with TBS, analysed by SDS page and visualized 
by autoradiography, the U90 polypeptide was never seen. Extensive 
investigations were initially carried out on RE cells in an attempt to isolate the 
U90 in control cells and sire described below.
(1) Cells were radiolabelled at two different stages in the cell cycle, when they 
were either quiescent or in a logarithmic growth phase. This was to determine 
if the expression of the U90 was cell cycle regulated.
(2) Cells were radiolabelled in 1% or 10% serum to investigate the possible 
involvement of a serum responsive element in the regulation of the U90. This 
was prompted by the discovery of such an element 5' of the transcriptional 
initiation signal of the c-fos gene (Treisman, 1985, 1986; Gilman et al. 1986; 
Greenberg et al. 1987).
(3) RE cells were also treated  with a glucocorticoid, dexam ethasone, as 
glucocorticoid responsive elements have also been reported to act as regulatory 
elements in gene expression (Kasambalides & Lanks, 1983). This has been well 
characterized in the case of the LTR of mouse mammary tumour virus (reviewed 
by Offord, 1988).
None of these conditions resulted in the visualization of the U90 in RE cells by 
immunoprecipitation of radiolabelled polypeptides.
In contrast to the above, when a similar IP reaction was repeated with RE 
control cells using at least 10 times more material and antibody than normal 
(around 4X10? cell per reaction) and the polypeptides visualized by Coomassie 
blue staining, a polypeptide of similar molecular weight to that of the U90 
immunoprecipitated from Bn5T cells could be seen in the RE cells (Figure 43). 
This was believed to be the correct band as the U90 from Bn5T cells was 
radiolabelled and could be localized by aligning the autoradiograph with the 
stained gel. This observation was made before the U90 purification strategy had 
been developed and as no antibody was available to test on a western blot if this 
90K polypeptide in RE cells was in fact the U90, this could not be tested further 
at this point. However, once the U90 purification strategy had been developed, 
Mr David McNab was able to raise a monospecific antibody against the U90 
(Methods Section 3b), by using the U90 purified by the method described in 
Results Section 4, and injecting rabbits with polyacrylam ide gel slices
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FIGURE 43 : IP reaction using TBS of RE cells (tracks 1 & 2) and Bn5T cells 
(tracks 3 & 4) using an estimated 4X10~ uninfected cells (tracks 1 & 3) or HSV-2 
infected cells (tracks 2 & 4) in each reaction. The IP reactions were analysed as 
normal by 7.5% SDS-page and the gel stained with 0.2% Coomassie blue as 
described previously. The additional Coomassie stained bands are bacterial 
polypeptides generated by the use of Pansorbin, (which is a suspension of 
S.aureus Cowan 1 strain which express a coat of protein A), as a alternative for 
protein A.
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containing the protein. This antibody was then used in conjunction with 
purification studies to investigate the presence of the U90 in control RE cells.
2 Purification of U90 From RE Cells
Using the purification strategy devised to isolate U90 from HSV infected 
Bn5T cells, attempts were made to try and purify the U90 from HSV-2 infected RE 
cells. The RE cells were infected by HSV-2 at 5-10pfu/cell for 17 hours at 37°C, 
the cytoplasmic fraction isolated, a 30% ammonium sulphate cut performed, the 
sample desalted into FPLC buffer A (50mM tris 0.1% triton), centrifuged, passed 
over the FPLC mono Q  column and the flow through samples analyzed as 
described in Results Section 4 and summarized in Figure 35.
Coomassie blue staining of the flow through samples indicated that a 
polypeptide of a similar molecular weight to U90 was present in the cytoplasmic 
fraction of HSV-2 infected Bn5T cells (Figure 44). This 90K protein was then 
further analyzed by western blotting using the monospecific U90 antibody.
3 U90 Isolated  From Control RE Cells Is R ecognised Bv The
M onospecific U90 Antibody
The U90 isolated from the flow through of HSV-2 infected RE cells was 
analyzed by western blotting using the monospecific U90 antibody raised in 
rabbits against purified U90. To confirm that the monospecific U90 antibody did 
in fact recognise the U90, western blots using this antibody were carried out 
following immunoprecipitation of the U90 from Bn5T cells and Bn5T cells 
infected with HSV-2. The resulting blot (Figure 45a) demonstrated that the U90 
antibody recognised the immunoprecipitated U90 and shows a quan tita tive  
difference in the amount of U90 in the infected cell compared to the uninfected 
Bn5T cell. The 90K protein seen in the RE cells was also recognised by TBS in IP 
reactions where the RE cells were immunoprecipitated with TBS, run on an SDS 
gel and then western blotted using the monospecific U90 antibody (Figure 45b). 
The former experiment was kindly done by Dr Joan Macnab confirming that the 
monospecific U90 antibody recognised the 90,000MW RE cell polypeptide 
immunoprecipitated by TBS. This showed that control RE cells express a U90 
homologue despite the fact that it had not been visualized by [ ^ s ]  L-methionine 
radiolabelling overnight.
4 U90 In RE Cells Is Also Increased Bv HSV Infection
U90 was purified from both HSV-2 infected and uninfected control RE cells, 
and the cytoplasmic and membrane associated fractions from each compared. 
2X109 cells were harvested as usual (approximately 10 burlers of primary RE
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FIGURE 44 : RE cells were infected by HSV-2 at 5-10pfu/cell for 17 hours at 
3 7°C, the cytoplasmic and membrane fractions isolated, a 30% ammonium 
sulphate cut performed on each, the samples desalted into FPLC buffer A (50mM 
tris 0.1% triton), centrifuged and injected onto the FPLC mono Q column as two 
separate runs. This was carried out in the same manner as described for Bn5T 
cells in Results Section 4 and summarized in Figure 35. The 1ml flow through 
samples were collected and lOOul of the membrane fraction flow through 
samples 1-6 analysed by Coomassie blue staining of a 7.5% SDS-page (tracks 1-6 
respectively) The similarly treated cytoplasmic flow through samples 1-6 can 
be seen in tracks 8-13 respectively. Molecular weight markers are present in 
track 7 and their values in kilodaltons indicated to the left of the gel.
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FIGURE 45A  : IP reactions with TBS of polypeptides extracted from the 
cytoplasmic fractions from each of Bn5T cells (track 1) and HSV-2 infected Bn5T 
cells (track 2) followed by western blotting with U90 monospecific antibody 
confirming that the U90 antibody does recognise the U90.
FIGURE 45B : IP reaction with TBS of polypeptides extracted from the 
cytoplasmic fractions from each of control RE cells (track 1) and HSV-2 infected 
RE cells (track 2) followed by western blotting with U90 monospecific antibody. 
This shows that a 90K homologue of the U90 is seen in RE cells which also 
accumulates following HSV infection. Molecular weight markers are illustrated 
to the left of the blot. Figure 45a kindly carried out by Dr JCM Macnab
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cells generated from a single pregnant rat), fractionated and the U90 
homologue isolated from both the cytoplasmic and membrane fraction of each 
sample using the FPLC in the m anner previously described. The flow through 
samples of each of the four conditions were analyzed by western blotting using 
the monospecific U90 antibody (Figure 46). From these experiments it could be 
concluded that a U90 homologue is present in RE cells, and that in both Bn5T and 
RE cells the U90 and the U90 homologue is situated mainly in the membrane but 
could also be detected in the cytoplasmic fraction. Secondly, following HSV-2 
infection of either cell type, the overall quantity of U90 (or its homologue in RE 
cells) was increased and that in a similar m anner to the Bn5T cells the vast 
majority of the U90 homologue was isolated in the cytoplasmic fraction.
5 The Half Life Of U90 Is Different In Transformed And Control Cells
The U90 in RE cells as already discussed, has been shown to react with both 
TBS in immunoprecipitation reactions, (ie the native form of the protein is 
recognised by the antibody) and the monospecific polyclonal antibody in 
western blots (ie the denatured from of the protein is recognised). In these 
circumstances the U90 was visualized by Coomassie blue staining and horse 
radish peroxidase conjugated second antibody respectively, but as it could not be 
visualized by [35s] L-methionine radiolabelling over a period of 17 hours the 
half life of the U90 in RE cells and tumour cells was investigated. This was done 
by carrying out pulse labelling experiments in Bn5T and RE cells using a large 
excess of [35 s] L-methionine.
The tumour specific U90 had previously been shown to have a half life of 
around 28 hours in Bn5T cells (Hewitt, 1988). To establish the half life of the U90 
isolated from RE cells, after a minimum of 2 hours methionine starvation, 2X10^ 
RE cells and 2X10^ Bn5T cells were each radiolabelled over a period of 5 minutes 
with 2.5mCi of [35 s] L-methionine/ml of medium (50 times more radiolabel than 
normal) This large amount of radiolabel was required due to the very short 
radiolabelling period and the half life of the U90 polypeptide in RE cells. These 
cells were harvested on ice, extracted immediately, immunoprecipitated with 
TBS then analyzed by SDS page as quickly as possible. A similar experiment was 
also carried out, however, after radiolabelling for 5 m inutes, the [35 s] L- 
methionine was removed, the cells washed three times with PBS and chased with 
cold methionine containing medium for 1 hour. These cells were also harvested, 
immunoprecipitated with TBS, run on the same gel in the shortest time possible 
and visualized by autoradiography.
Comparison of the Bn5T cells and the RE cells shows that the U90 and its 
homologue do incorporate radiolabel under the conditions outlined. When
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FIGURE 46 A & B: Western blot with U90 monospecific antibody showing 
the U90 homologue purified from 2X109 control RE cells (A) and HSV-2 infected 
RE cells (B) using the U90 purification scheme as described in Figure 35. Tracks 
1-4 show the flow through samples of the cytoplasmic fraction of control (A) 
and HSV-2 infected (B) RE cells, tracks 7-10 show the flow through samples of 
the membrane fraction of control (A) and HSV-2 infected (B) RE cells. U90 
isolated from the cytoplasmic fraction (tracks 5) and membrane fraction 
(tracks 6) of HSV-2 infected Bn5T cells are shown as controls.
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however, these samples were chased for one hour, the U90 and its homologue 
behaved in a different manner (Figure 47). In the Bn5T cells, the U90 was seen 
to loose relatively little radiolabel over a period of one hour, whereas when the 
autoradiographs were scanned the U90 homologue in RE cells had lost in excess 
of half of its incorporated radiolabel after one hour (Figure 48). This showed 
that the U90 homologue isolated from the control RE cells and the U90 isolated 
from the transformed Bn5T cells had a dramatically different half life. A large 
number of non-specific polypeptides can be seen in Figure 47. We and others 
find this if very large amounts of radioactivity are used (A Cross, personal 
communication).
These results were later repeated by Dr Joan Macnab and Mr David McNab 
and analyzed by an alternative method using a Molecular Dynamics Phosphor 
Imager. The radiolabel incorporated in the U90 and U90 homologue were 
quantitated using the volume integration function within the ImageQuant 
programme. The value obtained for each time point was then plotted against 
time using the Apple Macintosh Cricket Graph package version 1.3.2 and the 
equation of the line using exponential decay was obtained. From this the half 
life of the U90 homologue was calculated to be 29.8 minutes from the Phosphor 
Imager data, and 36 minutes from the previous experiment scanned in Figure 
48. An average value of 32.9 +/- 3.1 minutes for the half life of the U90 
homologue was obtained which is dramatically shorter than the half life of the 
U90 which was estimated to be 13 hours (Grassie et al. 1993).
FIGURE 47 : Autoradiograph of IP reactions with TBS of RE cells (tracks 3 & 4) 
and Bn5T cells (tracks 2, 5 & 6) using 2X10^ cells radiolabelled with 5mCi [3^S] L- 
methionine for 5 minutes and harvested either immediately (tracks 3 & 5) or 
chased with excess cold methionine for 60 minutes (tracks 4 & 6). Prior to 
radiolabelling cells were starved of methionine for 2 hours. Track 2 shows an IP 
reaction of 4X10^ cpm of Bn5T cells extracted using RIPA buffer. In tracks 3-6, 
cells were harvested, extracted with RIPA buffer and IP reaction carried out 
immediately. Molecular weight markers can seen in track 1 and their values in 
kilodaltons indicated to the left of the gel. Increased non-specific background 
protein in tracks 3-6 is thought to be as a consequence of the large amount of 
radiolabel required to incorporate [35S] L-methionine into the U90 homologue 
in control cells.
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FIGURE 48 : Densitometer scan of U90 IP from control RE and Bn5T cells after 
being radiolabelled for 5 minutes with 5mCi of [35 s] L-methionine and chased
for 0 or 60 minutes with medium containing excess cold m ethionine as
described for Figure 47. Data corresponds to the area under the peak when the 
1 U90 band on the autoradiograph was quantitated by scanning densitometery, as
| described previously.
ij The equations of the curves (as determined assuming exponential decay
[ using the Apple Macintosh program m e Cricket graph version 1.3.2) are
illustrated adjacent to the respective curves, which allows the half life of the 
U90 homologue in RE cells to be calculated as 36 minutes. From the graph it can 
be seen that the radiolabel present in the Bn5T U90 after a 0 and 60 minutes 
chase is almost unchanged when compared to the U90 homologue in RE cells.
e y = 1 . 8 6 9 9 e + 5  * 1 0 A( -1 .0 7
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DISCUSSION OF SECTION 6  : CHARACTERIZATION AND
PURIFICATION OF U 9 0  FROM PRIMARY RE CELLS.
To date work investigating the cell encoded polypeptides of molecular 
weights 200,000, 90,000 (U90 and L90), 40,000 and 32,000 detected in radiolabelled 
transform ed cells (Bn5T) could find no corresponding p ro teins to be 
immunoprecipitated from radiolabelled control (RE) cells (Macnab et al. 1985a; 
Hewitt 1988; Hewitt et al. 1991).
Extensive studies in RE cells as summarized in section 6.1 agreed with 
previous studies, as no treatm ent of the control cells resulted in the 
visualization of the U90 by autoradiography. However, it was discovered that if 
such an IP reaction was visualized by Coomassie blue staining following SDS 
page, a number of similar protein bands could be seen in both RE and Bn5T 
cells. By aligning the relevant autorad track containing Bn5T cells with the 
stained Bn5T track, the band corresponding to the U90 was identified on the 
stained gel. Comparison of the RE and Bn5T stained tracks led to the discovery 
that a similar molecular weight band was present in the RE cells. As the IP 
reactions were carried out using Pansorbin (Calbiochem, UK) as opposed to 
purified protein A, other background polypeptides were visualized (Pansorbin 
is a suspension of S.aureus Cowan 1 strain which expresses a coat of protein A). 
The possibility consequently existed that the 90K band of interest was a 
component of the bacteria instead of the U90. This was unlikely to be the case, as 
previous experiments had seen this band to increase in Bn5T cells following 
HSV-2 infection and was therefore most likely to be the U90. Despite this, no 
further investigations could be completed at this point until an antibody was 
available which could be used in western blotting experiments.
Studies of the potential presence of the U90 in RE cells were therefore 
halted  until the U90 purification was developed and subsequen tly  a 
monospecific antibody produced (Mr. D. McNab),
A series of experiments were carried out to investigate if this 90K b an d  
seen by staining of IP reactions of both RE and Bn5T polypeptides was in fact 
U90. A large number of primary RE cells were made from one pregnant rat and 
the strategy used to purify the U90 from Bn5T cells was applied in an identical 
m anner to the prim ary RE cells. The RE cells were infected with HSV-2 in  
anticipation that the U90 in RE cells, if it existed, would behave in a similar 
m anner to the U90 in Bn5T cells (ie with HSV-2 infection resulting in an 
increase in U90 in the cytoplasm of the cell). HSV infection was therefore used 
to maximize the chance of visualizing the U90 in RE cells as it was anticipated 
that it might be present only in very small amounts under normal conditions.
1 2 6
Experiments using the monospecific U90 antibody in conjunction with the 
purification demonstrated that not only did the control RE cells express the U90, 
but they expressed it in a highly similar m anner to the Bn5T cells. In the 
uninfected RE cells the U90 could be detected in the membrane fraction with 
some U90 also seen in the cytoplasm. Following HSV-2 infection, the U90 was 
seen to accumulate to higher levels in the cytoplasm with only a small 
proportion of the total U90 being found in the membrane fraction, as seen by 
western blotting using the monospecific antibody. These observations taken 
together with the preliminary experiments visualizing immunoprecipitated U90 
by Coomassie blue staining, and the IP reactions of the control and HSV-2 
infected RE cells with TBS followed by western blotting (using the monospecific 
antibody), indicated that it was unlikely that a conformational difference in the 
U90 in RE cells prevented the protein from being visualized by radiolabelling 
and IP.
These experiments suggested that a protein very similar to the U90 was 
present in control RE cells but for some reason could not be visualized by [35S] 
methionine. Two possible contrasting explanations were proposed - either the 
metabolic rate of the U90 in RE cells was so slow that it did not incorporate any 
radiolabel over a period of 17 hours, or the polypeptide lost the radiolabel so 
quickly by pro tein  degradation  tha t it could no t be visualized by 
autoradiography. Both experiments were investigated.
RE cells were radiolabelled over a period of 18, 22, 42, 48 and 72 hours then 
harvested and IP reaction carried out as before. No band could be seen which 
corresponded to the U90. When the RE cells were radiolabelled with a vast excess 
of radiolabel, harvested and the IP reaction completed in as short a time as 
possible, a band of similar molecular weight to the U90 could be visualized. 
When the cells were chased with methionine containing medium following 
radiolabelling, the 90K band identified in the RE cells was seen to lose label far 
more rapidly than the U90 in Bn5T cells. It is possible that the 90K band 
identified in the RE cells is not a U90 homologue (due to the high level of back­
ground in this immunoprecipitation reaction), however, this experiment has 
been independently repeated by Dr JCM Macnab and Mr David McNab who also 
found a 90K polypeptide to be immunoprecipitated in RE cells by TBS using the 
conditions defined previously. Densitometer scanning of the 90K bands (after 
IP) enabled an estimate to be made of the half lives of the two forms of U90. This 
was done assuming exponential decay of the radiolabel from the protein, and 
the equation of the line calculated using the computer software Cricket graph 
version 1.3.2 as indicated previously. From this equation the half life of the U90
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homologue in RE cells was found to be in the order of 36 minutes, which is 
considerably less than the 13 hours half life found for the U90 in Bn5T cells.
The half life of the U90 in Bn5T cells from the pulse-chase experiments 
was calculated to be in the order of 4 hours, which was much less than expected. 
This is most likely to be a consequence of the short chase period (relative to the 
previously reported half life of U90 in this thesis and Hewitt 1988, in Bn5T cells) 
and as any experimental error occurring in the densitometer reading would be 
considerably amplified. Due to the cost of this experiment, a minimal approach 
to time points had to be taken, and therefore the predicted half life of the U90 in 
RE cells can only be considered an estimate.
This experiment however was later repeated by Dr Joan Macnab and Mr 
David McNab using a Phosphor Imager. With chase periods of 15, 30 and 45 
minutes, they found the half life of the U90 homologue to be 29.8 minutes. Taken 
together with the previous results, it can be concluded that the U90 homologue 
has a half life of 32.9 +/- 3.1 minutes. These pulse-chase experiments clearly 
show that the half life of the U90 in Bn5T cells is extended by a considerable 
period when compared to the U90 homologue present in RE cells.
It should also be noted that the U90 seen by western blotting of RE cells, 
migrates very slightly slower than the transformed U90. This could be explained 
by a post-translational modification (eg phosphorylation , glycosylation, 
pamitoylation, myristoylation or sulphation), in the control U90 which is absent 
in the U90 isolated from transformed cells. All of the above modifications with 
the exception of sulphation have previously been shown to be absent in the U90 
in the transformed cell using appropriate radiolabelling techniques (Macnab, 
unpublished results). Whether sulphation accounts for the different half lives 
of the two forms of U90 is unknown. Exactly how an alteration in the half life of 
the U90 could affect the cell cannot be predicted until the function of the U90 
has been established. It is probable that U90 plays an important role in the cell 
since it is highly conserved (as it is present in hum an and rodent cells in 
addition to cells of different lineages).
It is interesting to note that when compared to control cells, a similar 
alteration in the half life of the tum our specific protein p53 occurs in 
transformed cells. In the normal cell, p53 has a half life of between 6 and 20 
minutes, but in the transformed cell this is increased to between 6 and 25 hours 
(Oren et al. 1981; Reich et al. 1983; Rogel et al. 1985). It has been proposed that 
this increase in half life is a consequence of the formation of protein complexes 
which stabilize the protein (Linzer & Levine 1979; Linzer et al. 1980), but 
whether a similar mechanism is involved with the increased half life of U90 in 
transformed cells cannot be predicted.
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It can be concluded from this section that the RE cells express a 90K 
polypeptide which is immunologic ally indistinguishable from the U90 and has 
the same properties as the U90 such that it can be purified in an identical 
manner. The expression of this 90K protein is also increased following HSV 
infection in the same manner as the U90. It is therefore concluded that RE cells 
express the U90 polypeptide, but in a form which has a considerably shorter 
half life compared to the U90 isolated from Bn5T cells. As the U90 is highly 
conserved it is probable that the U90 plays an im portant role in the cell. 
Previous work visualized the U90 by radio-immunoprecipitation in rat embryos 
up to 14 days gestation, but after this point the U90 could not be detected 
(Macnab, unpublished results). This observation and the fact that the ET90 is 
conserved in different cell types, suggests the function of the U90 in the cell 
maybe implicated with cell regulation or differentiation. The exact function of 
the U90 however remains to be disclosed.
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CHAPTER 5: CONCLUSIONS AND FUTURE PROSPECTS
1. Conclusions
The U90 polypeptide was originally identified as a cellular protein which 
was expressed in transform ed cells and accumulated on HSV infection as 
indicated by activity against this polypeptide found in tumour bearing sera and 
antisera raised against HSV infected cells (Macnab et al, 1985). F ro m  
experiments described in this thesis it can now be stated that the U90 is in fact a 
normal cellular polypeptide which is expressed in a number of different cell 
types originating from mouse, rat and human cells. The protein is also found in 
cells of d ifferent lineages including adrenal, epithelial, fibroblastic and 
lymphoid cells indicating that it is a highly conserved protein and as such is 
likely to play an im portant role in the cell. These cells were established in 
culture, a factor which has to date been found to be essential for the U90 to be 
visualized by radiolabelling.
By visualizing U90 in Bn5T cells using radiolabelling techniques, HSV 
types 1 and 2 were found to increase U90 in the infected cells by up to eight fold 
at 3 hours post infection (falling to between 2-5 fold at 17 hours post-infection). 
This increase was a consequence of an increase in the total amount of U90 in the 
cell and not a result of a significant increase in protein stability or increased 
rate of radiolabel incorporation. The use of tem perature sensitive (t£) mutants 
indicated that an early event in HSV infection was implicated with U 90 
induction where Vmw 175 played an important role in this induction. However, 
it is still not established if Vmwl75 acts in a direct or indirect manner. Pulse 
label experiments indicated that U90 accumulated prior to the onset of viral DNA 
synthesis with levels falling after the start of DNA synthesis.
HSV infection also was found to alter the sub-cellular location of the U90 
from being located in the mem brane to being located in the cytoplasmic 
fraction. This may occur as a result of the increased U90 present in the cell, with 
a "bottle neck" occurring at this point in the association of the U90 with the 
membrane. This may be a result of a limiting num ber of membrane pro teins 
with which the U90 may complex, or simply a consequence of the increased 
num ber of U90 molecules. Irrespective of which supposition is correct, the 
accumulation of the U90 in a soluble form in the cytoplasmic fraction facilitated 
the partial purification of the U90 to be carried out with much greater ease.
In addition to HSV infection resulting in the accumulation of the U90 
polypeptide, HSV-1, but not HSV-2 infection was found to increase the total 
amount of GRP94 in the cell. In contrast to the induction of U90 by HSV 
infection, immediate early viral expression is insufficient for the induction of
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GRP94. This increase in GRP94 was not detected as a consequence of 
transcriptional activation but rather due to an increase either at the level of 
translation or protein stability (perhaps due to post-translational modification).
Using the information obtained in the characterization studies the U90 
was partially purified using a combination of selective protein precipitation, 
FPLC analysis and gel electrophoresis. This enabled partial amino acid sequence 
data to be obtained despite the discovery that the U90 was naturally blocked. By 
comparing the partial amino acid sequence data to the databases it was 
established that the U90 was in fact a novel tumour associated polypeptide 
displaying no obvious homology with any of the proteins already sequenced and 
entered in the databases (assuming that the sequence data obtained was correct).
The purification of the U90 polypeptide also allowed the production of a 
mono-specific polyclonal antibody raised against the U90 protein which 
recognised the U90 in western blots. This facilitated the disclosure that control 
RE cells did in fact express a 90K polypeptide similar to the U90 as seen by 
western blotting, despite the fact that the U90 could not be visualized by radio- 
immunoprecipitation from RE cells. By using the U90 monospecific antibody it 
was concluded that the 90K protein present in RE cells behaved in a similar 
m anner to the U90 isolated from Bn5T cells, ie it was found to be associated with 
the membrane and it accumulated in the cytoplasm following HSV infection. 
Application of the U90 purification strategy developed in Bn5T cells to HSV 
infected RE cells, resulted in the 90K polypeptide being isolated in the same 
fractions after purification as the U90 purified from Bn5T cells fu rther 
confirming that this 90K polypeptide was possibly a homologue of U90. Pulse 
chase experiments identified that the U90 found in the Bn5T cells had a 
d ram atically  increased half life as compared to the half life of the U90 
homologue in the control RE cells. It appears that this difference in half life 
distinguishes the U90 homologue isolated from primary cells and U90 isolated 
from the Bn5T tumour cell line.
In attempts to identify the function of the U90 more extensive sequence 
data was sought by trying to either isolate the cDNA encoding the U90 by cDNA 
library  screening, or by generating genomic or cDNA sequence by the 
polymerase chain reaction to amplify the U90 DNA or mRNA followed by cloning 
and sequencing of these clones. Unfortunately time limitations and the absence 
of a highly homologous probe prevented these experim ents from being 
completed.
It can be concluded that the U90 is a highly conserved cellular 
polypeptide and as such is likely to play an important role in the cell. The U90 
has been previously reported to be visualized by radiolabelling in RE cells prior
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to 14 days gestation (Macnab, unpublished) suggesting a possible role in growth 
control or differentiation. The aberrant expression of the U90 could therefore 
be strongly implicated in transform ation and tumourigenesis. It can now be 
reported that a U90 homologue is expressed in control cells but has a reduced 
half life (ie a high turnover). Furtherm ore, HSV infection increases the 
expression of the U90 in control cells, but such an infection alone cannot 
convert the U90 homologue found in "normal" cells to that of the U90 with an 
increased half life (and a slow turnover) as is found in the transformed cell. 
Since the U90 is increased prior to the onset of viral replication (most probably 
by transcriptional activation) it may be that on rare occasions the host cell can 
survive and continue to replicate in an abnormal manner. If this was to occur, 
such an increase in U90 expression by HSV infection may be one of the many 
changes which leads to a transformed phenotype.
2. FUTURE PROSPECTS
Despite the progress which has been made in the characterization of the 
U90 polypeptide, some aspects of this work still needs to be clarified. This 
includes the question as to whether Vmwl75 is responsible for the increase in 
the U90 and if it is, is this increase a consequence of transcriptional activation, 
as might be expected for Vmwl75. Alternatively, an abnormal Vmwl75 may 
induce a conformational change as previously proposed for Hsp90 (Russell et a l. 
1987).
By obtaining accurate cDNA sequence for U90 to generate a h ig h ly  
homologous probe, (by PCR or sequencing a  U90 cDNA clone) northern blotting 
could be used to answer the question of transcriptional activation. Further 
sequence data could also be used to search for functional domains within the U90 
and hence indicate the function of this protein.
Comparison of sequence data generated from Bn5T and RE cells could also 
be used to investigate if any differences occur at the DNA level which might 
explain the alteration in the half life of the protein in normal and transformed 
cells. Additionally, it would be intriguing to discover if the U90 in transform ed 
cells was similarly regulated in ra t embryos prior to 14 days gestation by 
culturing prim ary RE cells generated from embryos of 13 days gestation and 
younger.
To answer the question of the role of U90 in transformation, the cDNA will 
need to be cloned. Transfection studies using the cloned U90 may determine if 
the altered half life of the U90 is fundam ental for some stage in the 
transformation of cells or is a consequence of transformation.
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